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Abstract  
 
Burkitt’s lymphoma (BL) is an aggressive B cell neoplasm that is characterized by a chromosomal 
translocation, which brings the proto-oncogene c-MYC under the control of Immunoglobulin (Ig) 
enhancer elements leading to c-MYC overexpression. While high levels of c-MYC are important for 
the proliferation of BL cells, c-MYC overexpression leads to apoptosis in non-malignant cells. Studies 
have identified the pro-survival Phosphoinositide-3-kinase (PI3K)-AKT pathway to be continuously 
activated in BL cells and more recently it was shown that this pathway is activated by low levels of 
antigen-independent, tonic B cell antigen receptor (BCR) signals. During B cell development, 
continuous tonic BCR signaling is necessary for maturation and survival of B cells. Similar to its 
physiological function, tonic BCR signaling in BL contributes to survival of malignant BL cells. While 
we know that tonic BCR signals activate the PI3K-AKT pathway, the BCR-proximal molecular 
networks regulating tonic BCR signaling are less well defined. The goal of this thesis was therefore 
to characterize new BL-specific BCR effector proteins previously identified by phospho-proteomic 
approaches for their contribution to survival of BL cells with respect to tonic BCR signaling.   
In this thesis, BL-specific effector proteins were selected based on previous reports stating their role 
for PI3K-AKT BCR signaling or based on a potential survival relevant role established in preliminary 
shRNA screens. CRISPR/Cas9 “knockout” BL cell lines for the adaptor proteins Nck1 and Nck2 as well 
as the guanine nucleotide exchange factor BIG2 and the inositol-5’ phosphatase SHIP2 showed a 
decline in proliferation. For Nck1- and Nck2-deficient cells, the proliferative defect could be linked 
to a decrease in PI3K-AKT signaling mediated by tonic BCR signals, thus identifying Nck proteins as 
novel, proximal regulators of tonic BCR-dependent PI3K-AKT signaling.  Moreover, I identified SHIP2 
and BIG2 being relevant for BL survival as their absence increased apoptosis of BL cell lines, which, 
for BIG2, was accompanied by decreased c-MYC expression levels. Despite their survival relevant 
role, SHIP2 and BIG2 were identified as negative regulators of AKT signaling, thereby contrasting 
previous beliefs that survival of BL cells was mainly dependent on the PI3K-AKT pathway. BL-
effectors analyzed here promoted signaling via the Mitogen-activated protein kinase (MAPK) c-Jun 
N-terminal kinase (JNK) pathway, indicating the relevance for this pathway for BL. Despite findings 
that JNK activation promotes apoptosis in other cell types, JNK was shown to have a unique pro-
survival role in B cell malignancies. Here, I provide evidence that tonic BCR signals also involve JNK 
signaling and that the analyzed BL-effector proteins are regulators in this pro-survival pathway. 
Therefore, the identified effectors may not only be new therapeutic targets themselves but also 
revealed a novel, potentially druggable pathway dependent on tonic BCR signaling in BL.  
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1 Introduction 
 
1.1 Burkitt’s lymphoma - why we still need improved therapeutic approaches 
 
Burkitt’s lymphoma (BL) is a rare but highly aggressive form of mature B cell neoplasm arising from 
a sub-population of B lymphocytes, which are an integral part of our immune system that defends 
us against a broad range of pathogens. BL is one of the fastest growing human tumors, with a 
doubling time of only 24 - 48 h (Molyneux et al. 2012; Klein et al. 1968) and was first described as a 
jaw tumor in children by Dr. Denis Burkitt in 1958 while working in malarial areas in Africa (Burkitt 
1958). Even today, BL is most prevalent in children living in malarial regions of equatorial Africa who 
are also frequently infected with Epstein-Barr virus (EBV) (Schmitz et al. 2012). This type of BL is 
labeled as endemic BL. Outside of continental Africa, cases of BL can be separated into sporadic or 
immunodeficiency-associated BL. For these forms of BL, EBV infection is less common. 15% of 
patients with sporadic and 40-50% of patients with immunodeficiency-associated BL are infected 
with EBV (Spender & Inman 2014). It is not yet entirely clear, how EBV infection contributes to BL 
pathogenesis. However, EBV has been shown to provide signals for transformation and survival of 
B cells that can induce malignant transformations through the expression of viral proteins such as 
Epstein-Barr virus nuclear antigen 2 (EBNA-2), EBV latent membrane proteins (LMP)-2A and LMP-1 
(reviewed by Spender & Inman 2014).  
 
Due to its high rate of proliferation, BL is generally treated with a combinatorial therapy of different 
genotoxic agents and rituximab, a chimeric monoclonal antibody targeting the B cell marker CD20 
(Fowler & Davis 2013; Jacobson & LaCasce 2014; Jabbour & Kantarjian 2016). In countries with a 
high median household income, chances of successful treatment can be considered excellent as the 
cure rate of the sporadic form of BL is roughly 90% (reviewed by Klumb 2012). Although this regimen 
is successful in most cases, short- and long-term toxicities of high-dose chemotherapy limits the 
application for older patients and those suffering from endemic BL (Staudt 2012). Especially for 
patients in less developed countries, the necessary supportive care for high-dose chemotherapy 
regimens is often not available and lower-dose therapies must be given to avoid treatment-related 
mortality (Klumb 2012). In addition, prognosis of refractory or relapsed patients is very poor and 
highlights the need of novel therapeutic approaches (Jacobson & LaCasce 2014). While the available 
therapeutic agents interfere with the proliferation of BL cells, they are rather unspecific as they do 
not exclusively target BL cells. Although the genetic background in BL has been known for some 
time, the scientific community has just recently begun to understand the molecular signaling 
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networks driving high rates of proliferation and survival which are characteristic for BL cells. To 
explain why especially BL cells proliferate so aggressively, we need to shed some light on their 
cellular origin.  
 
1.2 B cell neoplasms arise at different stages of B cell development 
 
While the existence of antibody-producing cells was already proposed by Paul Ehrlich in 1897, it was 
not until 1965 that B cells were described as a distinct lymphoid cell lineage (Cooper et al. 1965). B 
cells are named after the bursa of Fabricius, a hindgut lymphoid organ in birds that was identified 
as the site of antibody production in chicken (Glick, Chang, & Jaap, 1956; reviewed in Cooper, 2015). 
In mammals, B cells develop in the bone marrow, where they irreversibly rearrange immunoglobulin 
(Ig) gene segments, in a process termed V(D)J recombination (Hozumi & Tonegawa 1976) (Figure 1). 
This re-arrangement occurs randomly, only one locus is re-arranged at a time at different stages of 
B cell development and allelic exclusion ensures that each B cell expresses only one receptor 
specificity. In the first step, B cells only rearrange the Ig heavy chain, which can pair with a surrogate 
light chain to form the pre-B cell antigen receptor (BCR), which promotes high levels of proliferation. 
During this process, chromosomal translocations and mutations can also lead to B cell acute 
lymphocytic leukemia (B-ALL) (Iacobucci et al. 2012). In the next developmental stage, B cells 
rearrange their Ig light chains and the pre-BCR is replaced by a functional BCR composed of a heavy 
and a light chain. Theoretically, V(D)J recombination could thereby result in a diversity of at least 
1012 distinct B cell antigen receptors enabling the immune system to fend off a plethora of antigens 
(Alberts et al. 2002).  While this random process increases the B cell repertoire, it can also generate 
B cells that react to ubiquitous self-antigens and thus could induce auto immune reactions. These 
auto-reactive B cells are removed from the B cell repertoire during B cell development by different 
processes selecting for self-tolerance (Pelanda & Torres 2012).  
 
Immature B cells then leave the bone marrow to become mature naïve B cells in the spleen. Mature 
B cells can give rise to indolent non-mutated B cell chronic lymphocytic leukemia (B-CLL) or mantle 
cell lymphoma (MCL) (Seifert et al. 2012). Naïve B cells circulate via the bloodstream and enter 
secondary lymphoid tissues such as lymph nodes and spleen. Thereby, they increase the probability 
to bind to their respective antigen, which can either be soluble or provided in a cell-bound manner 
e.g. by macrophages (Unanue 1984). Upon binding of most antigens, naïve B cells require a 
secondary co-stimulatory signal of an activated helper T cell to become fully activated. Activation 
leads to proliferation and differentiation into either antibody-secreting plasma cells or memory B 
cells.  
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Additionally, activation can induce a germinal center (GC) reaction in secondary lymphoid organs. 
In the dark zone of the GC, B cells proliferate rapidly and undergo immunoglobulin somatic 
hypermutation of Ig genes to increase antigen affinity. B cells then migrate into the light zone of the 
GC, where the newly arranged Igs are selected for their antigen affinity with the help of follicular 
dendritic cells and T helper cells (Basso & Dalla-Favera 2015). Notably, positively selected light zone 
cells can re-enter the dark zone for further rounds of cell division and somatic hypermutation to 
potentially further improve antigen affinity. Besides somatic hypermutation, Ig genes are remodeled 
by class-switch recombination in the light zone of GC to produce different isotype classes (De Silva 
& Klein 2015). Class-switching depends on the support of helper T cells and functionally optimizes 
the antibody since each Ig class has particular functions and a unique distribution. While in naïve B 
cells, alternative splicing leads to expression of IgM or IgD, GC B cells can rearrange this DNA locus 
and to eventually produce IgG, IgA, or IgE isotypes with different effector functions.  
 
Somatic hypermutation and class switch recombination are regulated by Activation-induced 
cytidine deaminase (AID). AID induces DNA mutations and double strand breaks which are 
susceptible to error-prone repair thereby increasing antibody diversity. However, AID activation 
must be tightly regulated to avoid chromosomal translocations and development of B cell 
malignancies (Pettersen et al. 2015). Therefore, it not surprising that GC B cells are the origin of 
different B cell lymphomas including Follicular lymphoma, Diffuse large B cell lymphoma (DLBCL) 
and BL, which together account for ~80% of mature B cell neoplasms (Basso & Dalla-Favera 2015). 
While gene expression profiling reveled BL cells to derive from rapidly proliferating dark zone GC B 
cells, the germinal center B cell like (GCB)-DLBCL and follicular lymphoma cells resemble light zone 
B cells and Activated B cell like (ABC)-DLBCL is derived from GC cells arrested in early stages of 
plasma cell differentiation (Victora et al. 2012; Dave et al. 2006; Alizadeh et al. 2000; Basso & Dalla-
Favera 2015).  
 
In addition, GC-derived plasma cells can give rise to multiple myeloma while GC-derived memory B 
cells are discussed to be the origin of a mutated form of B-CLL (Seifert et al. 2012; Röllig et al. 2015). 
Moreover, marginal zone B cells are mature B cells resident in the marginal zone of the spleen, which 
are also believed to be generated through a GC reaction in humans (Weill et al. 2009; Dunn-Walters 
et al. 1995). They can give rise to splenic marginal zone lymphoma and mucosa-associated lymphoid 
tissue (MALT) lymphoma (Baliakas et al. 2015; Isaacson & Spencer 1987).  
 
Considering the diversity of B cell neoplasms arising from different developmental stages, it is not 
surprising that the drivers for abnormal proliferation are characteristic for each subtype, which have 
been nicely reviewed by others (Rickert 2013; Vaqué et al. 2014). Despite these differences - with 
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the exception of multiple myeloma - B cell malignancies discussed here retain their BCR expression 
after their neoplastic transformation indicating that they remain dependent on BCR signaling for 
survival and proliferation (Küppers 2005; Buchner & Müschen 2014).  
 
 
 
 
Figure 1: B cell neoplasms arise at different stages of B cell development.  
In the bone marrow, B cell acute lymphocytic leukemia (B-ALL) arises from large pre-B cells expressing a pre-
BCR with a surrogate light chain. Small pre-B cells undergo light chain re-arrangement and the complete BCR 
is expressed in immature B cells. Immature B cells leave the bone marrow and become mature naïve B cells 
in the periphery. They are the cellular origin of B cell chronic lymphocytic leukemia (B-CLL) and Mantle cell 
lymphoma (MCL). Burkitt’s lymphoma (BL), Follicular lymphoma or Diffuse large B cell lymphoma (DLBCL) 
originate from germinal center (GC) B cells. GC B cells can either differentiate into memory B cells or antibody-
secreting plasma cells. Memory B cells are the cellular origin of a mutated subtype of B-CLL while plasma cells 
can give rise to multiple myeloma. In humans, marginal zone B cells are also reported to have undergone GC 
reaction and can give rise to splenic marginal zone lymphoma (SMZL) and mucosa-associated lymphoid tissue 
(MALT) lymphoma. Adapted from Rickert, 2013. 
 
 
1.3 Signaling via the B cell antigen receptor  
 
1.3.1 The B cell antigen receptor (BCR) 
 
The B cell antigen receptor (BCR) contains a transmembrane version of Ig, which consists of two 
identical heavy and two identical light chains, forming a Y-shaped molecule. The two heavy chains 
are connected to each other by a disulfide bond in addition to disulfide bonds connecting heavy and 
light chains. The heavy chains are encoded by VH, DH, JH and CH gene segments, whereas the light 
chains are encoded by VL, JL, and CL either of the κ or λ subtype.  
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To form a functional BCR, the membrane Ig is non-covalently associated to CD79A (Igα) and CD79B 
(Igβ). CD79A and CD79B are invariant protein chains which are connected by disulfide bonds to form 
a heterodimer (Reth et al. 1991). The CD79A-CD79B heterodimer is required for both surface 
expression of the Ig as well as signal transduction via their immunoreceptor-tyrosine-based 
activation motifs (ITAMs) in their cytoplasmic tails. ITAMs share a consensus sequence of 
YXX(L/I)X6-8 YXX(L/I) (where X denotes any amino acid) (Reth 1989) and are also found in signaling 
chains associated to T cell or natural-killer cell receptors as well as in certain Fc receptors (Humphrey 
et al. 2005). In B cells, stimulation of the BCR and activation of protein tyrosine kinases triggers ITAM 
tyrosine (Y) phosphorylation thus initiating a cascade of several signaling pathways. 
 
1.3.2 BCR signaling upon stimulation 
 
It is still under debate how the BCR in resting cells is organized and how the dynamics of the 
cytoskeleton interfere with this process. The first model, known as the confirmation-induced 
oligomerization model or cross-linking model, proposes that BCR monomers are dispersed in the 
membrane in a closed, inactive confirmation in resting B cells. Upon cross-linking with a multivalent 
antigen or monovalent antigen presented by antigen-presenting cells, a conformational change in 
the Ig allows oligomerization and formation of BCR microclusters in lipid rafts and opens cytoplasmic 
domains for signaling (Treanor 2012; Treanor et al. 2010; Pierce & Liu 2010). Reth and colleagues 
previously proposed a different model named dissociation activation model based on findings of 
large macromolecular complexes of IgM and IgD in resting cells (Schamel & Reth, 2000; Yang & Reth, 
2010a). Their model proposes that BCRs are organized in auto-inhibitory oligomers in resting B cells. 
Binding of a polyvalent antigen to the receptor triggers BCR oligomer dissociation, which exposes 
the cytoplasmic domains of CD79A and CD79B for subsequent signal transduction in defined areas 
(Treanor, 2012; Yang & Reth, 2010b).  
 
While there is still an ongoing debate about BCR dynamics in resting B cells, early events of BCR-
dependent signaling have been characterized in-depth in recent years and are generally agreed 
upon. The engagement of the BCR with its cognate antigen leads to phosphorylation of ITAMs in the 
CD79A-CD79B heterodimer and a non-ITAM tyrosine residue in CD79A by Src-family kinases (SFK) 
such as Lyn, Fyn and spleen tyrosine kinase (Syk) (Pao et al., 1998; Schmitz et al., 1996) (Figure 2). 
The phosphorylated ITAMs serve as docking sites for tandemly arranged Src homology 2 (SH2) 
domains of Syk (Fütterer et al. 1998) thereby compromising autoinhibition and leading to full 
activation of Syk (Engelke et al., 2007; Rolli et al., 2002). Once activated, Syk can additionally 
phosphorylate other ITAMs of neighboring BCRs thereby amplifying BCR signaling (Rolli et al. 2002).  
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Besides Syk, the SH2-domain containing leucocyte adapter protein of 65 kDa (SLP65, also known as 
BLNK or BASH) is recruited to the phosphorylated non-ITAM tyrosine residue (pY204) in CD79A and 
is subsequently phosphorylated by Syk at various tyrosine residues (Engels et al. 2001). Tyrosine 
phosphorylated SLP65 then recruits Burton’s tyrosine kinase (Btk) and phospholipase C (PLC) ɣ2 into 
a multiprotein complex known as the Ca2+ initiation complex (Engelke et al., 2007; Hashimoto et al., 
1999). In context of this complex, Btk is activated and subsequently phosphorylates and thereby 
activates PLCɣ2. The complex localizes at the plasma membrane with the help of Pleckstrin 
homology (PH) domains of Btk and PLCɣ2 binding to phosphatidyl-inositol-3,4,5-trisphosphate 
[PI(3,4,5)P3] (Salim et al. 1996; Falasca et al. 1998), while membrane recruitment of SLP65 requires 
the constitutive interaction with CBL-interacting protein of 85 kDa (CIN85) (Oellerich et al. 2011). At 
the plasma membrane, activated PLCɣ2 hydrolyzes its substrate phosphatidyl-inositol-4,5-
bisphosphate [PI(4,5)P2] to produce the second messengers inositol-1,4,5-trisphosphate (IP3) and 
membrane-resident diacylglycerol (DAG).  
 
The second messenger IP3 induces Ca2+ mobilization from the endoplasmic reticulum (ER) and the 
extracellular space. IP3 serves as a ligand for IP3 receptors (IP3R1-3) being Ca2+ channels in the in the 
ER, which open upon binding of IP3 and release Ca2+ stored in the ER into the cytosol (Taylor & Tovey, 
2010).  The fast decrease of Ca2+ in the ER is sensed by transmembrane proteins of the ER, named 
stromal interaction molecules (STIMs) that upon binding of Ca2+ can activate Calcium release 
activated channels (CRACs) in the plasma membrane (Baba & Kurosaki 2015; Kar et al. 2012). 
Activation of CRACs leads to sustained influx of extracellular Ca2+ into the cytosol (reviewed by 
Engelke et al. 2007; Oh-hora & Rao, 2009). One target of sustained Ca2+ flux in B cells is the 
transcription factor nuclear factor of activated T cells (NFAT). In the cytosol, phosphorylated NFAT is 
inactive and activation requires the dephosphorylation by the phosphatase Calcineurin, which is 
activated by the Ca2+ sensor Calmodulin (Klee et al. 1979). De-phosphorylated NFAT can then rapidly 
translocate into the nucleus and activate its target genes. NFAT regulates cell cycle progression in 
naïve B cells via Cyclin E and was shown to be involved in efficient plasma cell differentiation 
(Engelke et al. 2007). 
 
Among other pathways, membrane-bound DAG regulates activation of the transcription factor NFĸB 
(nuclear factor of kappa light polypeptide gene enhancer in B cells) via recruitment of the 
serine/threonine protein kinase C (PKC)β. Ca2+ binding fully activates PKCβ, which subsequently 
activates the IĸBα kinase complex and releases NFĸB from its negative regulator IĸB. When released, 
NFĸB translocates into the nucleus and induces transcription of its target genes. NFĸB signaling plays 
an important role in innate and adaptive immune responses by regulating genes involved in 
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proliferation, survival, and differentiation  (Hayden et al. 2006; Oeckinghaus & Ghosh 2009).  
 
Additionally, Mitogen-activated protein kinases (MAPKs) are activated following BCR stimulation. 
While BCR-induced activation of the MAPK extracellular signal-regulated kinase (ERK) in chicken and 
mouse B cells requires the DAG-dependent recruitment of Ras guanyl nucleotide-releasing proteins 
(GRPs), in human B cells, ERK is primarily activated by the adaptor function of SLP65 (Oh-hora et al. 
2003; Coughlin et al. 2005). SLP65 binds the adaptor Growth factor receptor-bound protein 2 (Grb2), 
thereby mediating the recruitment of Sos, a guanine nucleotide exchange factor (GEF) (Wienands 
et al. 1998; Aronheim et al. 1994). Sos in turn activates the small G-protein Ras thereby initiating 
ERK activation (Aronheim et al. 1994). Moreover, SLP65 is also central protein in the activation of 
MAPK c-Jun N-terminal kinase (JNK). SLP65 is associated with the small GEF Vav, which activates 
Rho-family GTPases like Rac1. (Brezski & Monroe 2007; Wienands et al. 1998). In addition, SLP65 
recruits PLCɣ2, and activation of both PLCɣ2 and Rac1 is necessary for subsequent JNK activation 
(Ishiai et al. 1999). Moreover, DAG-mediated activation of PKCβ promotes signaling pathways 
leading to MAPK p38 activation (Hashimoto et al. 1998). MAPK signaling induces activation of many 
transcription factors, which are involved in lymphocyte proliferation, survival and differentiation 
(Khiem et al. 2008; Yasuda et al. 2011; Kyriakis & Avruch 2001).  
 
Besides the formation of the Ca2+ complex and activation of its downstream effectors, BCR 
engagement and activation of the co-receptor CD19 also initiates the recruitment of 
Phosphoinositide-3-kinase (PI3K) to the plasma membrane. Protein tyrosine kinases Syk, Fyn, and 
Btk phosphorylate CD19 and the B cell adapter for PI3K (BCAP), which provides binding sites for the 
p85 subunit of PI3K (Okada et al. 2000). In addition, the adapter protein Nck can bind to the 
phosphorylated non-ITAM tyrosine residue (pY204) in CD79A and recruit BCAP, serving as a direct 
link between BCR activation and PI3K signaling (Castello et al. 2013). Upon recruitment and 
activation, PI3K phosphorylates PI(4,5)P2 to PI(3,4,5)P3, which mediates the translocation of the AKT 
kinase (also referred to as PKB) and the 3’-phosphoinositide dependent kinase (PDK)1 to the plasma 
membrane (Vanhaesebroeck & Alessi 2000). AKT is phosphorylated at T308 by PDK1 in the 
activation loop and at S473 in the carboxylterminal hydrophobic motif by a complex of rictor and 
mammalian target of rapamycin (mTOR) to become fully activated (Sarbassov et al. 2005; 
Vanhaesebroeck & Alessi, 2000). Among the multitude of effectors functions, AKT promotes survival 
signaling through phosphorylation and inactivation of apoptosis-inducing targets such as pro-
apoptotic BCL-2 related protein Bad, Caspase-9 and forkhead transcription factors (FOXOs) (Cardone 
et al. 1998; Downward 2004), while promoting cell cycle progression by inhibition of glycogen 
synthase kinase 3β (GSK3β)-mediated phosphorylation of Cyclin D (Diehl et al. 1998).  
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The 3’-phosphatase and Tensin homolog (PTEN) and the 5’-phospatases SHIP2 and SHIP2 are 
important negative regulators of the PI3K-AKT signaling pathway as they decrease the pool of 
PI(3,4,5)P3 to PI(4,5)P2 or PI(3,4)P2, respectively (Leslie et al., 2012). However, PI(3,4)P2 can also 
serve as a membrane anchor for both AKT and PDK1, even though PDK1 preferentially binds to 
PI(3,4,5)P3 (Alessi et al., 1997; Manna et al., 2007; Xie, Erneux & Pirson, 2013). 
 
 
 
 
 
Figure 2: Schematic depiction of B cell antigen receptor (BCR) signaling.  
Upon BCR engagement, activation of Src-family kinases such as Lyn and Syk phosphorylate ITAMs in CD79A 
and CD79B as well as one non-ITAM tyrosine (Y204) in CD79A. This leads to phosphorylation of SLP65 which 
recruits Btk and PLCɣ2 for the formation of the Ca2+ initiation complex. In the complex, PLCɣ2 is 
phosphorylated by Btk and hydrolyzes PI(4,5)P2 to the second messengers DAG and IP3. IP3 in turn induces 
Ca2+ mobilization from the ER leading to subsequent NFAT activation. Membrane bound DAG mediates 
recruitment of PKCβ and activation of the NFĸB and the p38 pathway. ERK signaling is triggered by Sos, while 
JNK signaling is mediated by activation of Rac1. Additionally, the PI3K pathway can be activated by recruitment 
of Nck to the phosphorylated non-ITAM in CD79A and subsequent binding to BCAP. BCAP is also 
phosphorylated upon CD19 activation and recruits PI3K, which phosphorylates PI(4,5)P2 to PI(3,4,5)P3. PDK1 
and AKT are recruited to the plasma membrane by PI(3,4,5)P3 leading to PDK1-dependent AKT 
phosphorylation and activation. Activation of the AKT pathway promotes survival and proliferation signaling, 
by increasing cell cycle and glucose metabolism and by inhibition of apoptosis. SHIP1 and SHIP2 decrease the 
pool of PI(3,4,5)P3 by de-phosphorylation to PI(3,4)P2, although PI(3,4)P2 can also serve as a membrane anchor 
for PDK1 and AKT.  
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1.3.3 BCR signaling in B cell malignancies 
 
Activation of BCR signaling by foreign or self-antigens 
 
Indolent B cell neoplasms such as splenic marginal zone lymphomas, B-CLL and MALT lymphomas 
are characterized by their recognition of foreign or self-antigens that induce aberrant BCR signaling 
(Craig et al. 2010; Rossi & Gaidano 2010). A subset of these lymphomas expresses near-identical, 
stereotyped BCRs, leading to the suggestion that they were selected for with a restricted repertoire 
of antigen epitopes (Henry Dunand & Wilson 2015). In B-CLL, one of the most frequent B cell 
malignancies in the United States (Morton et al. 2006), stereotyped monoclonal antibodies can for 
example react to self-antigens derived from apoptotic cells, which correlates with poor prognosis 
(Chu et al. 2010). Stereotyped BCRs can also signal autonomous and thereby independent of 
external antigens. The heavy chain complementary determining region of these stereotyped BCRs 
can bind to an internal epitope of neighboring BCRs on the same cell, thus constantly activating BCR 
signaling (Minden et al. 2012).  
 
Constitutive BCR activation by somatic mutations in BCR signaling components 
 
In most aggressive B cell lymphomas, such as DLBCL, mutations in BCR effector molecules initiate a 
chronic, constitutive activation of the BCR signaling cascade. In the case of ABC-DLBCL, proximal 
BCR signaling proteins such as CD79A and CD79B are mutated in ~20% of cases thereby preventing 
BCR endocytosis and inhibiting the negative regulation of Src-family kinase Lyn (Davis et al., 2010). 
Additional mutations in CARD11 and MyD88 promote survival of cells by constitutive NF-kB 
activation, independent of BCR engagement (Lenz et al. 2008; Ngo et al. 2011). In B-ALL, mutations 
downstream the pre-BCR including the expression of the breakpoint cluster region-ABL1 fusion 
protein, impaired expression of SLP65 or Ras and SHP2 gain of function mutations contribute to 
ligand-independent survival signaling (reviewed by Rickert 2013). Despite their aggressive nature, 
BL cells do not harbor genetic mutations in proximal BCR-signaling effector proteins (Schmitz et al. 
2012; Richter et al. 2012). The following chapter will therefore discuss the molecular characteristics 
contributing to their malignancy.  
 
 
 
 
 
Introduction 
10 
 
1.4 Molecular characteristics of Burkitt’s lymphoma 
 
On a molecular level, BL is characterized by a reciprocal chromosomal translocation of the c-MYC 
proto-oncogene and one of three immunoglobulin genes. Upon translocation, c-MYC is brought 
under the control of transcriptionally active Ig enhancer elements either of the Ig heavy chain 
[t(8;14)] in 80% of cases (Hayday et al. 1984) or Ig κ [t(2;8)] or λ [t(8;22)] light chains, respectively,  
accounting for the remaining 20% (reviewed by Allday, 2009). As a result, c-MYC, which is normally 
repressed in dark zone B cells, is overexpressed in BL cells (Dominguez-Sola et al. 2012) while the 
normal c-MYC allele is silent in BL (ar-Rushdi et al. 1983). In a physiological context, c-MYC 
expression increases the cell mass prior to its division and subsequently promotes cell division by 
upregulation of cyclin D, E2F, and cyclin-dependent kinase 4, while repressing genes involved in cell 
cycle arrest (Spender & Inman 2014). To avoid uncontrolled cell growth, expression of c-MYC is 
tightly regulated. The c-MYC protein is degraded very rapidly with a half-life of only 20-30 min and 
if overexpressed triggers a stress-response leading to apoptosis (Spender & Inman 2014). However, 
BL cells depend on continuous c-MYC expression for survival and G1 cell cycle progression (Gomez-
Curet et al., 2006; Marinkovic et al., 2004; Spender & Inman, 2012).  
 
Thus, BL cells must have acquired additional properties to escape the apoptosis-inducing c-MYC 
regulation. High throughput RNA-sequencing data showed that besides mutations in c-MYC itself, 
the tumor-suppressor p53 (encoded by TP53), which is known to play a central role for c-MYC-
induced apoptosis (reviewed in Allday, 2009), is frequently mutated in more than 30% of sporadic 
BL cases (Bhatia et al., 1992; Schmitz et al., 2012). Moreover,  the transcription factor TCF3 (E2A) or 
its negative regulator ID3 are mutated in 70% of sporadic and immunodeficiency-related and in 40% 
of endemic BL cases (Schmitz et al. 2012; Love et al. 2012; Richter et al. 2012). E2A promotes G1-S 
cell-cycle progression by CCND3 activation (encoding cyclin D3), which is frequently mutated in 
sporadic and HIV-associated BL (Schmitz et al. 2012). Additionally, E2A regulates expression of BCR 
signaling components by repressing mRNA and protein expression of the phosphatase SHP1, a 
negative regulator of BCR signaling while transactivating Ig heavy and light chain genes (Schmitz et 
al. 2012; Schmitz et al. 2014). Thereby, E2A activates the PI3K-AKT pathway, which drives 
proliferation and survival in B cells. In addition, also PI3KR1, encoding for the regulatory subunits 
p85α, p55α and p50α of the heterodimeric class 1 PI3K, is recurrently mutated in BL (Love et al. 
2012) further highlighting the importance of this pathway for BL.  
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Besides the aforementioned mutations affecting this signaling pathway, PI3K signaling in BL is driven 
by tonic, antigen-independent low-level BCR signaling (Schmitz et al. 2012). Since tonic signaling via 
the BCR is considered to be a driving force for survival of BL cells, the next chapter will discuss tonic 
BCR signaling in more detail.  
 
1.5 Tonic BCR signaling 
 
BCR signaling is commonly associated with antigen-induced signaling, however, low levels of BCR 
signaling can also occur in the absence of the antigen, referred to as tonic BCR signaling. The direct 
molecular mechanism of tonic BCR signaling remains unclear, but the central role of Syk regulation 
by protein tyrosine phosphatases (PTPs) is well established in this context (Rolli et al. 2002; Monroe 
2006; Wienands et al. 1996). Treating living cells with pervanadate/H2O2, an inhibitor of PTPs, 
suggests the existence of a pre-formed BCR transducer complex containing protein tyrosine kinases 
(PTKs) such as Syk and PTPs. BCR signaling could be activated by inhibition of PTPs and H2O2 even in 
the absence of BCR stimulation (Wienands et al. 1996). These findings are the cornerstone for a 
tonic signaling model that is based on stochastic phosphorylation and subsequent 
dephosphorylation of the BCR and its positive and negative co-receptors by PTKs and PTPs (Monroe 
2006). In this model, the resting state of B cells is maintained as an equilibrium of stochastic 
triggering and termination of the signal by negative regulators (Figure 3). Stochastic interactions 
between the positive co-receptors such as CD45 and Src-family PTKs like Lyn result in single 
phosphorylation of the membrane proximal tyrosine in the ITAM in CD79A leading to subsequent 
partial Syk activation (Fütterer et al. 1998). However, PTKs also phosphorylate immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) in negative co-receptors like CD22. This leads to recruitment 
of PTPs such as SHP1, which de-phosphorylate the ITAMs, thus terminating tonic signaling (Cornall 
et al. 1998; Nitschke 2005). Additionally, Src-family PTKs phosphorylate Syk at Y317, thereby 
targeting it for Casitas-B-lineage lymphoma (CBL)-dependent ubiquitinylation and proteasomal 
degradation (Yankee et al., 1999). Beyond this model, also the interaction of the co-receptors CD45 
and CD22 fine tunes tonic BCR signaling. CD45, by virtue of its extracellular domain, restrains CD22 
inhibitory function to maintain tonic BCR signaling, presumably by restricting the pool of Src-family 
PTK Lyn to CD22 (Coughlin et al. 2015). Hence, tonic BCR signaling is believed to be a tightly 
regulated process of phosphorylation and de-phosphorylation of the BCR complex and its co-
receptors thus resembling an equilibrium between low activation and negative regulation.  
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Figure 3: Dynamic equilibrium model for tonic BCR signaling.  
The resting state of the non-aggregated BCR signaling complex is maintained as an equilibrium between 
stochastic triggering and negative regulation. (a) Stochastic triggering. ① Stochastic interactions between the 
positive co-receptor CD45 and Src-family kinases induces ② the phosphorylation of membrane-proximal 
ITAM tyrosine residues of CD79A and CD79B. ③ Syk is subsequently recruited and partially activated, leading 
to initiation the BCR signaling cascade as described in Figure 2. (b) Negative regulation. ① Src-family kinases 
phosphorylate ITIM motifs in negative co-receptors such as CD22. Phosphorylated ITIMs recruit protein 
tyrosine phosphatases like SHIP1 to the BCR complex and ② de-phosphorylate the ITAMs. ③ Src-family-
kinases also mediate phosphorylation of Syk at Y317, thereby labeling it for CBL-dependent proteasomal 
degradation. Adapted from Monroe, 2006. 
 
 
The importance of BCR expression and physiological tonic signaling for B cell survival is highlighted 
by several studies. These studies showed that the inducible knockdown of the BCR, ablation of 
CD79A or the selective excision of  the CD79A ITAM leads to loss of mature B cells (Lam et al. 1997; 
Kraus et al. 2004). However, mature B cells without a BCR could be fully rescued from apoptosis by 
activating the pro-survival PI3K pathway, but not by NFĸB signaling (Srinivasan et al. 2009). This 
indicates that tonic BCR signaling is promoting signaling via the PI3K pathway.  
 
The concept that tonic BCR-induced PI3K signaling, beyond the MYC translocation, is the driving 
force in BL pathogenesis was first published by the group of Louis Staudt in 2012. They identified 
several genes involved in the PI3K pathway to be mutated in BL and could show that tonic BCR 
signaling via the PI3K pathway is essential for BL cell survival (Schmitz et al. 2012). The relevance of 
both c-MYC and PI3K activity for BL pathogenesis was also confirmed in vivo, leading to BL-like 
tumors in mice (Sander et al. 2012). Interestingly, although BL cells have acquired oncogenic pro-
survival mutations, they still rely on BCR signals for their survival. This fact makes tonic BCR signaling 
a promising target for novel therapeutic approaches.  
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1.6 Aim of this study 
 
Although the relevance of tonic BCR signaling via the PI3K pathway for BL cell survival is well 
established, the proximal cascade of the tonic BCR signaling network is not yet defined. Studies on 
Syk inhibition revealed that Syk is involved in tonic BCR signaling. Quantitative phospho-proteomics 
has furthermore identified multiple proteins within BL cell lines that are differentially 
phosphorylated upon Syk inhibition or CD79A knockdown (Corso et al. 2016). All of these findings 
indicate that also proteins upstream or independent of Syk are involved in proximal tonic BCR 
signaling. Based on the phospho-proteomics data combined with preliminary shRNA screens testing 
for a potential pro-survival role, I chose three BL-specific BCR effector proteins for detailed analysis 
of their role in BL-specific BCR signaling and addressed the following questions: 
 
1. Are the BL-specific proteins identified by phospho-proteomics relevant BL cell proliferation 
and survival? 
2. How do BL-specific BCR effectors regulate tonic signaling? Which pathways are affected that 
might contribute to BL cell proliferation and survival?  
 
These aims were addressed by generating BL cell lines deficient for selected BCR effector proteins. 
Cells were functionally characterized by focusing on proliferation, apoptosis, and tonic BCR signaling.  
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2 Materials and Methods 
2.1 Materials 
 
2.1.1 Instruments 
 
Table 1: Instruments used in this study. 
Name Manufacturer 
Agarose Gel Electrophoresis System Peqlab 
Amaxa Nucleofector™ Lonza 
Amnis ImageStream®X MarkII Imaging Flow Cytometer Merck 
Balance BP61 Sartorius 
Balance H95 Sartorius 
Cell Culture Incubator Hera Cell 150 CO2 Heraeus 
Centrifuge Sorvall RC3B Plus Sorvall 
Chemi Lux Gel Imager Intas Science Imaging 
Countess Cell Counter Invitrogen 
Electrophoresis Power Supply EPS 301 Amersham Biosciences 
Electrophoresis System Hoefer SE600 Amersham Biosciences 
Flow Cytometer LSR II Becton Dickinson 
Freezer HeraFreeze Heraeus 
Freezer Platilab 340 Angelantoni life science 
GenePulser II Electroporation system Bio-Rad Industires 
Ice Machine Ziegra 
Incubation Shaker Unitron Infors 
Incubator Kelvitron T Heraeus 
Laminar Flow Cabinet HeraSafe Heraeus 
Light Microscope Teraval 31 Zeiss 
LSM 510 Meta Zeiss 
Magnetic stirrer M21/1 Framo Gerätetechnik 
Mastercycler Epgradient Eppendorf 
Microcentrifuge 5417R Eppendorf 
Microcentrifuge MiniSpin™ Eppendorf 
Microplate Reader Powerwave 340 BioTEK 
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Name Manufacturer 
Mini Protean Tetra Cell Bio-Rad Laboratories 
Multifuge 3SR Heraeus 
NanoDrop 2000 Thermo Scientific 
Neubauer improved counting chamber Laboroptik 
pH-Meter inoLab® WTW 
Pipettes Eppendorf 
Rocking Shaker Neolab 
Rocking Shaker Duomax 1030 Heidolph 
Rotor SW41 Ti Beckman 
Semiphor Transphor Unit TE77 Amersham Biosciences 
Sprout Minizentrifuge Biozym 
Thermomixer Comfort Eppendorf 
ThermoMixer® C Eppendorf 
UV-Illuminator Intas Systems 
Vortex Genie 2 Scientific Industries 
Water Bath Schütt Labortechnik 
Water Purification System Milli-Q Millipore, Sartorius 
 
 
2.1.2 Software and databases 
 
Table 2: Software. 
Application Software Manufacturer 
Citation Management Software Mendeley Elsevier 
Flow cytometry data acquisition FACSDiva BD Bioscience 
Flow cytometry data analysis FlowJo 7.6.5 Treestar 
Illustration Software BioRender biorender.io 
Image processing ImageJ W.Rasband, NIH 
Sequence Data Analysis Serial Cloner Serial Basics 
Sequence Data Analysis Finch TV Geospiza 
Text processing, spreadsheets, illustrations Microsoft Office Microsoft 
Western Blot Data Acquisition Chemostar professional Intas 
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Table 3: Databases. 
Database Application 
http://crispr.mit.edu/ CRISPR design 
http://mfeprimer.igenetech.com/ Primer quality control 
http://multalin.toulouse.inra.fr/multalin/ Sequence alignment 
http://www.uniprot.org/ General protein data 
https://blast.ncbi.nlm.nih.gov/Blast.cgi Sequence Alignment 
https://thebiogrid.org/ Protein-Protein Interactions 
https://www.ensembl.org/index.html Genomic and mRNA data 
https://www.ncbi.nlm.nih.gov/ Genomic and mRNA data 
https://www.ncbi.nlm.nih.gov/tools/primer-blast/ Primer design 
https://www.proteinatlas.org/ Protein expression data 
     
2.1.3 Consumables 
 
Table 4: Consumables used in this study. 
Name Manufacturer 
1.5 ml, 2 ml reaction tubes Greiner bio-one 
10 ml syringes BD Biosciences 
14 ml, 15 ml, 20 ml reaction tubes Greiner bio-one 
2 ml, 5 ml, 10 ml, 25 ml serological pipettes Greiner bio-one 
5 ml flow cytometry tubes Sarstedt 
6-, 12-, 24-, 96-well suspension culture plates Greiner bio-one 
60 mm, 100 mm, 145 mm cell culture plates Greiner bio-one 
Cryo tubes Greiner bio-one 
Electroporation cuvettes Peqlab 
Filter tips Greiner bio-one 
Nitrocellulose membrane Hybond ECL Amersham Biosciences 
Parafilm American national can 
PCR tubes 0.2 ml Sarstedt 
Pipette tips Greiner bio-one 
Sterile filter Filtropur, S 0.2, S 0.45 Sarstedt 
Whatman filter paper GE Healthcare 
Minisart® filter 0.45 Sartorius 
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2.1.4 Chemicals and reagents 
 
All chemicals and solutions, which are only mentioned in the corresponding method section, were 
purchased from Carl Roth, Sigma or Merck, if not stated otherwise. Further reagents and solutions 
are specified in Table 5. 
 
Table 5: Chemicals and reagents. 
Name Manufacturer 
100x Bovine Serum albumin NEB 
Agarose Peqlab 
Bleomycin Calbiochem 
Bovine Serum albumin Serva 
Cytofix™ Fixation Buffer Becton Dickinson 
Deoxynucleoside triphosphate (dNTP) mix NEB 
DNA Ladder GeneRuler 1 kb Fermentas 
Fetal Calf Serum (FCS) Biochrom 
Fetal Calf serum (FCS), dialyzed PAN biotech 
Indo-1 AM Life technologies 
L-Arginine:HCL (13C6 15N4) Cambridge Isotype Laboratories, Inc 
L-Lysine:2HCL (13C6 15N2) Cambridge Isotype Laboratories, Inc 
NEBuffer 1, 2, 3, 4, Cutsmart NEB 
Pluronic F-127 Life technologies 
Prestained Protein Ladder PageRuler Plus Thermo Scientific 
Puromycin InvivoGEN 
RetroNectin® Clonetech 
T4-Ligase Buffer NEB 
Tans-IT X-239 Mirus 
Trypan blue solution (0.4%) Thermo Scientific 
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2.1.5 Buffers and solutions 
 
Table 6: Buffers and solutions. 
Name Composition 
Antibody dilution solution 1% BSA, 0.01% NaN3, in TBS-T 
Blocking solution 5% BSA, 0.01% NaN3, in TBS-T 
Blotting buffer 48 mM Tris, 39 mM glycine, 0.0375% SDS, 0.001% NaN3, 
20% MeOH, in ddH2O 
 
DNA loading buffer (6x) 60 mM EDTA (pH 8.0), 10 mM Tris/HCl (pH 7.6), 60% glycerol, 
0.03% bromophenol blue, in ddH2O 
 
ECL solution  4 ml ECL solution A, 400 µl ECL solution B, 1.2 µl H2O2 (30%) 
ECL solution SA 100 mM Tris/HCl pH 8.6, 0.28 mM Luminol 
ECL solution SB 6.7 mM p-coumaric acid in 100% DMSO, stored in the dark 
HeBS 20 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM 
dextrose, in ddH2O 
 
Krebs-Ringer buffer 140 mM NaCl, 10 mM D-Glucose, 10 mM HEPES, 4 mM KCl, 1 mM 
CaCl2, in ddH2O 
 
Laemmli buffer (5x) 150 mM Tris-HCl (pH 6.8), 15% SDS, 50% glycerol, 0.05% 
bromophenol blue, 0.5 M DTT, in ddH2O 
 
NP-40 lysis buffer 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, add fresh: 5 mM NaF, 
0.5% NP-40, 1mM sodium orthovanadate, 1:50 protease inhibitor 
cocktail, in ddH2O 
 
PBS (1x) 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4x12H2O, 1.4 mM 
KH2PO4 (pH 6.6) 
 
Pervanadate solution 50 µl 50 mM PerVO4 and 15 µl 30% H2O2 were mixed and 
incubated for 5 min at RT. Then, 520 µl H2O was added and the 
solution was used 1:50. 
 
Resolving gel buffer 1.5 M Tris-HCl (pH 8.8), 14 mM SDS, in ddH2O 
RIPA lysis buffer (modified) 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 
0.1% sodium deoxycholate, add fresh: 1:50 protease inhibitor 
cocktail, 5 mM β-glycerophosphate, 5 mM NaF, 1 mM sodium 
orthovanadate, 10 mM N-ethylmaleimide (prepare fresh every 
time), in ddH2O 
 
SDS-PAGE buffer 25 mM Tris, 192 mM glycine, 0.1% SDS, in ddH2O 
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Stacking gel buffer 0.5 M Tris-HCl (pH 6.8), 14 mM SDS, in ddH2O 
TAE (1x) 40 mM Tris, 20 mM glacial acetic acid, 1 mM EDTA, in ddH2O 
TAG lysis buffer 10 mM Tris (pH 8.0), 50 mM KCl, 0.45% NP-40, 0.45% Tween 20, 
in ddH2O 
 
TBS-T (1x) 20 mM Tris, 137 mM NaCl (pH 7.6), 0.1% Tween 20, in ddH2O 
Urea lysis buffer  20 mM HEPES (pH 8.0), 9 M urea, 1 mM sodium orthovanadate, 
2.5 mM sodium pyrophosphate, 1mM β-glycerophosphate 
 
2.1.6 Enzymes 
 
Table 7: Enzymes used in this study. 
Enzyme Manufacturer 
Calf-intestine phosphatase (CIP) NEB 
PasI Thermo Scientific 
Phusion® DNA polymerase NEB 
 Proteinase K  Macherey-Nagel 
restriction endonucleases NEB 
 T4 DNA ligase  NEB 
 T4 DNA polymerase  NEB  
 Taq DNA polymerase  NEB 
 Taq PCR Master Mix   Qiagen 
 
2.1.7 Oligonucleotides 
 
Table 8: Synthetic oligonucleotides used in this study. 
Oligonucleotides Sequence  Application 
ARFGEF2_cDNA_fw TCAAAACCCCAGTCCCCTGT CRISPR clone analysis 
ARFGEF2_cDNA_rev TATCCACAACACACTGGGCATC CRISPR clone analysis 
ARFGEF2-1_fw AGCGGAAAAGCATGGTCTGA CRISPR activity test 
ARFGEF2-1_rev AGCCCAGGACTGTGTGACTA CRISPR activity test 
ARFGEF2-2_fw GAAGGACCCAACTCATGCCA CRISPR activity test 
ARFGEF2-2_rev CGTGAGTCCTGAATACGGGG CRISPR activity test 
EGFP-C1_fw GTCCTGCTGGAGTTCGTG Sequencing 
NCK1_cl_fw_BglII TAATAGATCTCATGGCAGAAGAAGTGGTGGTAGTA Cloning 
NCK1_cl_rev_NotI TAATGCCGCCGCTCATGATAAATGCTTGACAAGATA Cloning 
NCK1_fw GGATACCTTAGGCATTGGAAAAGTG CRISPR activity test 
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Oligonucleotides Sequence  Application 
NCK1_mRNA_fw AAGAGGACATGAAGGGGATTTCC Expression analysis 
NCK1_mRNA_rev CAGTCACTTCTGGTCAGCAGTAT Expression analysis 
NCK1_rev AGGTTATTGACGACTGCTGCTAA CRISPR activity test 
 NCK2.1_seq_fw GACCGCATCTACGACCTCAAC  CRISPR activity test 
NCK2.1_seq_rev CCGGTGTAGCTTATCTGTGGG CRISPR activity test 
NCK2_mRNA_fw TAAAGCGTCAGGGAAGAACAAAC Expression analysis 
NCK2_mRNA_rev GACCAAGCGACCTGAACATAAAG Expression analysis 
pLU6_rev TGGATCTCTGCTGTCCCTGT Sequencing 
pMSCV-for CCCTTGAACCTCCTCGTTCGACC Sequencing 
pMSCV-rev GAGACGTGCTACTTCCATTTGTC Sequencing 
sgARFGEF2.1 GGAAAGGACGAAACACCGGCAACGGGATAGCCGATGA
CGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG 
 
 CRISPR LIC assembly 
sgARFGEF2.2 GGAAAGGACGAAACACCGGTCCCATGAGCTGCGTTCC
AGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG 
 
CRISPR LIC assembly 
sgNCK2.1 GGAAAGGACGAAACACCGCGAGAAGGGGGAGACCAT
GGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG 
 
CRISPR LIC assembly 
 SHIP2_mRNA_fw  GTACCACCGCGACCTGAG  CRISPR clone analysis 
SHIP2_mRNA_rev CCATTGGGAGCACTCTCAGCA CRISPR clone analysis 
universal reverse oligo AACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAA
AAC 
CRISPR LIC assembly 
 
2.1.8 Plasmids 
 
Table 9: CRISPR plasmids used for transient expression. 
Vector Source 
 pLU6-CMV-GFP  Dr. T. Schmidt 
pLU6 sghNck1-CMV-GFP Dr. T. Schmidt 
pLU6-sghNck2.1-CMV-GFP This thesis 
pLU6-sghSHIP2-CMV-GFP Dr. T. Schmidt 
pLU6-sghARFGEF2.1-CMV-GFP This thesis 
pLU6 sghARFGEF2.2-CMV-GFP This thesis 
 pRZ-CMV-mCherry-Cas9  Dr. T. Schmidt 
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Table 10: Expression plasmids used in this study.  
Cit (Citrin-tag), puro (puromycin resistance), bleo (bleomycin resistance), *linearized using ScaI HF. 
Vector cDNA  Source 
LT3-GECIR shCD79a-1 Dr. C. Doebele, backbone Dr. J. Zuber 
LT3-GECIR shGL2 Mohr et al. 2017, backbone Dr. J. Zuber 
pApuro II  hARFGEF2* Dr. M. Engelke 
pcDNA3.1-HisC hSHIP2 Prof. C. Erneux 
pcDNA3-HA hNck1 Addgene #45892 (Kebache et al. 2002) 
pcDNA4-HisMax-C hBIG2 Prof. K. Nakayama 
pCMV ΔR8.91 Dr. C. Doebele (Zufferey et al. 1997) 
 pCR2.1  hNck1  This thesis 
pCR2.1 hSHIP2 This thesis 
pCR2.1 hARFGEF2 This thesis 
phCMV VSV-G  Addgene #8454 (Stewart et al. 2003) 
phCMV GAL-V Collins et al. 1996 
pMSCV-bleo-RFP chNck2 Dr. M. Engelke 
pMSCV-puro EGFP Dr. M. Engelke 
pMSCV-puroCit hNck1 This thesis 
pMSCV-puroCit hSHIP2 Dr. M. Engelke 
pMSCV-puroCit chNck2 Dr. M. Engelke 
 
 
2.1.9 Reaction Systems (Kits) 
 
Table 11: Ready-to-use kits used in this study. 
Kit Manufacturer 
Amaxa®Cell Line Nucleofector® Kit L Lonza 
APC Annexin V Apoptosis Detection Kit with PI Biolegends 
Cell Proliferation Assay XTT, BC Applichem 
Nucleobond® XTRA Midi EF Plasmid Kit Macherey-Nagel 
Nucleospin® Gel and PCR Clean-up Kit Macherey-Nagel 
Nucleospin® Plasmid easy pure Kit Macherey-Nagel 
Nucleospin® RNA  Macherey-Nagel 
One Taq® RT-PCR Kit NEB 
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Kit Manufacturer 
ProtoScript® First Strand cDNA Synthesis Kit NEB 
TA™ cloning Kit with pCR™2.1 Invitrogen 
 
2.1.10 Antibodies 
 
Table 12: Primary antibodies used for Western blot analysis.  
Antibodies were diluted in 1% BSA and 0.01% NaN3 according to the manufacturer’s instructions.  
Antibody Isotype  Manufacturer 
α-actin IgG2b CST 
α-ARFGEF2 rabbit Abcam 
α-BCAP (E-5) mouse IgG1 Santa Cruz 
α-CD79a (EP3618) rabbit Abcam 
α-c-MYC mouse IgG1 Biolegends 
α-GFP mouse IgG1 Roche Diagnostics 
α-Grb2 (3F2) mouse IgG1 Millipore 
α-JNK rabbit CST 
α-Nck (2) (8.8) mouse IgG2b Santa Cruz 
α-Nck1 (15B9) rabbit CST 
α-pAkt (S473) (D9E) rabbit CST 
α-pan Akt (40D4) mouse IgG1 CST 
α-pan Erk (Clone16) mouse IgG2a Becton Dickinson 
α-pCD79a (Y182) rabbit CST 
α-pErk (T202/Y204) rabbit CST 
α-pFOXO1 (T24)/FOXO3 (T32) rabbit CST 
α-pJNK (T183/Y185) (G9) mouse IgG1  CST 
α-pp38 (T180/Y182) mouse IgG1 Becton Dickinson 
 α-pp85 (Y458)/p55 (Y199)  rabbit  CST 
α-pPTEN (S380/T382/383) rabbit CST 
α-pSyk (Y525/Y526) rabbit CST 
α-SHIP1 rabbit CST 
α-SHIP2 (C76A7) rabbit CST 
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Table 13: Secondary antibodies used for Western blot analysis. Antibodies were diluted 1:10000 in TBS-T. 
Antibody Isotype  Manufacturer 
α-mouse IgG - HRPO goat Southern Biotech 
α-mouse IgG1 - HRPO goat Southern Biotech 
α-mouse IgG2a - HRPO goat Southern Biotech 
α-mouse IgG2b - HRPO goat Southern Biotech 
α-rabbit IgG - HRPO goat Southern Biotech 
 
Table 14: Antibodies used for flow cytometry or stimulation.  
Antibody Fluorochrome Isotype  Manufacturer 
F(ab’)2 goat α-human IgG + IgM n/a goat Dianova 
α-human IgM APC mouse IgG1 Southern Biotech 
α-pJNK (T183/Y185) Alexa Fluor® 647 mouse IgG1 Becton Dickinson 
 
 
2.1.11 Inhibitors 
 
Table 15: Inhibitors. 
Inhibitor Solvent Manufacturer 
AS1949490 (SHIP2 Inhibitor) DMSO Sigma 
Wortmannin (PI3K inhibitor) DMSO Tocris 
 
 
2.1.12 Bacteria and bacteria medium 
 
Table 16: Bacterial strains used in this study. 
Bacterial Strain Manufacturer 
One Shot TOP10F’ chemically competent E.coli Invitrogen 
Electrocomp™ GeneHogs® E.coli Invitrogen 
 
For amplification of plasmid DNA, E.coli were grown in lysogeny broth (LB) medium (10 g/l tryptone 
peptone, 5 g/l yeast extract, 5 g/l NaCl, pH 7). Before use, LB medium was autoclaved for 30 min at 
121°C, 1.25 bar. For production of agar plates, 2% agar-agar was added to the LB medium. For 
selection, medium was supplemented with 100 µg/ml ampicillin or 50 µg/ml kanamycin. 
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2.1.13 Eukaryotic cell lines and cell culture media 
 
 
DG75 (DSMZ: ACC-83) 
Human Burkitt lymphoma cell line of the sporadic subtype derived from the pleural effusion from a 
10-year old Caucasian boy with refractory, terminal Burkitt lymphoma in 1975 (Ben-Bassat et al. 
1977). DG75 cells a have a t(8;14)(q24;q32) translocation and have no mutation in TP53, coding for 
p53 (Wiman et al. 1991). They express IgM paired with a ĸ light chain and are negative for EBV 
(Gabay et al. 1999). 
 
Daudi (DSMZ: ACC-78) 
Human Burkitt lymphoma cell line of the endemic subtype derived in a left orbital biopsy of a 16-
year old African boy with Burkitt lymphoma (Klein et al. 1968). Cells express IgM paired with a ĸ 
light chain and are positive for EBV, but infection is classified as a latent infection without production 
of active viruses. Daudi cells have a nonsense mutation in TP53, a confirmed t(8;14)(q24;q32) 
translocation and an inactivating ID3 mutation (Kreck et al. 2013; Gaidano et al. 1991).  
 
BL60 
Human Burkitt lymphoma cell line of the endemic subtype derived in a maxillary biopsy from a north 
African 4-year old girl (Bornkamm et al. 1984). Cells express IgM, are positive for EBV and have a 
(8;22) chromosomal translocation and a mutation in TP53 (Gaidano et al. 1991). 
 
HEK293T/17 (ATTC: CRL-11268) 
In this study, HEK239T/17 cells were used for generation of lentiviral particles. They are derived from 
the HEK293T cell line, established from a primary embryonal kidney and transformed with 
adenovirus type 5 (Russell et al. 1977). HEK293T/17 cells constitutively express a temperature 
sensitive simian virus large T antigen and clone 17 was chosen for high transfection levels (Pensiero 
et al. 1999).  
 
Platinum-E (PlatE) 
In this study, PlatE cells were used for generation of retroviral particles. Plat-E is a HEK293T-derived 
packaging cell line stably transfected with the moloney murine leukemia virus (MMLV) packaging 
genes gag, pol and env (Morita et al. 2000). The Plat E system is an ecotropic packaging system but 
retroviral particles can be pseudotyped by co-transfecting the envelope glycoprotein of vesicular 
stomatitis virus (VSV-G) for infection human cell lines.  
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Table 17: Knock-out cell lines generated in this study.  
Parental cell line Genetic background 
DG75 Nck1-/- 
Nck2-/- 
Nck1-2-/- 
 
Daudi SHIP2-/- 
BIG2-/- 
 
BL60 SHIP2-/- 
 
 
Table 18: Media for eukaryotic cell lines.  
Medium Company Cell type  Supplements 
DMEM Merck Millipore PlatE 
HEK293T/17 
10% FCS 
1% Penicillin/Streptomycin 
1 mM L-glutamine 
 
RPMI 1640 Merck Millipore DG75, Daudi, 
BL60 
10% FCS  
(1% FCS for apoptosis assays) 
(5% FCS for XTT proliferation assays)  
(20% FCS for stressed cells to recover) 
1% Penicillin/Streptomycin 
1 mM L-glutamine 
50 µM β-mercaptoethanol 
 
SILAC RPMI 
1640 
Thermo Scientific  10% dialyzed FCS 
0.115 mM L-arginine (13C6 15N4) 
0.27 mM L-lysine (13C6 15N2) 
1 mM L-glutamine 
0.2 g/l L-proline 
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2.2 Methods 
2.2.1 Molecular Biology  
 
If not stated otherwise standard molecular biology methods were performed as recommended by 
the manufacturer’s protocol or as described in “Molecular Cloning: A Laboratory Manual” 
(Sambrook & Russell 2001). 
 
2.2.1.1   Isolation of genomic DNA 
 
To isolate genomic DNA of human B cell lines, 1x106 cells were washed once with PBS and 
subsequently lysed in 200 µl TAG lysis buffer containing 1 µl proteinase K (20 mg/ml, Macherey-
Nagel) for at 56°C for 3 h followed by heat-inactivation at 95°C for 15 min. Samples were either 
directly used for polymerase chain reaction (PCR) or stored at 4°C until further use. 
 
2.2.1.2   Generation of cDNA 
 
Isolation of mRNA 
 
For isolation of mRNA the NucleoSpin® RNA reaction kit (Macherey-Nagel) was used. Concentration 
of mRNA was measured by the NanoDrop 2000 (Thermo Scientific). mRNA was either directly used 
for reverse transcription into cDNA or stored at -80° C. 
 
Reverse transcription of mRNA 
 
Reverse transcription of mRNA into cDNA was performed using the ProtoScript® First Strand cDNA 
Synthesis Kit or the One Taq® RT-PCR Kit (NEB). cDNA was directly used for PCR or stored at -20°C. 
 
2.2.1.3   Polymerase chain reaction (PCR) 
 
Polymerase chain reaction is used to rapidly amplify specific DNA sequences in vitro (Mullis et al. 
1986). Here, PCR was used to generate DNA sequences harboring specific restriction sites for cloning 
purposes or for analytical purposes to amplify potential sites of double-strand breaks induced by 
CRISPR/Cas9 gene editing. 
Phusion® DNA polymerase (NEB) was used to amplify DNA for cloning purposes, since it harbors a 
proof-reading activity. The reaction set up is depicted in Table 19. 
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Table 19: Composition of the PCR reaction mix for cloning. 
Reagent Volume [ul] Final concentration 
5x Phusion HF buffer 10 1x 
dNTPs (10 mM, NEB) 1 200 µM 
Forward primer (10 µM) 2.5 0.5 µM 
Reverse primer (10 µM) 2.5 0.5 µM 
Template 1 50-200 ng/µl 
Phusion polymerase (2000 U/ml, NEB) 0.5 1 U/reaction 
ddH2O  to final volume of 50 µl  
 
To study potential sites modified by CRISPR/Cas9 gene editing, the Taq PCR master mix (Qiagen) was 
used due to its easy reaction set up. As the master mix already contains the Taq polymerase, the 
adequate buffer and dNTPS, only the template with its corresponding primers and ddH2O needed 
to be added (Table 20). The standard PCR programs for both Phusion and Taq polymerase are 
depicted in Table 21. The annealing temperature was adjusted 3-5°C below the lowest primer 
melting temperature (Tmprimer). 
 
Table 20: Composition of the PCR reaction mix for analytical purposes. 
Reagent Volume [ul] Final concentration 
2x Taq PCR master mix 5 1x 
Forward primer (100 µM) 0.1 1 µM 
Reverse primer (100 µM) 0.1 1 µM 
Template 1 50-200 ng/µl 
ddH2O  to final volume of 10 µl  
 
Table 21: Standard PCR programs. 
 Step PCR with Phusion® polymerase PCR with Taq polmerase 
 Initial denaturation 98°C, 30 s 94°C, 2 min 
 Denaturation 98°C, 10 s 94°C, 20 s 
35x Annealing x°C*, 30 s x°C *, 30 s 
 Extension 68°C, 30 s/kb 72°C, 60 s/kb 
 Final Extension 68°C, 2-fold extension time 72°C, 2-fold extension time 
 Stop 10°C, ∞ 10°C, ∞ 
* Annealing temperature = Tmprimer-3-5°C 
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Primers were designed by using the web-based Primer-BLAST program (NCBI). Common guidelines 
were considered for primer design (Primer guidelines, Howard Judelson, 10.06, p. 1) which include 
a Tm between 55°C and 65°C, which usually corresponds to a base composition 50-60% (G+C) and 
a primer length of 17-28 bp, if possible. To avoid mispriming, low specific binding at the 3’ end was 
considered as well as lack of secondary priming sites in the template. Dimerization and hairpin 
formation capability was kept to a minimum. To this end, primers were additionally checked for 
formation of secondary structures using the web-based program MFEprimer-3.0. Primers were 
ordered and synthesized by eurofins MWG. 
 
2.2.1.4   Enzymatic digest of DNA 
 
Site-directed enzymatic digest of plasmid DNA or PCR products was either used to obtain DNA 
fragments containing the desired sequence for molecular cloning or to screen for alterations in the 
genomic DNA induced by CRISPR/Cas9 genome editing. DNA was incubated with the respective 
restriction enzyme(s) (NEB or Thermo Scientific) according to the manufacturer’s recommendations 
for 1-2 h. Samples were subjected to agarose gel electrophoresis followed by gel extraction of the 
desired DNA fragments if necessary. 
 
2.2.1.5   Agarose gel electrophoresis 
 
PCR products or plasmid DNA were separated using agarose gel electrophoresis. 1-2% (w/v) agarose 
was melted in Tris-acetate-EDTA (TAE) buffer, cooled down to ~50°C before ethidium bromide (Roth) 
was added to a concentration of 0.5 µg/ml. Agarose gels were casted and samples were mixed with 
6x DNA loading buffer (NEB) before loading. Gels were run at 220mA and 100V for 30-45 min and 
visualized using UV light. 
 
2.2.1.6   Purification of DNA from agarose gels or PCR reactions 
 
Extraction of DNA was performed using the NucleoSpin® Gel and PCR Clean-Up system (Macherey-
Nagel). DNA samples were eluted in 15-30 µl of 5mM Tris-HCl (pH 8.5) and were either directly used 
or stored at -20°C.  
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2.2.1.7   Ligation of DNA fragments 
 
After enzymatic digest and purification, DNA inserts and vector backbones were ligated using T4 
DNA ligase (NEB). In case only one restriction enzyme was used, the vector backbone was 
additionally treated with calf intestine phosphatase for 1h at 37°C. Calf intestine phosphatase 
removes the 5’ and 3’ phosphate groups from DNA thereby preventing vector self-ligation. Ligation 
reactions were either incubated for 1h at RT or overnight at 16°C before proceeding with 
transformation of bacteria. 
 
2.2.1.8   Transformation of chemically competent bacteria 
 
To amplify bacterial plasmid DNA, E.coli TOP10F’ and GeneHog (50 µl) were transformed using a 
pre-existing plasmid (1-2 µl) or ligation reaction (5-10 µl). After 30 min incubation on ice, heat-shock 
was performed at 42°C for 45 s followed by an incubation on ice for 5 min. For recovery, 200 µl pre-
warmed antibiotic-free LB medium was added and samples were incubated on a shaker at 37°C for 
30 min. Bacteria were plated on agar-plates containing the appropriate antibiotic and cultured 
overnight at 37°C. For transformations of E.coli TOP10F’ using the pCR2.1 plasmid, blue-white 
screening was performed by equally distributing 50 µl X-gal (5-bromo-4-chloro-3-indolyl-beta-D-
galacto-pyranoside, 50 mg/ml in DMF) and 50 µl IPTG (isopropyl-β-D-thiogalacto-pyranoside, 0.1M) 
on agar plates prior to plating bacteria. 
 
2.2.1.9   Preparation of plasmid DNA 
 
Mini Preparation 
 
To isolate plasmid DNA from bacteria, 4 ml of LB medium containing the appropriate antibiotic 
(100µg/ml ampicillin or 50µg/ml kanamycin) were inoculated with a single E.coli colony and 
incubated overnight with constant agitation at 37°C. Plasmid DNA was isolated using the 
NucleoSpin® Plasmid Easy Pure kit. 
 
Midi Preparation 
 
To obtain higher yields of bacterial plasmid DNA, 4 ml LB medium containing an E.coli colony was 
prepared as described above and incubated for 8 h with constant agitation at 37°C. This pre-culture 
was then used to inoculate 200 ml of LB medium with the same antibiotic. Bacteria cells were grown 
overnight with constant agitation at 37°C. Isolation of bacterial plasmid DNA was performed using 
the NucleoBond® Xtra Midi EF Plasmid kit. DNA was eluted in 100-200 µl nuclease free H20. 
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2.2.1.10   Sequencing of DNA 
 
Validation of plasmids and PCR products was performed by the company Microsynth Seqlab 
(Sequence Laboratories, Göttingen). Samples were prepared mixing 1.2 µg of DNA, 0.3 µl of primer 
(100 pmol/µl) and ddH2O to a final volume of 12 µl.  
 
2.2.1.11   CRISPR/Cas9 genome editing 
 
To generate stable “knockout” cell lines, the Clustered Regularly Interspaced Palindromic Repeats 
(CRISPR)/Cas9-based genome editing was used. The CRISPR/Cas system was originally discovered 
as a microbial adaptive immune response in bacteria and archaea which utilizes RNA-guides 
nucleases to cleave foreign genetic elements such as plasmids and viruses (Ran et al. 2013; Deveau 
et al. 2010; Garneau et al. 2010; Horvath & Barrangou 2010; Bhaya et al. 2011). The CRISPR/Cas9 
technique uses a single-guide RNA (sgRNA) that binds to a target DNA through Watson-Crick base 
pairing to guide the Cas9 nuclease to the target site (Figure 4). The Cas9 nuclease (derived from 
Streptococcus pyrogenes) recognizes the protospacer adjacent motif (PAM, 5’NGG) sequence and 
induces a double strand break (DSB) between the 17th and 18th base in the target sequence (3 bp 5’ 
of the PAM) (Jinek et al. 2012). DSB are re-ligated by the cell’s DNA repair machinery via 
nonhomologous end joining (NHEJ) which in many cases induces errors in the form of 
insertion/deletion (indel) mutations. As indel mutations in exons often lead to frameshift and 
premature stop codons, the CRISPR/Cas9 technique is especially suitable to induce gene knockouts 
(Ran et al. 2013). 
 
Figure 4: Schematic depiction of CRISPR/Cas9 gene editing.  
The Cas9 nuclease is targeted to genomic DNA by an sgRNA, which consist of a 20-nucleotide guide sequence 
and a scaffold, forming a hairpin structure (violet). The guide aligns with the target DNA upstream of the PAM 
(5’NGG motif; orange). Cas9 induces a DSB ~ 3 bp upstream of the PAM sequence. The endogenous and error-
prone DNA repair machinery of the cell rejoins and repairs the DNA ends via nonhomologous end joining 
(NHEJ; pink), leading to indel mutations (modified from Ran et al. 2013). 
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Ligation-independent cloning assembly for sgRNA expression 
 
Ligation-independent cloning (LIC) assembly was used to generate vectors expressing an sgRNA for 
CRISPR/Cas9-genome editing from synthesized ssDNA. The sgRNA sequence was selected using the 
CRISPR Design software (http://crispr.mit.edu/) based on a high sore for specificity and a restriction 
site to evaluate the activity of editing. The ssDNA was ordered from MWG and used for LIC assembly 
with pLU6-sgRNA-CMV-GFP as described previously (Schmidt et al. 2015). 
 
CRISPR/Cas9 activity Test 
 
Following electroporation (see section 2.2.3.4), a batch of sorted cells were expanded and genomic 
DNA was isolated as described in section 2.2.1.1. to test for the activity of the CRISPR constructs. 
Therefore, the loci spanning the sgRNA sequence were amplified by PCR and an enzymatic digest 
with the appropriate enzyme was performed according to the manufacturer’s instructions. Samples 
were analyzed by agarose gel electrophoresis. Active CRISPR/Cas9 constructs alter the genomic DNA 
leading to absence of the restriction site and hence to incomplete digest with the respective 
restriction enzyme. 
 
Screening of CRISPR/Cas9 clones 
 
In order to obtain single cell clones, sorted cells were seeded in 96-well plates at a concentration of 
0.6 cells per well in 20% FCS culture medium. Cells were expanded and analyzed either using the 
CRISPR/Cas9 activity test (see section) or analyzed for the deficiency of the respective protein by 
Western Blot analysis (2.2.2.4). Single cell clones lacking the protein of interest were subjected to 
sequence analysis. Therefore, primers spanning the genomic loci were used to amplify either 
genomic DNA or cDNA via PCR. PCR products were cloned into pCR2.1 to distinguish individual 
sequences. Cells were considered to be deficient for the respective protein, if both alleles showed 
an alteration, leading to a premature stop codon.  
 
2.2.2 Biochemistry 
 
2.2.2.1   Stimulation of B cells 
 
To analyze BCR stimulation events, cells were harvested and washed once with PBS and counted. 
They were then starved in serum-free RPMI at 37°C for 20 min at 650 rpm to reduce the stimulatory 
effects of FCS. After starvation, cells were either stimulated with 5-10 µg/ml F(ab’)2 goat α-human 
IgG/IgM for indicated times or left unstimulated.  For analysis of phosphorylation events after SHIP2 
inhibition, cells were incubated with 5 µM AS1949490 for 30 min during starvation. To identify 
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general protein phosphorylation, cells were starved and incubated for 10 min with the phosphatase 
inhibitor pervanadate (1:50). After stimulation, cells were quickly moved to ice and then pelleted at 
4°C. The supernatant was removed and cells were subjected to cellular lysis (refer to 2.2.2.2). 
 
2.2.2.2   Preparation of cleared cellular lysates 
 
For preparation of cleared cellular lysates (CCLs), cells were lysed in 15-20 µl of 0.5% NP40 lysis 
buffer per 1x106 cells. Samples were incubated on ice for at least 25 min. If higher cell numbers cells 
were used, lysis was performed at 4°C under mild agitation. After cell lysis, nuclei and cell debris 
were pelleted by centrifugation (16000 rcf, 4°C for 30 min) and the supernatant was collected and 
mixed with 0.25 volumes of 5x Laemmli buffer. Samples were then boiled at 95°C for 5 min and 
stored at -20°C until further use.  
 
2.2.2.3   SDS polyacrylamide gel electrophoresis 
 
To separate proteins from CCL samples, discontinuous SDS polyacrylamide gel electrophoresis 
(PAGE) was performed. It allows separation of proteins according to their size and is based on a 
protocol originally described by Weber & Osborn in 1969. The discontinuous gel system consists of 
a stacking gel (5% acrylamide) to concentrate the proteins before they are separated in the resolving 
gel (10% acrylamide) (Table 22). 
 
 
Table 22: Composition of Resolving and Stacking gel. *TEMED and APS were added just before pouring. 
Reagent Resolving Gel Stacking Gel 
Resolving gel Buffer 
375 mM Tris/HCl (pH 8.8), in 
ddH2O 
 
Stacking gel Buffer  
125 mM Tris/HCl (pH 6.8) in 
ddH2O 
Acrylamide/bis-Acrylamide 10 % 5 % 
SDS 0.1% 0.1% 
TEMED* 0.1% 0.1% 
10 % APS* 10% 10% 
ddH2O add to final volume add to final volume 
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Gels were casted in between two glass plates starting with adding the mix for the resolving gel. 
Isopropanol was used to flatten the surface of the gel and to prevent oxygen diffusion into the gel. 
After polymerization, the isopropanol layer was discarded and the mix of the stacking gel was added. 
A comb was placed on top to form sample wells. Once the stacking gel polymerized, gels were ready 
for gel electrophoresis using the Mini-PROTEAN system (Bio Rad). Samples were boiled for 5 min at 
95°C prior to loading and were run alongside Page Ruler Prestained protein Ladder (Thermo 
Scientific) to determine the molecular weight of proteins. Gels were run using SDS running buffer 
at a current of 10 mA/gel. After the samples reached the resolving gel, the current was increased to 
20 mA/gel. Once the dye front migrated to the bottom of the gels, gels were subjected to 
immunoblotting. 
 
2.2.2.4   Western Blot analysis 
 
For detection of proteins separated by SDS PAGE, proteins were transferred to a nitrocellulose 
membrane by using semi-dry western blot (Towbin et al. 1989). The gel, nitrocellulose membrane 
and two pieces of Whatman paper were equilibrated in 1x blotting buffer.  The gel and nitrocellulose 
membrane were then placed between the Whatman papers to facilitate the transfer of negatively 
charged proteins onto the membrane. Air bubbles were removed by rolling the stack with a pipette. 
The transfer was performed at 16V, 240 mA for 70 min.  
 
After successful transfer, the membrane was incubated with 5% bovine serum albumin (BSA) in 
TBS-T + 0.1% NaN3 for 1 h at 4°C or at least 30 min at RT at constant agitation. Primary antibodies 
were diluted according to the manufacturer’s instructions in 1% BSA in TBS-T + 0.01% NaN3. 
Incubation with the primary antibody was performed at 4°C overnight at constant agitation. After 
washing the membrane 3-4 x with TBS-T for 10-15 min, the secondary HRPO-conjugated antibody 
was added at a dilution of 1: 10,000 in TBS-T and incubated for 1 h at RT. The membrane was then 
washed again 3-4 x with TBS-T for 10-15 min. The proteins were visualized using an enhanced 
chemoluminescence (ECL) solution. In presence of H2O2, the HRPO catalyzes the oxidation of 
luminol resulting in emission of light. The emitted chemoluminescence was detected by the 
ChemiLux Gel Imager (Intas). In case the membrane was to be incubated with another primary 
antibody, the HRPO was inactivated by incubation of 1% NaN3 in TBS-T for 1 h, followed by washing 
3-4 x with TBS-T for 10-15 min before adding the antibody.  
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2.2.3 Cell Biology 
 
2.2.3.1   Cell culture and maintenance 
 
All cell culture work was carried out under aseptic conditions using a laminar-flow clean bench. Cells 
were cultured in the appropriate cell culture media (see 2.1.13) at 37°C and 5% CO2 in a humidified 
incubator. For maintenance, DG75 and BL60 were passaged every other day 1:10. Daudi cells were 
usually passaged daily 1:3-1:4. For passaging of adherent Plat-E cells, cells were detached by adding 
0.05% trypsin-EDTA (Thermo Fisher Scientific) and plated 1:5-1:10 every other day. Cells were 
counted using a Neubauer improved counting chamber by mixing the cell suspension with an equal 
volume of 0.4% trypan blue solution to distinguish between living and dead cells. If not indicated 
otherwise, all centrifugation steps were carried out at 300 rcf for 4 min at RT. 
 
2.2.3.2   Storage and revitalization of cells 
 
For long term storage of cells, cells were resuspended in freezing medium (10% DMSO in FCS) at a 
density of approximately 5x106 cells per ml. Cryotubes were stored at -80°C in a polystyrene box 
before being transferred to -150°C for long-term storage. Frozen cell stocks were thawed in a 37°C 
water bath and quickly transferred into pre-warmed medium. Subsequently, cells were centrifuged 
and resuspended in fresh culture medium.  
 
2.2.3.3   SILAC labeling of human B cell lines 
 
To identify changes in the phospho-proteome of “knockout” cells, cells were labeled for quantitative 
mass spectrometry in SILAC RPMI-1640 medium devoid of arginine and lysine containing either 
“heavy” amino acids 0.115 mM L-arginine (13C6,15N4) (+10) and 0.27 mM L-lysine (13C6,15N2) (+8) or 
“light” non-labeled amino acids (Sigma). Additionally, the medium was supplemented with 10-20% 
dialyzed FCS, Penicillin/Streptomycin, 1 mM L-glutamine and 0.2 g/l L-proline. Expansion of cells for 
7-13 days in their respective medium ensured complete incorporation of amino acids. Cells were 
harvested at 300 rcf, RT, for 4 min, washed 1-2x in PBS and 1x107 cells were lysed in Urea Buffer at 
RT for phospho-tyrosine enriched analysis. For global phospho-proteome analysis, 5x106-1x107 cells 
were lysed in modified RIPA buffer at 4°C on ice for 30 min. To ensure lysis of nuclei, all samples 
were passed through a 20G needle 5-10 times before freezing them at -80°C until further processing. 
Samples were sent for mass spectrometry analysis to the DKTK Proteomics Core Facility, University 
Hospital Frankfurt. There, samples were separated by size by SDS-PAGE and processed for 
quantitative mass spectrometry analysis as described in Corso et al. 2016. 
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2.2.3.4   Electroporation of human B cells lines 
 
For transient transfection of cells, 1x107 cells were washed twice with cold PBS, resuspended in 
700 µl serum-free RPMI-1640 and transferred to an electroporation cuvette.  Subsequently, 12.5 µg 
pLU6-sgRNA-CMV-GFP and 20 µg pRZ-CMV-mCherry-Cas9 plasmid were added and the suspension 
was incubated on ice for 30 min. Electroporation was performed using a GenePulser II (BioRad) with 
a capacitance extender at 260 V and 960 µF. Cells were incubated on ice for additional 15 min before 
seeding them in 10 ml pre-warmed medium. 
 
2.2.3.5   Amaxa® Nucleofection 
 
Daudi BIG2-deficient cells were nucleofected using the Amaxa®Cell Line Nucleofector® Kit L. For 
nucleofection, 2x106 subconfluently cultured cells were harvested by centrifugation and the 
supernatant was carefully aspirated. Cells were mixed with 82 µl Nucleofector solution, 18 µl 
Supplement and 2 µg of plasmid DNA and transferred into a certified cuvette which was placed into 
the NucleofectorTM II device (Amaxa/Lonza). Cells were transfected by running the program A-020 
twice, before transferring them into 1 ml pre-warmed 20% FCS medium for regeneration.  
 
2.2.3.6   Retroviral transduction of human B cell lines 
 
Transfection of Plat-E cells 
 
To generate virus particles for retroviral transduction of human B cell lines, the packaging cell line 
Plat-E was transfected with the respective plasmid DNA. To this end, Plat-E cells were grown on 6 cm 
dishes at 70-80% confluency. For transfection, 1.8 µg plasmid DNA, 7 µl Trans-IT transfecting reagent 
and 0.8 µg pCMV-VSV-G were mixed in 300 µl serum-free RPMI-1640 and incubated for 30 min at 
RT. Meanwhile, Plat-E cell medium was replaced by 3 ml pre-warmed fresh target cell medium and 
DNA was added dropwise to the Plat-E cells. After 24 h, 1 ml fresh medium was added to enhance 
virus-production. 
 
Infection of target cells 
 
On the second day after transfection, the supernatant containing retroviral particles was harvested 
and centrifuged to pellet residual Plat-E cells. The clarified supernatant was carefully aspirated and 
mixed with 1.5x106 target cells and 2 ml fresh medium. In addition, polybrene was added to a final 
concentration of 3 µg/ml to improve the efficiency of the infection. The next day, the medium was 
changed to remove the polybrene. Selection started the day after using either 1 µg/ml puromycin 
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(InvivoGen) for BL60 and Daudi or 3 µg/ml for DG75 cells for 3 days. In case bleomycin (Calbiochem) 
was used for selection, 50 µg/ml were applied for 2 days to select DG75 cells.  
 
Concentration of retroviral particles and spinfection 
 
To improve infection efficiency of Daudi and BL60 cells, the virus-containing supernatant was 
clarified using a Minisart® filter with 0.45 µm pore size (Sartorius). Additionally, the supernatant 
was concentrated by centrifugation in 2x2 ml reaction tubes per sample at 4°C 20000 rcf for 90 min. 
Per tube, 1.25 ml of the supernatant was discarded and the remaining 2x750 µl were then used for 
spinfection. The spinfection protocol used here was originally described for transduction of primary 
B cells (see PhD thesis Dr. L. König). To this end, 1x106 target cells were mixed with 1.5 ml 
concentrated virus-containing supernatant and polybrene (3 µg/ml) in a 50 ml Falcon® tube and 
were spun at 1200 rcf for 3.5 h at 33°C. Cells were then transferred into fresh 20% FCS medium to 
recover. Selection with puromycin started 2 days after the infection.   
 
2.2.3.7   Lentiviral transduction of human BL cell lines 
 
The lentiviral transduction of human B cell lymphoma cell lines was performed in collaboration with 
Dr. C. Doebele, Department of Medicine II, Hematology & Oncology, University Hospital Frankfurt.  
 
Calcium Phosphate Transfection  
 
For production of lentiviral particles, HEK293T/17 cells were plated the day before the transfection 
at a density of 0.5x106 cells per ml medium without antibiotics. At the day of the transfection, 
14.5 µg pCMV-dR8.91, 15.2 µg LT3-GECIR and 6 µg phCMV-GALV were mixed with 150 µl 2.5 M CaCl2 
and 1350 µl sterile water. The mixture was added dropwise under constant vortexing to a tube 
containing 1.5 ml HeBS and incubated at RT for 30 min. For transfection, 1 ml of the reaction mixture 
was added to the HEK293T/17 cells. After 4 h, the medium was replaced with 20 ml fresh medium.  
 
Viral Transduction using RetroNectin® reagent 
 
At day 4 after the transfection, cells were transduced with lentiviral particles using RetroNectin® 
reagent (Clonetech) to promote co-localization of virus and target cells to enhance transduction 
efficiency. To this end, a 24-well plate was coated with 20 µg/ml RetroNectin® at RT for 1 h. After 
aspiration of the reagent, the plate was incubated with 2% BSA in PBS solution for 30 min before 
washing twice with HBSS/Hepes. Per well, 1.5 ml of virus supernatant was added and the plate was 
centrifuged at 32°C at 1500 rcf for 30 min to facilitate binding of the virus particles with the 
RetroNectin® reagent. The virus supernatant was aspirated and approximately 0.5x106 target cells 
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were mixed with remaining virus supernatant and 10 µg/ml polybrene. The plate was centrifuged 
at 500 rcf for 5 min and incubated overnight at 37°C. The next day, cells were transferred to a new 
virus-coated plate before adding 600 µl fresh medium on the following day.  
 
2.2.3.8   Proliferation assay 
 
To determine the growth rate of cells, the Cell Proliferation Assay XTT (Applichem) was used. The 
assay is based on the 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt 
(XTT), a yellow tetrazolium salt, which is reduced by succinate dehydrogenase system of the 
mitochondrial respiratory chain to formazan, an orange colored water-soluble dye (Scudiero et al. 
1988). As only living cells have an intact mitochondrial membrane and therefore active 
dehydrogenase, the intensity of the dye is proportional to the number of metabolically active cells. 
Phenazine methosulfate (PMS) also needs to be added, which serves as an intermediate electron 
acceptor.   
 
XTT assays were performed in 96-well plates. Cells were plated at a density of 6000 cells per 100 µl 
5% FCS medium per well. If applicable, AS1949490 and DMSO were added to a final concentration 
of 5 µM. 3-4 wells containing only medium were used for blank absorbance readings. The XTT 
reagent solution and the activation solution were defrosted immediately prior to use, were mixed 
and added to the cells according to the manufacturer’s instructions. Plates were incubated at 37°C, 
5% CO2 for 4 h before being measured with an ELISA reader (Powerwave 340, BioTek) at 450 nm for 
specific absorbance and 630 nm for reference absorbance. 
 
2.2.3.9   Flow cytometry  
 
Analysis of expression levels by flow cytometry 
 
For detection of cell surface proteins or fluorescent-labeled proteins, 1x106 cells were harvested, 
washed twice with PBS and, if applicable, were stained with the respective fluorescent-labeled 
antibody in 100 µl PBS according to the manufacturer’s recommendations. Cells were incubated on 
ice for 20-30 min, then washed 2x with cold PBS and resuspended in 300 µl PBS for flow cytometric 
measurement. 
 
Intracellular flow cytometry of phosphorylated proteins 
 
For the detection of phosphorylated proteins by intracellular flow cytometry, 1x106 subconfluently 
cultured cells per sample were harvested, washed with PBS and reconstituted in 100 µl RPMI only 
for serum starvation for 20 min at 37°C at 650 rpm. If applicable, cells were stimulated for 10 min 
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using 10 µg/ml F(ab’)2 goat α-human IgG/IgM. To stop the reaction, an equal volume of Cytofix™ 
Fixation Buffer (BD) was added and samples were incubated at 37°C for 10 min for fixation (final 
concentration 2% PFA). Following, samples were centrifuged at 500 rcf for 6 min, the supernatant 
was discarded and cells were permeabilized using 400 µl 0.2% Triton-X100 in PBS at RT for 5 min. 
Following centrifugation, cells were reconstituted in 300 µl 100 mM glycine in PBS and incubated 
for another 10 min at RT under mild agitation. Cells were spun again and reconstituted in 100 µl 
1% BSA in PBS and stained with Alexa Fluor® 647 Mouse α-JNK (pT183/pY185) (BD) according to the 
manufacturer’s recommendations for 30-60 min in the dark at RT under mild agitation. After 
staining, samples were filled up with 400 µl 1% BSA in PBS for washing. Cells were reconstituted in 
200-400 µl PBS and filtered through Falcon® tubes with cell strainer snap cap (BD) for flow 
cytometric measurement.  
 
Ca2+ mobilization assay 
 
Mobilization of Ca2+ from the ER into the cytoplasm is a key event following BCR stimulation. 
Intracellular Ca2+ concentration can be measured by using Indo-1-AM, a cell-permeable, ratiometric, 
UV-light excitable Ca2+ indicator. Upon Ca2+ binding, emission of Indo-1-AM shifts from 475 nm (blue) 
to 400 nm (violet).  For Ca2+ mobilization assays, cells were grown to a density of 0.5-0.75x106 cells 
per ml to avoid pre-activation. Per sample, 1x106 cells were harvested, reconstituted in 700 µl pre-
warmed 5% FCS Medium and transferred into light-opaque microcentrifuge tubes. Cells were 
loaded with 1 µM Indo-1-AM and pluronic F-127 to a final concentration of 0.015% and incubated 
at 30°C for 25 min under mild agitation. To each sample, 800 µl of pre-warmed 10% FCS medium 
was added and samples were incubated for another 10 min at 37°C. Cells were washed 1x with 
Krebs-Ringer buffer containing 1 mM CaCl2 at 300 rcf for 4 min before finally reconstituting them in 
300 µl Krebs-Ringer buffer containing 1 mM CaCl2. To minimize pre-activation of cells, cells were 
rested at 25-30°C for 20-30 min before the measurement. Ca2+ flux was measured 25 s before 
stimulation to establish a baseline of resting cells and up to 5 min after the stimulation of the BCR. 
Cells were stimulated by using 5-10 µg/ml F(ab’)2 goat α-human IgG/IgM. 
 
Apoptosis assay 
 
Apoptosis assays were performed to assess the amount of apoptotic and necrotic cells in different 
cell lines. For that purpose, the APC Annexin V Apoptosis Detection Kit with PI (Biolegends) was 
used. Annexin V is an intracellular protein that binds phosphatidylserine, which normally resides on 
the inner leaflet of the plasma membrane. During early apoptosis, the membrane symmetry is lost 
and phosphatidylserine is also found in the outer leaflet and therefore can be detected by 
fluorophore-labeled Annexin V. Propidium Iodide (PI) is a fluorescent dye that binds DNA. As early 
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apoptotic cells exclude the dye, it is used to distinguish early apoptotic from late apoptotic and 
necrotic cells (Vermes et al. 1995). For apoptosis assays, cells were plated 1-3 days before the 
measurement at a density of 0.25-0.5x106 cells per ml in either 1% FCS medium or RMPI only. On 
the day of analysis, 0.5-1x106 cells were harvested and washed 1x with cold Staining buffer (2% FCS 
in PBS + 0.1% NaN3). For staining, cells were reconstituted in 100 µl Annexin-V Binding buffer and 
Annexin V and PI and were incubated at RT for 20 min in the dark according to the manufacturer’s 
instructions. Subsequently, 400 µl Annexin V Binding buffer was added and samples were subjected 
to flow cytometric measurement.  
 
Cell sorting by flow cytometry 
 
Fluorescent cell populations from a heterogenous cell population were separated by using flow 
cytometry-based cell sorting. Sorting of cells was either performed at the Institute for Multiple 
Sclerosis Research (IMSF) in Göttingen or at the Central Service Unit Cell Sorting at the University 
Medical Center in Göttingen.
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3  Results  
 
3.1 The role of Nck proteins in BL-specific BCR signaling  
 
Our group has previously shown that the adaptor protein Nck activates the PI3K signaling pathway 
in a BCR-dependent manner in DT40 chicken B cells (Castello et al. 2013). By binding to the 
phosphorylated non-ITAM tyrosine residue Y204 in CD79A (Igα) Nck recruits BCAP and activates the 
PI3K pathway. In BL, tonic BCR signaling promotes survival and proliferation of malignant B cells via 
the PI3K pathway. Given the role of Nck as a link between BCR activation and PI3K signaling, I 
assessed a relevance for tonic BCR signaling. Compared to chicken, mice and humans have two Nck 
paralogs, Nck1 and Nck2. In a phospho-proteomic approach of screening BL cell lines Daudi and 
DG75, Nck1 was identified to be moderately phosphorylated at tyrosine 105 in tonic BCR signaling 
(Corso et al. 2016), whereas Nck2 was not identified. To gain more insight into the role of Nck 
proteins, I aimed to analyze if they are also relevant for BL-specific tonic BCR signaling and if so 
whether Nck isoforms have similar or diverging functions in this context. To this end, I used 
CRISPR/Cas9 gene editing to generate DG75 sub-cell lines deficient for Nck1, Nck2 or both.  
 
3.1.1. Generation of a Nck1-deficient cell line 
 
For targeting the Nck1 gene locus, exon 3 was chosen as it is present in all 3 complete transcription 
variants of Nck1 deposited in the NCBI Nucleotide database (Figure 5 a). Possible guide sequences 
were picked by using the web-based “CRISPR Design” program (http://crispr.mit.edu/). The guide 
sequence was chosen to have minimal off-target activity and a restriction site for the PasI restriction 
enzyme at the site of the predicted double-strand break (DSB) induced by Cas9. In case of a 
successful site-directed modification by Cas9, the restriction site is no longer intact. The guide 
sequence was cloned into the pLU6-CMV-GFP backbone and together with pRZ-CMV-mCherry-Cas9 
introduced into the cells using electroporation. After 48 h, cells were sorted for a GFP+ mCherry+ 
sub-population. The sorted cell batch was tested for the presence of gene editing by use of a PasI 
endonuclease recognition site 5’ of the PAM motif. Genomic PCR and subsequent PasI treatment 
revealed the sorted cell batch contained both, cells harboring mutations in Nck1 (340 bp band) as 
well as the wt allele (260 bp band) (Figure 5 b). Following, cells were plated in 96-well plates for 
expansion of single cell clones. 48 single cell clones were analyzed by PCR and PasI digest, 9 of which 
showed a modified restriction site. 3 of these clones showed no expression of the protein using 
Western Blot analysis and 2 of those were confirmed for genomic DNA deletions by sanger 
sequencing (clone #11 and clone #25) (Figure 5 c).  
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Deletions in the genomic DNA led to premature stop codons, abrogating the translation of Nck1 as 
shown for clone #11 (Figure 5 d).  
 
 
 
 
 
 
 
Figure 5: Generation of a Nck1-deficient cell line using CRISPR/Cas9 gene editing.  
(a) Scheme of human Nck1 gene locus with CRISPR targeting strategy. The chosen guide sequence (blue) 
targets exon 3. The PAM sequence (red) directs the Cas9 nuclease, which initiates a double strand break (DSB, 
indicated with an arrow). Predicted site of DSB is recognized by the PasI endonuclease (purple). (b) CRISPR 
activity test. Genomic DNA of exon 3 was amplified by PCR, treated with PasI and analyzed by gel 
electrophoresis. The size of DNA fragments is indicated on the left. (c) Overview of screening process for Nck1-
deficient clones. (d) Analysis of clone #11 showed a deletion of 2 bp and 22 bp on the genomic DNA level 
leading to frameshift mutations and premature stop codons (*). 
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Cells were retrovirally transduced with pMSCV-puro-hNck1Cit (see 2.2.3.6) and were analyzed for 
expression of Citrine-tagged-Nck1 using flow cytometry (Figure 6 a) and Western Blot analysis 
(Figure 6 b) compared to non-transduced and DG75 wild-type (wt) cells. Western Blot analysis 
showed the correct apparent molecular weight of Citrine-tagged-Nck1. The faint residual signal of 
Nck as seen in the samples from Nck1 deficient cells might be due to an antibody’s cross-reactivity 
with Nck2. Probing the blot with antibodies against the Nck1-interacting protein BCAP revealed an 
attenuated expression of BCAP in both clones with a more pronounced decrease in clone #25. 
Staining for IgM-BCR expression with APC-tagged a-human IgM antibody confirmed unaltered IgM 
surface expression levels in Nck1-deficient cells compared to their reconstituted sub-clones and 
DG75 wt cells (Figure 6 c). 
 
 
 
 
 
Figure 6: Reconstitution of Nck1-deficient cells with Citrine-tagged Nck1.  
(a) Nck1-deficient (Nck1-/-) cells were left untreated or transduced with constructs encoding a Citrine-tagged 
version of Nck1 (Nck1Cit) and were analyzed by flow cytometry. Wild-type (wt) DG75 cells served as control. 
(b) Western Blot analysis of lysates derived from DG75 wt, Nck1-deficient clones #11 and #25 and their 
reconstituted sub-clones. Blots were probed with α-Nck (upper panel), α-BCAP (second panel) and α-actin 
(lower panel) for loading control. Standard protein molecular masses are indicated in kDa. (c) Staining of DG75 
wt, Nck1-deficient and Nck1Cit-expressing cells with APC-conjugated α-human IgM antibody for surface IgM 
expression. Samples were analyzed by flow cytometry. Unstained cells served as control.  
 
 
3.1.2 Generation of Nck2 and Nck1-2-double deficient cell lines 
 
Although according to phospho-proteome data Nck1 may be the prominent Nck family protein 
involved in BCR-signaling, Nck2 is also expressed in DG75 cells. Depending on cell type and signaling 
network, Nck1 and Nck2 have been described to exert both overlapping and protein-specific 
functions (Ngoenkam et al. 2014; Buvall et al. 2013; Chen et al. 1998). Hence, I generated a Nck2-
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deficient DG75 cell line in addition to a Nck1-2-double-deficient cell line on the background of the 
DG75 Nck1-/- cell line using CRISPR/Cas9 gene editing targeting Nck2. Guide RNA containing a StyI 
endonuclease restriction site 5’ of the PAM motif was designed to target exon 4 in transcript variant 
1 and 2 encoding for Nck2A, the only Nck variant comprising the full set of SH3 domains (Figure 7 a). 
Plasmids encoding the guide and Cas9 were introduced using electroporation, GFP+ mCherry+ cells 
were sorted and subjected to activity testing as described previously. Genomic DNA was amplified 
by PCR and treated with StyI (Figure 7 b). Agarose gel electrophoresis revealed the existence of 
edited alleles. After sub-cloning, 65 single clones from the Nck2 CRISPR batch and 39 single clones 
from the Nck1-2 CRISPR batch were analyzed and 4 potential clones per approach were picked for 
Sanger sequencing (Figure 7 c). Nck2-deficient clone #29 showed a 1 bp insertion and a 2 bp deletion 
in exon 4, thereby leading to a frameshift mutation resulting in a premature stop codon (Figure 7 d). 
Clone #29 is in the following referred to as Nck2-deficient DG75 cells (Nck2-/-). For the Nck1-2 double 
deficient CRISPR approach, clone 13.1 was confirmed to have a 2 bp and a 26 bp deletion in exon 4, 
also leading to a frameshift mutation and premature stop codon (Figure 7 e). Following, clone #13.1 
is referred to as Nck1-2-deficient DG75 cells (Nck1-2-/-).  
 
A BLAST search revealed that the Nck2 protein is highly conserved among species. The Nck2 protein 
from gallus gallus (chicken) shares 93% sequence identity with human Nck2A and resembles Nck2A 
in all functional domains including the peptide binding sites in the SH3 domains and the 
phosphotyrosine and hydrophobic binding pocket in the SH2 domain. Since a plasmid encoding for 
Nck2 from gallus gallus (chNck2) was readily available, Nck2-/- and Nck1-2-/- cells were reconstituted 
with a Citrine-tagged version of chNck2. For double expression of Nck1 and Nck2 in Nck-double 
deficient cells, cells were transduced with constructs encoding Citrine-tagged Nck1 and RFP-tagged 
chNck2. Cells were sorted for the expression of the respective fluorophore and were analyzed for 
protein expression using flow cytometry (Figure 8 a & b) and Western Blot analysis (Figure 8 c). 
Staining for IgM-BCR expression with APC-conjugated α-human IgM antibody confirmed unaltered 
IgM surface expression levels in Nck2-deficient (Figure 8 d) and Nck1-2-deficient (Figure 8 e) cells 
compared to their reconstituted sub-clones and wt DG75 cells.  
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Figure 7: Generation of Nck2- and Nck1-2-deficient cell lines using CRISPR/Cas9 gene editing.  
(a) Scheme of human Nck2 gene locus with CRISPR targeting strategy. The chosen guide sequence (blue) 
targets exon 4. The PAM sequence (red) directs the Cas9 nuclease, which initiates a double strand break (DSB, 
indicated with an arrow). Predicted site of DSB is recognized by the StyI endonuclease (purple). (b) CRISPR 
activity test. Genomic DNA of exon 4 was amplified by PCR, treated with StyI and analyzed by agarose gel 
electrophoresis. The size of DNA fragments is indicated on the left. (c) Overview of screening process for Nck2- 
and Nck1-2-deficient clones. (d) Sequencing analysis of Nck2-deficient clone #29 showed a deletion of 2 bp 
and in insertion of 1 bp. (e) Nck1-2-deficient clone 13.1 displayed a deletion of 26 bp and 2 bp. In both clones, 
mutations led to frameshift mutations resulting in a premature stop codons (*). 
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Figure 8: Reconstitution of Nck2- and Nck1-2-deficient DG75 cells.  
(a) Nck2-deficient DG75 cells (Nck2-/-) were left untreated or transduced with constructs encoding Citrine-
tagged Nck2 and analyzed in comparison to DG75 wild-type (wt) cells for Citrine expression by flow cytometry. 
(b) Plasmids encoding fluorophore-tagged Nck1 and Nck2 were transduced into Nck1-2 deficient cells 
(Nck1-2-/-) and cells were sorted to enrich for the positive cell population. Reconstituted cells were analyzed 
in comparison to Nck1-2-deficient and DG75 wt cells for Citrine expression (left panel) and double 
reconstituted cells additionally for Citrine/RFP expression (right panel) by flow cytometry. (c) Expression of 
ectopic fluorophore-tagged proteins was tested using Western Blot analysis by probing with α-Nck (upper 
panel) and α-Nck1 (second panel) antibodies. α-actin (lower panel) served as loading control. Standard 
protein molecular masses are expressed in kDa. Staining with APC-tagged α-human IgM antibody to test for 
surface IgM expression in (d) Nck2-deficient and (e) Nck1-2-deficient cells compared to reconstituted sub-
clones and DG75 wt cells.  
 
 
 
3.1.3 Nck1 positively regulates Ca2+ mobilization in DG75 cells 
 
Before examining tonic BCR signaling in the generated cell lines, I first aimed to verify whether Nck 
exerts functions in activated BCR signaling similar to those published earlier. In the DT40 chicken B 
cell line, loss of Nck decreased the Ca2+ influx upon BCR activation (Castello et al. 2013).  Because I 
found Nck1 to be the predominantly expressed Nck protein in human DG75 cells (data not shown), 
I first tested Ca2+ mobilization in DG75-derived Nck1-deficient cells. For comparison, I included Nck1-
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deficient cells reconstituted with Citrine-tagged Nck1 and DG75 wild-type cells. Cells were stained 
with Indo-1-AM and were analyzed for their ability to mobilize Ca2+ by the ratio of a blue to violet 
shift in the emission spectrum of Indo-1-AM upon complex formation with free Ca2+. After 25 s of 
baseline recording, cells were stimulated with 5 µg/ml F(ab’)2 α-IgM and Ca2+ flux was recoded up 
to 5 min. Ca2+ profiles of clone #11 and #25 were plotted against parental cells (wt) and Nck1-
deficient cells reconstituted with Citrine-tagged Nck1 (Figure 9). Comparable to Nck-deficient DT40 
cells, DG75 Nck1-deficient cells showed an attenuated response upon BCR stimulation. 
Reconstitution with the Citrine-tagged Nck1 variant was able to restore Ca2+ mobilization partially 
in clone #11 (Figure 9 a) and entirely in clone #25 (Figure 9 b). For further experiments, clone #11 
was chosen because of the reconstitution of BCR-induced Ca2+ mobilization and because BCAP 
expression was more comparable to parental cells (Figure 6 b). Clone #11 is in the following referred 
to as Nck1-deficient DG75 cells (Nck1-/-).  
 
 
 
 
Figure 9: Nck1 positively regulates Ca2+ mobilization in human DG75 cells.  
Nck1-deficient (Nck1-/-) DG75 cells of clone #11 (a, orange line) and clone #25 (b, light blue line), Citrine-
tagged Nck1 reconstituted cells (Nck1-/- + Nck1Cit) (red and blue lines, respectively), and wt DG75 controls 
(grey lines), were loaded with the calcium-sensitive dye Indo-1-AM. A baseline was recorded for 25 s before 
cells were stimulated with 5 µg/ml F(ab’)2 α-IgM and Ca2+ flux was monitored for up to 300 s. Plots are 
representative of three independent experiments. 
 
 
To test whether the Nck1-mediated augmentation of Ca2+ signals is caused by the PI3K-AKT pathway 
in human B cells similar to DT40 chicken B cells, I repeated the Ca2+ mobilization assays using the 
PI3K inhibitor Wortmannin. As expected, Wortmannin was able to reduce the BCR-induced Ca2+ 
response in DG75 wt (Figure 10 a) and in reconstituted cells (Figure 10 c). In contrast, Nck1-/- cells 
were only mildly affected by the inhibitor (Figure 10 b), indicating the decreased BCR-induced Ca2+ 
mobilization in Nck-deficient cells is mainly caused by a reduced PI3K activity.  In summary, these 
results indicate that Nck1 is relevant for BCR-induced PI3K activation also in human B cells.   
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Figure 10: Ca2+ mobilization assays after treatment with PI3K inhibitor Wortmannin.  
(a) DG75 wild-type (wt), (b) Nck1-deficient (Nck1-/-) DG75 and (c) Nck1-deficient DG75 cells reconstituted with 
Citrine-tagged Nck1 (Nck1Cit) cells were stained with the calcium-sensitive UV-light excitable dye Indo-1-AM. 
Cells were left untreated or were treated with 100 nM Wortmannin for 10 min before each measurement. 
After recording a 25 s baseline, cells were stimulated with 10 µg/ml F(ab’)2 α-IgM and Ca2+ flux was monitored 
for up to 300 s. Plots are representative of two independent experiments. 
 
 
3.1.4 Nck1 enhances JNK activity upon BCR activation 
 
Having shown that Nck1 positively regulates Ca2+ mobilization upon BCR activation, I aimed to 
analyze the impact of Nck1 in BCR-dependent signaling in more detail. To this end, I left the different 
DG75 cell lines described above untreated or stimulated them via the BCR for 3, 7 or 10 minutes. 
Following, cells were lysed and samples were subjected to Western Blot analysis. Blots were probed 
with phospho-specific antibodies against pivotal signaling proteins involved in both the PI3K (p85, 
AKT, FOXO1) and MAPK (ERK, pp38, JNK) signaling pathways.  
 
While phosphorylation of the regulatory subunit of PI3K, p85, at Y458, appears to be constitutive 
and not BCR-inducible, AKT (S473) and its downstream target FOXO1 (T24) are phosphorylated with 
comparable intensity in all cell lines upon stimulation of the BCR (Figure 11 a). Interestingly, 
phosphorylation of FOXO1 in unstimulated cells was reduced in Nck1-/- cells in comparison to wt 
cells and reconstituted cells. Therefore, it is tempting to speculate that Nck1 might be also involved 
in tonic BCR signaling.  
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Figure 11: Analysis of pivotal signaling proteins in Nck1-deficient DG75 cells downstream of BCR activation. 
DG75 wild-type (wt), Nck1-deficient (Nck1-/-) and their Citrine-tagged Nck1 reconstituted sub-clone (Nck1-/- + 
Nck1Cit) were stimulated with 10 µg/ml F(ab’)2 α-human IgM for 3,7, or 10 min or left unstimulated. Lysates 
were subjected to Western Blot analysis and analyzed for phosphorylation of key signaling proteins in the PI3K 
and MAPKs pathways. (a) Phosphorylation of effector proteins downstream of the PI3K pathway, AKT and 
FOXO1, was tested by using α-pAKT (S473) (upper panel), α-panAKT (second panel), α-pp85 (Y458) (third 
panel), α-pFOXO1 (T24) (fourth panel) and α-actin (lower panel) antibodies. (b) Phosphorylation of effector 
proteins downstream of the MAPKs pathways, ERK and p38 was tested by using α-pERK (T202/Y204) (upper 
panel), α-pp38 (T180/Y182) (second panel) and α-actin (lower panel). (c) Phosphorylation of the effector 
protein JNK downstream of the MAPK pathways was assessed by using α-pJNK (T183/Y185) (upper panel), 
α-JNK (second panel) and α-actin (lower panel). (d) Expression of Nck1 and its adaptor BCAP was tested by 
using antibodies against Nck1 (upper panel), BCAP (second panel) and actin (lower panel). Standard protein 
molecular masses are indicated in kDa. 
 
 
Since MAPKs are important signaling hubs after BCR stimulation, I probed blots with antibodies 
detecting phosphorylated forms of central MAPKs ERK, p38 and JNK (Figure 11 b & c). The MAPK 
ERK is known to be phosphorylated after IgM BCR stimulation and ERK phosphorylation at T202 and 
Y204 was similar among cell lines (Figure 11 b). MAPK p38 was constitutively phosphorylated at 
T180 and Y182, indicating that it is not regulated upon BCR stimulation in DG75 cells. While 
phosphorylation of MAPK JNK (T183/Y185) was induced by BCR stimulation in all cells, the 
phosphorylation efficiency was markedly reduced in absence of Nck1 (Figure 11 c). Impaired JNK 
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phosphorylation could be rescued to some extent by expression of Citrine-tagged Nck1, thereby 
excluding clonal or off-target effects. Similar quantities of JNK, BCAP and Nck1 were confirmed by 
re-probing the membrane with α-JNK (Figure 11c, second panel), α-BCAP and α-Nck1 (Figure 11 d), 
respectively. In conclusion, while an impact of Nck1 on effectors of the PI3K pathway was not 
detectable, Nck1 was required for efficient BCR-induced activation of the JNK pathway. 
 
 
3.1.5 Nck2 is dispensable for BCR-induced Ca2+ mobilization in DG75 cells  
 
To further test the impact of Nck proteins on activated BCR signaling in BL cell lines, I examined the 
role of Nck2 in the presence or absence of Nck1. Therefore, I analyzed Nck2-deficient and Nck1-2-
deficient cells for their ability to mobilize Ca2+ upon BCR stimulation. Cells described in 3.1.2 were 
stimulated via the BCR using 5 µg/ml F(ab’)2 α-human IgM. Nck2-deficient cells displayed no change 
in their Ca2+ response compared to parental and Citrine-tagged Nck2 reconstituted cells 
(Figure 12 a). The response of Nck1-2-deficient cells was decreased upon BCR stimulation, in a 
similar manner like Nck1-deficient cells (Figure 12 b). Reconstitutions with Nck1, Nck2, and both 
proteins were only mildly effective. In summary, I concluded that Nck2 is dispensable for Ca2+ 
mobilization upon BCR stimulation.  
 
 
 
 
 
 
Figure 12: Nck2 is dispensable for Ca2+ mobilization in the presence of Nck1.  
Nck2-deficient (Nck2-/-) (a, light green line) and Nck1-2-deficient (Nck1-2-/-) cells (b, dark blue line) and their 
reconstituted sub-clones expressing Citrine-tagged Nck1 (Nck1Cit) (green line in (a) and light blue line in (b)), 
Citrine-tagged Nck2 (Nck2Cit) (purple line in (b)) or RFP-tagged Nck2 (Nck2RFP) in combination with Citrine-
tagged Nck1 (pink line in (b)) and wt DG75 controls (grey lines) were loaded with the calcium-sensitive dye 
Indo-1-AM for flow cytometry analysis. After recording a 25 s baseline, cells were stimulated with 5 µg/ml 
F(ab’)2 α-human IgM and Ca2+ flux was monitored for up to 300 s. Plots are representative of two independent 
experiments. 
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3.1.6. Functional analysis of Nck1 and Nck2 BL-specific BCR signaling 
 
Based on the reported role of Nck for BCR-induced activation of the PI3K pathway and the Nck-
functions in activated BCR signaling described above, I next assessed the impact of Nck proteins on 
BL-specific processes like proliferation, apoptosis, as well as tonic BCR signaling. 
 
3.1.6.1 Proliferation of Nck-deficient DG75 cells 
 
To investigate BL survival, I performed XTT-based proliferation assays, which are commonly used to 
analyze the growth rate of cells (Scudiero et al. 1988). At d0, cells were plated at quadruplicates at 
a number of 6000 cells per well in 96-well plates under serum-limiting conditions in 5% FCS medium. 
I measured tests at d0 to establish a baseline level and at d2 and d4 to test for differences in cell 
proliferation. 
 
Compared to parental cells, Nck1-deficient DG75 cells showed a reduced proliferation rate at d2 
and d4, which, however, could not be enhanced by expression of Citrine-tagged Nck1 (Figure 13 a 
& b). For Nck2-deficient cells, the decrease was even more pronounced at d4, but the impaired 
proliferation could also not be rescued upon expression of Citrine-tagged Nck2 (Figure 13 c & d). 
Whereas for single Nck-deficient clones a significant reduction in proliferation became only 
apparent at d4, Nck1-2 double deficient clones showed an impaired cell growth already at d2 (Figure 
13 e & f). Also in this experimental setup, the proliferative defect could not be reconstituted by re-
expression of Nck1 and Nck2.  
 
Although Nck-deficient cell lines displayed a profound reduction in proliferation compared to wt 
cells, the lack of functional reconstitution did not allow to draw conclusions because clonal effects 
could not be excluded. However, since this assay only measures metabolically active cells, possible 
differences in the number of cells undergoing apoptosis during the proliferation assay might 
obscure the overall results.  
 
Due to the small sample size in this study (n ≤ 5), descriptive statistics were used for sample analysis. 
The average is calculated as the mean and the standard deviation (SD), describing the spread of 
values in reference to the mean.   
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Figure 13: Proliferation is decreased in Nck-deficient DG75 cells.  
For XTT-proliferation assays, single- and double-deficient Nck cells in comparison to their reconstituted sub-
clones and DG75 wild-type (wt) were grown in 5% FCS medium and analyzed at d0, d2 and d4 for their growth 
rate. Mean ΔOD values of two independent experiments were normalized to d0 (a, c, e) and quantified for d2 
and d4 + standard deviation (SD) (b, d, f). (a & b) Proliferation data of DG75 Nck1-deficient cells (Nck1-/-, 
orange) and their Citrine-tagged Nck1 expressing sub-clone (Nck1-/- + Nck1Cit, red). DG75 wt cells (grey) 
served as control. (c & d) Proliferation of Nck2-deficient cells (Nck2-/-, light green), their Citrine-tagged Nck2 
expressing sub-clone (Nck2-/- + Nck2Cit, dark green) and DG75 wt cells (grey). (e & f) Proliferation of DG75 
Nck1-2-deficient cells (Nck1-2-/-, purple) and their Citrine-tagged Nck1 and RFP-tagged Nck2 expressing sub-
clone (Nck1-2-/- + Nck1Cit + Nck2RFP, blue) in comparison to DG75 wt cells (grey). 
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3.1.6.2 Apoptosis rates are increased in absence of Nck1 
 
To analyze the relevance of Nck proteins on apoptosis in BL cells, I grew 1x106 cells in 2-3 ml 1% FCS 
medium for three days. At d3, I used APC-tagged Annexin V to stain for apoptotic cells and 
additionally used propidium iodide (PI) to stain late apoptotic cells (Vermes et al., 1995). Samples 
were processed as described in section 2.2.3.9 and analyzed by flow cytometry. For analysis, I gated 
for live (AnnexinV-/PI-), early apoptotic (AnnexinV+/PI-) and late apoptotic (AnnexinV+/PI+) cells. The 
apoptosis assays of wt, Nck1-deficient, and reconstituted DG75 cells revealed an overall higher 
number of living cells in the absence and slightly increased number of apoptotic cells at d3 in the 
presence of Nck1 (Figure 14 a). In contrast, the apoptosis analysis of Nck2-deficient DG75 cells 
showed a reduction of living and an increase of apoptotic cells compared to wt and reconstituted 
cells (Figure 14 b). These data indicate that Nck2 but not Nck1 reduces the apoptosis rate of DG75 
cells. 
 
 
 
 
Figure 14: Assay for apoptosis in Nck-single-deficient DG75 cells. For legend, see next page. 
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Figure 14 (previous page): Assay for apoptosis in Nck-single-deficient DG75 cells.  
After culturing single Nck-deficient cells, their reconstituted sub-clones and DG75 wild-type (wt) cells in 1% 
FCS medium for three days, cells were stained with APC-tagged Annexin V and PI to distinguish between living 
(left upper panel), early (right upper panel), late (left lower panel) and all apoptotic (right lower panel) cells 
by flow cytometry. (a) Apoptosis assay for Nck1-deficient cells (Nck1-/-, orange) and their Citrine-Nck1 
expressing sub-clone (Nck1-/- + Nck1Cit, light grey) in comparison to DG75 wt cells (dark grey). (b) Apoptosis 
assay for Nck2-deficient cells (Nck2-/-, green), their Citrine-Nck2 expressing sub-clone (Nck2-/- + Nck2Cit, light 
grey) and DG75 wt cells (dark grey). Data represent means of four experiments, error bars show SD.  
 
 
 
To further asses the differential impact of Nck proteins on apoptosis in BL cells, I analyzed Nck1-2 
deficient cells and their reconstituted sub-clones in the same experimental set-up. Compared to wt 
DG75 cells, the proportion of living cells was markedly increased while the apoptosis rate decreased 
for all cells based on the Nck1-2-deficient clone, indicating a clonal effect (Figure 15). In support of 
the apoptosis data derived from the single-deficient DG75 cells described above, reconstitution of 
Nck1-2-deficient cells with only Nck2 did not alter the proportion of living or apoptotic cells 
compared to the parental clone whereas expression of Nck1 slightly reduced the proportion of living 
cells and augmented apoptosis rates. Collectively, despite the obstacles in apoptosis measurements 
due to clonal effects, these data further imply opposite functions of Nck isoforms in the induction 
of apoptosis. 
 
 
 
 
Figure 15: Assay for apoptosis in Nck1-2-deficient DG75 cells.  
After culturing Nck1-2-deficient (Nck1-2-/-, purple) DG75 cells, their sub-clones expressing Nck1Cit (light grey), 
Nck2Cit (beige) or Nck1Cit and Nck2RFP (lavender) and DG75 wt cells (dark grey) in 1% FCS medium for three 
days, cells were stained with APC-tagged Annexin V and PI to distinguish between living (left upper panel), 
early (right upper panel), late (left lower panel) and all apoptotic (right lower panel) cells by flow cytometry. 
Data represent means of four experiments, error bars show SD.  
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3.1.7 Role of Nck1 and Nck2 in tonic BCR signaling 
 
The data described above indicate that Nck1 promotes a pro-apoptotic response in DG75 cells under 
serum-limiting conditions. At first sight, this observation contradicts its supposedly signaling 
promoting function via the survival and proliferation-promoting PI3K pathway. Therefore, I 
proposed that among its function in the PI3K pathway, Nck1 might also play a role in other signaling 
pathways which net result is induction of apoptosis. To test this hypothesis, I prepared lysates of 
unstimulated cells and subjected them to Western Blot analysis by probing with phospho-specific 
antibodies for proteins playing central roles in different signaling pathways. 
 
3.1.7.1 Nck1 and Nck2 augment the activation of the PI3K pathway in tonic BCR 
signaling  
 
Considering that I identified an impact of Nck1 in the PI3K-AKT pathway upon BCR-induced Ca2+ 
mobilization, I next aimed to analyze the role of Nck proteins in the context of tonic BCR signaling. 
Phosphorylation of the PI3K regulatory subunit p85 is an early event in activation of the PI3K 
pathway. Similar levels of p85 phosphorylation were identified in all cell lines although Nck2-
deficient cells and their Nck2-reconstituted sub-clone showed a mildly enhanced signal for 
phosphorylation of p85 (Figure 16 a). Hence, the PI3K pathway is constitutively activated in DG75 
cells. In Nck1-deficient cells, AKT phosphorylation was decreased but could not sufficiently be 
restored by re-expression of Citrine-tagged Nck1 (Figure 16 b). In Nck2-deficient cells overall AKT 
phosphorylation was also reduced compared to parental cells, although the decrease was less 
pronounced than in Nck1-deficient cells. Nck1-2 deficient cells displayed a medium reduction in AKT 
phosphorylation, which could not be enhanced by re-expression of Nck1 or Nck2 alone, but partially 
upon expression of both Nck isoforms.  
In the PI3K pathway, FOXO1 is one of many targets to be phosphorylated by AKT. Phosphorylation 
of FOXO1 was reduced in Nck1-deficient cells and here, re-expression of Nck1 was able to restore 
the effect partially (Figure 16 c).  A similar effect, however less pronounced, was detected in Nck2-
deficient cells and could also be rescued by ectopic expression of Citrine-tagged Nck2. Although I 
could identify regulation of phosphorylation in the single Nck-deficient cell lines, phosphorylation 
of FOXO1 was not regulated in Nck1-2 deficient cells and their reconstituted sub-clones, thus 
indicating a clonal effect promoting constitutive FOXO1 phosphorylation. Notably, expression of 
BCAP, the pivotal Nck interaction partner for BCR-dependent PI3K signaling, was reduced in Nck1-
deficient and Nck1-2-deficient cells and their sub-clones (Figure 16 d). Although clonal differences 
in BCAP expression thereby conceal which Nck isoform is primarily relevant, data suggest both Nck1 
and Nck2 to augment signaling via the PI3K pathway also in tonic BCR signaling. 
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Figure 16: Nck proteins augment PI3K pathway activation in tonic BCR signaling.  
Single (Nck1-/-, Nck2-/-) and double-deficient Nck (Nck1-2-/-) DG75 cells in comparison to their reconstituted 
sub-clones (expressing Nck1Cit, Nck2Cit or Nck1Cit and Nck2RFP, respectively) and DG75 wild-type (wt) cells 
were lysed and subjected to Western Blot analysis. For each protein analyzed, exemplary immunoblots are 
shown in addition to ratios of signal intensities which were calculated and depicted as a bar diagram as the 
means + SD of three independent experiments. (a) Phosphorylation of PI3K subunit p85 was tested by using 
α-pp85 antibody (upper panel). Blots were re-probed with α-actin for loading control (second panel) and the 
ratios of signal intensities are depicted as a bar diagram (lower panel). (b) Immunoblots were decorated with 
α-pAKT (upper panel), α-panAKT (second panel) and α-actin (third panel). Ratios of α-pAKT to α-panAKT signal 
intensities are depicted as a bar diagram (lower panel). (c) Phosphorylation of the AKT downstream effector 
FOXO1 was determined using a-pFOXO1 antibody (upper panel) and membranes were re-probed with α-actin 
(second panel) for quantification of signal intensities which are depicted in a bar chart (lower panel). (d) 
Probing membranes with α-BCAP antibody to test for total levels of BCAP (upper panel) and α-actin (second 
panel). Ratio of signal intensities are depicted as a bar diagram (lower panel). Standard protein molecular 
masses are indicated in kDa. 
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3.1.7.2 Regulation of MAPK-pathway signaling upon Nck1 deletion 
 
To complement the results obtained from PI3K pathway analysis, I additionally analyzed the main 
effectors involved in MAPK pathways downstream of BCR signaling namely ERK, JNK and p38. Since 
the ERK pathway can be activated by tonic BCR signals during B cell development (Rowland et al. 
2010), I tested if ERK phosphorylation is also a relevant target of tonic BCR signaling in BL. By probing 
with phospho-specific α-ERK antibody, I could identify a basal level of ERK phosphorylation already 
in unstimulated cells (Figure 17 a). Nck2-deficient cells and their reconstituted sub-clone showed 
relatively comparable levels of ERK phosphorylation. In contrast, Nck1-deficient and Nck1-2 
deficient cells and their sub-clones showed a strongly decreased level of basal ERK phosphorylation, 
which is probably caused by the clonality of cell lines. Since upon BCR stimulation, Nck1-deficient 
cells displayed no defect in ERK phosphorylation (Figure 11 b), the reduced basal phosphorylation 
levels of ERK seem to be negligible at least for activated BCR signaling. 
 
Next, I tested for MAPK JNK phosphorylation and subsequent activation. Phosphorylation of JNK 
was decreased in Nck1- and Nck1-2 deficient cell lines (Figure 17 b). Re-expression of Nck1 could 
partially elevate the level of phosphorylation in Nck1-deficient cells, whereas in Nck1-2 deficient 
cells, only expression of both Nck isoform had a similar effect. Nck2-deficienct cells showed no 
relevant decrease, thereby indicating that JNK phosphorylation is mainly dependent on Nck1, 
however Nck1 could only reach full activation in the presence of Nck2.  
 
Basal p38 phosphorylation levels were decreased in Nck1- and Nck1-2-deficient cells, which could 
be elevated by expression of Citrine-tagged Nck1, but not by Nck2 (Figure 17 c). p38 
phosphorylation in Nck2-deficient cells remained unchanged. However, in Nck1-2 deficient cells, 
expression of both Nck isoforms increased p38 phosphorylation compared to expression of Nck1. 
In summary, JNK and p38 MAPK signaling pathways were mainly influenced by loss of Nck1 instead 
of Nck2, but Nck2 was supporting Nck1-dependent p38 and JNK activation in tonic BCR signaling.  
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Figure 17: Analysis of signaling via MAPK pathways in Nck-deficient DG75 cell lines.  
Single (Nck1-/-, Nck2-/-) and double-deficient Nck (Nck1-2-/-) DG75 cells in comparison to their reconstituted 
sub-clones (expressing Nck1Cit, Nck2Cit or Nck1Cit and Nck2RFP, respectively) and DG75 wild-type (wt) cells 
were lysed and subjected to Western Blot analysis. Blots were decorated with phospho-specific antibodies for 
key MAPK effector proteins. For each protein analyzed, exemplary immunoblots are shown in addition to 
ratios of signal intensities which were calculated and depicted as a bar diagram as the means + SD of three 
(ERK, p38) and two (JNK) independent experiments. (a) Phosphorylation of ERK was tested by using α-pERK 
antibody (upper panel). Blots were re-probed with α-pan ERK (second panel) and α-actin for loading control 
(third panel). Ratios of α-pErk to α-panERK signal intensities are depicted as a bar diagram (lower panel). (b) 
Immunoblots were decorated with α-pJNK (upper panel), α-JNK (second panel) and α-actin (third panel). 
Ratios of α-pJNK to α-JNK signal intensities are depicted as a bar diagram (lower panel). (c) Phosphorylation 
of p38 was determined by using α-pp38 antibody (upper panel) and membranes were re-probed with α-actin 
(second panel) for quantification of signal intensities which are depicted in a bar diagram (lower panel). 
Standard protein molecular masses are indicated in kDa. 
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3.2 BIG2 is relevant for proliferation and survival of BL cell lines 
 
The Brefeldin A-inhibited guanine nucleotide-exchange factor (BIG)2 was found to be 
phosphorylated in resting BL cell lines and phosphorylation was compromised upon knockdown of 
CD79A (Corso et al. 2016). Additionally, shRNA targeting BIG2 was toxic for BL cell lines DG75 and 
Daudi, while cell lines derived from other lymphoma subtypes such as GCB-DLBCL cell lines were 
not affected, suggesting a BL-specific role of BIG2. Moreover, BIG2 knockdown increased numbers 
of both early and late apoptotic cells compared to non-specific control shRNAs (Corso et al. 2016). 
Since these data indicate an important role of BIG2 for survival and proliferation of BL cells in an 
BCR-dependent manner, I aimed to identify the underlying signaling pathways affected by BIG2. To 
this end, I generated a BIG2-deficient cell line on the background of Daudi cells.     
 
3.2.1 Generation of a BIG2-deficient cell line 
 
For targeting BIG2, guide sequences for exon 8 and exon 10 of the ARFGEF2 gene (encoding for BIG2) 
were chosen based on minimal off-target activity and restriction sites for AhdI and StyI, respectively 
(Figure 18 a). Guide sequences were cloned into pLU6-CMV-GFP backbone and together with pRZ-
CMV-mCherry-Cas9 introduced into the cells by electroporation. Since the number of mCherry+GFP+ 
cells after sorting was low, cells were directly sub-cloned in 96-well plates. Following, clones were 
tested for CRISPR/Cas9 activity. To this end, genomic DNA spanning the predicted site of the DSB 
was amplified by PCR, treated with AhdI or StyI and analyzed using agarose gel electrophoresis 
(Figure 18 b). Out of 25 clones, only clone #24 showed a modified restriction site for exon 10 upon 
StyI digest, while no cell clone displayed an alteration in exon 8 upon AhdI digest (Figure 18 b & c). 
Western Blot analysis of cellular lysates derived from clone #24 confirmed the absence of BIG2 
protein (Figure 18 d). Because sanger sequencing of genomic DNA was inconclusive, I isolated mRNA 
of clone #24 and synthesized cDNA to exclude intron sequences from the sequence analysis. On 
cDNA level, I could confirm an insertion of 162 bp as well as an indel mutation of 183 bp, leading to 
frameshift mutations and premature stop codons (Figure 18 e). Clone #24 is hereafter referred to 
as Daudi BIG2-deficient (BIG2-/-) cells. 
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Figure 18: Generation of BIG2-deficient Daudi cells.  
(a) Scheme of human ARFGEF2 gene locus with CRISPR targeting strategy. The chosen guide sequences (blue) 
target exon 8 and 10. The PAM sequence (red) directs the Cas9 nuclease, which initiates a DSB (indicated with 
an arrow). Predicted sites of DSB are recognized by the AhdI or StyI endonucleases, respectively (purple). (b) 
CRISPR activity test. Genomic DNA of exon 8 and 10 was amplified by PCR, treated with AhdI or StyI and 
analyzed by gel electrophoresis. The size of DNA fragments is indicated on the left. (c) Screening process for 
Daudi BIG2 clones. (d) Western Blot analysis testing for BIG2 expression. Actin served as a loading control. 
Standard protein molecular masses are indicated in kDa. (e) cDNA analysis for clone #24 revealed an insertion 
(+) of 162 bp and an indel mutation (+Δ) of 183 bp, leading to frameshift mutations and which result in 
premature stop codons (*). 
 
 
 
3.2.2 BIG2 is dispensable for Ca2+ mobilization in Daudi cells 
 
To test the role of BIG2 in activated BCR signaling, I reconstituted BIG2-deficient cells with a 
construct encoding a Citrine-tagged version of BIG2. After two rounds of sorting for Citrine-positive 
cells, successful reconstitution was confirmed by flow cytometry (Figure 19 a) and Western Blot 
analysis (Figure 19 b), respectively. Staining for IgM-BCR expression with APC-conjugated α-human 
IgM antibody confirmed unaltered IgM surface expression levels in BIG2-deficient cells compared 
to their reconstituted sub-clones and DG75 wt cells (Figure 19 c). 
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Ca2+ mobilization assays revealed a higher pre-activation of BIG2-deficient cells and their sub-clones 
indicated by a higher baseline level (Figure 19 d). Upon BCR activation, BIG2-deficient cells showed 
a Ca2+ profile comparable to Daudi wt cells. The response of both high and low expressing Citrine-
tagged BIG2 cells was minimally decreased compared to BIG2-deficient cells. Since BCR expression 
levels were comparable and differences in the Ca2+ response were minimal, I concluded that BIG2 
is likely to be dispensable for Ca2+ mobilization in Daudi cells.  
 
 
 
 
 
Figure 19: Reconstitution, IgM expression and Ca2+ mobilization of BIG2-deficient Daudi cells.  
(a) BIG2-deficient cells (BIG2-/-, light green) were reconstituted with constructs encoding Citrine-tagged BIG2, 
sorted for high and low expression (BIG2-/- + CitBIG2high (cyan) and BIG2-/- + CitBIG2low (dark green)) and 
analyzed for Citrine expression by flow cytometry. Daudi wild-type (wt, grey) cells served as control. (b) 
Western Blot analysis with α-BIG2 antibody. Re-probing with α-actin was used as loading control. Standard 
protein molecular masses are indicated in kDa. (c) Cells were stained with APC-tagged α-human IgM antibody 
for analysis of surface IgM expression by flow cytometry in comparison to unstained cells (dark grey). Color 
code as seen in (a). (d) Cells were stained with Ca2+ sensitive dye Indo-1-AM. Following a baseline recording 
for 25 s, cells were stimulated with 10 µg/ml F(ab’)2 α-human IgM and Ca2+ flux was monitored for up to 5 min. 
Color code as seen in (a). Data represent results of three independent experiments. 
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3.2.3 BIG2-deficiency decreases proliferation and increases apoptosis in Daudi cells 
 
Since shRNA experiments for BIG2 showed an effect on proliferation of BL cells (Corso et al. 2016), 
I aimed to confirm this effect in my cell line model as well. To this end, I performed XTT-based 
proliferation assays in 5% FCS medium as described previously. Proliferation assays were measured 
at d0 to establish a reference and at d3 and d4 to measure for the effect of BIG2 deficiency on 
proliferation. In accordance with the results obtained from the shRNA tests, BIG2-deficient cells 
displayed a growth defect, which was approximately half of the proliferation rate observed for Daudi 
wt cells (Figure 20). Reconstitution with a Citrine-tagged BIG2 variant did not increase proliferation 
of BIG2-/- cells, which is an indicator that BIG2-deficient cells might have acquired secondary pro-
survival mutations.  
 
 
Figure 20: XTT-based proliferation assays of BIG2-deficient cells.  
Daudi wild-type (wt, grey), BIG2-deficient (BIG2-/-, light green) cells and their reconstituted sub-clones (BIG2-/- 
+ CitBIG2high (cyan) and BIG2-/- + CitBIG2low (dark green)) were cultured in 5% FCS medium and their growth 
was monitored in an XTT-based proliferation assay at d3 and d4 after plating (d0). Mean ΔOD values of three 
independent experiments performed in duplicates were normalized to d0 and quantified for d2 and d4 + SD.  
 
 
 
Besides affecting proliferation, shRNA targeting of BIG2 was also reported to enhance the number 
of apoptotic BL cells (Corso et al. 2016). To analyze the relevance of BIG2 on apoptosis in this BL cell 
line model, I grew cells for one day in RPMI 1640 medium without any supplements. Cells were then 
stained with APC-tagged Annexin V and PI as described previously and were measured by flow 
cytometry. BIG2-deficient Daudi cells showed a reduced number of living cells, while numbers of 
both early- and late apoptotic cells were increased (Figure 21). Similar results were observed for 
CitBIG2high-expressing cells. However, CitBIG2low-expressing were less prone to apoptosis. Therefore, 
although BIG2-deficient cells might have acquired pro-survival mutations, they could still benefit 
from BIG2 expression levels comparable to the endogenous situation (Figure 19 b).  
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Figure 21: BIG2-deficient Daudi cells are more prone to apoptosis.  
Daudi wild-type (wt, dark grey), BIG2-deficient (BIG2-/-, cyan) cells and their reconstituted sub-clones (BIG2-/- 
+ CitBIG2high (beige) and BIG2-/- + CitBIG2low (light grey)) were cultured in RPMI 1640 medium without 
supplements for one day before staining with APC-tagged Annexin V and PI for analysis of living (left upper 
panel), early apoptotic (right upper panel), late apoptotic (left lower panel) and all apoptotic (right lower 
panel) cells. Data are means of three independent experiments, one of which measured in duplicates. Error 
bars indicate SD.  
 
 
 
3.2.4 Aberrant regulation of protein expression and downstream signaling pathways in 
BIG2-deficient Daudi cells 
 
Following up on the proliferation and apoptosis assay, I aimed to identify which signaling pathways 
might be affected in BIG2-deficient cells. To this end, I prepared lysates of Daudi wt, BIG2-deficient 
and reconstituted cells to evaluate by Western Blot analysis. First, I tested for total protein levels of 
the adaptor protein Grb2, because its expression was described to be increased upon treatment of 
HeLa cells with small interfering RNA (siRNA) for BIG2 (Shen et al. 2012). In accordance with the 
results reported for HeLa cells, Grb2 levels were slightly enhanced in Daudi BIG2-deficient Daudi 
cells compared to wt and reconstituted cells (Figure 22 a).  
 
In a different study also performed in HeLa cells, siRNA for BIG2 decreased mRNA levels of c-MYC 
(Li et al. 2016), which is overexpressed in BL. Protein expression of c-MYC was reduced in BIG2-
deficient Daudi cells and could be restored with high levels of BIG2 almost to wt level, whereas 
lower levels of BIG2 were only partially able to restore c-MYC expression levels (Figure 22 b).  
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Figure 22: BIG2 regulates expression of Grb2 and c-MYC.  
Lysates of unstimulated Daudi wild-type (wt), BIG2-deficient (BIG2-/-) cells and their reconstituted sub-clones 
(BIG2-/- + CitBIG2high and BIG2-/- + CitBIG2low) were evaluated by Western Blot analysis and probed for total 
expression of (a) Grb2 and (b) c-MYC. Blots were re-probed with α-actin for loading control. For each protein, 
exemplary immunoblots are shown (upper panels). Standard protein molecular masses are indicated in kDa. 
Ratios of signal intensities of α-Grb2 and α-c-MYC to that of α-actin were calculated and depicted as bar 
diagrams as the means + SD of three independent experiments (a and b, respectively, lower panels). 
 
 
To analyze the role of BIG2 in tonic BCR signaling, I probed membranes with phospho-specific 
antibodies of key effector proteins in the PI3K-AKT pathway.  For the regulatory PI3K subunit p85, 
phosphorylation was comparable among cell lines, although slightly decreased in BIG2-deficient 
cells (Figure 23 a). Downstream of p85 phosphorylation, phosphorylation of AKT (Figure 23 b) and 
its target FOXO1 (Figure 23 c) was increased in BIG2-deficient cells compared to both wt and 
reconstituted cells. Thus, BIG2 directly or indirectly attenuates AKT signaling. 
 
Additionally, I analyzed activation of MAPK pathways by probing membranes with phospho-specific 
antibodies for MAPK key effector proteins ERK, JNK and p38. Basal phosphorylation of ERK was 
slightly decreased in BIG2-deficient cells compared to Daudi wt and reconstituted cells expressing 
low levels of Citrine-tagged BIG2 (Figure 24 a). Moreover, phosphorylation of JNK and p38 was 
slightly decreased in BIG2-deficient Daudi cells compared to wt cells and could be increased upon 
re-expression of high levels of BIG2 (Figure 24 b & c).  
 
In conclusion, BIG2 was identified to influence c-MYC and Grb2 expression levels in BL cells as seen 
in HeLa cells. In addition, BIG2 attenuates AKT signaling while promoting JNK, ERK and p38 pathway 
signaling to varying degrees, indicating a possible dose-dependent effect of BIG2.  
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Figure 23: BIG2 attenuates PI3K signaling in Daudi cells.  
Lysates of Daudi wild-type (wt), BIG2-deficient (BIG2-/-) cells and their reconstituted sub-clones (BIG2-/- + 
CitBIG2high and BIG2-/- + CitBIG2low) were subjected to Western Blot analysis and probed with phospho-specific 
antibodies detecting (a) p85 (b) AKT and (c) FOXO1. Re-probing with α-actin and α-panAKT served as loading 
control. For each protein, exemplary immunoblots are shown (upper panels). Standard protein molecular 
masses are indicated in kDa. Ratios of signal intensities of α-pp85 and α-pFOXO1 to that of α-actin (a and c, 
respectively, lower panels) and α-pAKT to that of α-panAKT (b, lower panel) were calculated and depicted in 
a bar diagram as the means + SD of three independent experiments. 
 
 
 
 
Figure 24: BIG2 augments MAPK signaling in Daudi cells.  
Lysates of Daudi wild-type (wt), BIG2-deficient (BIG2-/-) cells and their reconstituted sub-clones (BIG2-/- + 
CitBIG2high and BIG2-/- + CitBIG2low) were subjected to Western Blot analysis and probed with phospho-specific 
antibodies for (a) ERK (b) JNK and (c) p38. Re-probing with α-actin served as loading control, total protein 
expression was determined using α-pan antibodies. For each protein, exemplary immunoblots are shown 
(upper panels). Standard protein molecular masses are indicated in kDa. Ratios of signal intensities of α-pERK 
and α-pJNK to that of their respective pan antibodies (a and b, respectively, lower panels) and α-pp38 to that 
of α-actin (c, lower panel) were calculated and depicted in a bar diagram as the means + SD of four (JNK & 
ERK) and three (p38) independent experiments.  
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3.3 The role of SHIP2 in BCR signaling 
 
The 5’-inositol phosphatase SHIP2 is a negative regulator of PI3K signaling, since it decreases the 
pool of PI(3,4,5)P3, which is a membrane anchor for PH-domain containing proteins, such as AKT 
(Frech et al. 1997).  SHIP2 was found to be phosphorylated at S132 in tonic BCR signaling of DG75 
cells and appears to be essential for BL cell survival according to shRNA-based drop out screening 
(unpublished results, Dr. Thomas Oellerich). Therefore, I aimed to identify the role of SHIP2 with 
respect to tonic BCR signaling in BL cell lines. 
 
3.3.1 Generation of SHIP2-deficient cells 
 
I used CRISPR/Cas9 gene editing to generate SHIP2-deficient cell lines on the background of BL60 
and Daudi cells. The guide sequence was designed to target exon 1 in the INPPL1 gene (coding for 
SHIP2 protein) (Figure 25 a). The pLU6-sghSHIP2-CMV-GFP plasmid encoding for the guide sequence 
was alongside the pRZ-CMV-mCherry-Cas9 plasmid introduced into the cells using electroporation. 
After 48 h, cells were sorted to enrich the mCherry+GFP+ subpopulation and subsequently sub-
cloned. Following, I prepared lysates of the single clones and screened for the presence of the SHIP2 
protein by Western Blot analysis. For BL60 cells, in 4 out of 42 clones, SHIP2 was not detected (Figure 
25 b). Figure 25 c shows an exemplary Western blot analysis for lysates derived from clone #19 and 
BL60 wt cells. Sanger sequencing of cDNA confirmed clone #19 to have a 5 bp Indel mutation and 
an 83 bp deletion leading to frameshift mutations resulting in premature stop codons (Figure 25 d). 
In the following, clone #19 is referred to as SHIP2-deficient (SHIP2-/-) BL60 cells.  
 
For Daudi cells, in lysates of 3 out of 20 clones SHIP2 protein expression was not detected (Figure 
25 e). 2 clones were analyzed by sanger sequencing of cDNA (Figure 25 f) confirming for clone #1 a 
1 bp insertion and a 2 bp deletion, leading to frameshift mutations and subsequent premature stop 
codons (Figure 25 g). Clone #1 is hereafter referred to as SHIP2-deficient (SHIP2-/-) Daudi cells. A 
reported SHIP2 splice variant lacking amino acids 1-242 due to alternative splicing was detected in 
lysates of both Daudi and BL60 wt but not in SHIP2-deficient cells (Figure 25 e and 26 b, respectively). 
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Figure 25: Generation of SHIP2-deficient BL cell lines.  
(a) Overview of genomic organization of INPPL1 gene (encoding SHIP2). Guide RNA sequence targeting exon 1 
of INPPL1. Predicted site of DSB by Cas9 nuclease is depicted with an arrow. (b) Overview of screening for 
SHIP2-deficient clones in BL60 cells. (c) Exemplary Western Blot analysis of cellular lysates derived from BL60 
wt and clone #19 detecting SHIP2 expression. Re-probing with α-actin served as loading control. Standard 
protein molecular masses are indicated in kDa. (d) cDNA sequence analysis of clone #19 verified genomic 
alterations in both alleles (5 bp indel mutation (+Δ) and 83 bp deletion (Δ)) leading to frameshift mutations 
resulting in premature stop codons (*). (e) Western Blot analysis showed absence of SHIP2 protein in Daudi 
derived clones #1, #12 and #14. Re-probing with α-actin served as loading control. Molecular weight of 
proteins is indicated in kDa. (f) Screening process to identify Daudi SHIP2-deficient clones. (g) Sequence 
analysis of Daudi SHIP2-deficient clone #1. Both alleles were targeted by Cas9, leading to a 1 bp insertion (+) 
and a 2 bp deletion (Δ). Mutations identified in the cDNA lead to frameshift and premature stop codons (*) 
upon translation. 
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To exclude CRISPR-induced off-target or clonal effects influencing further experiments, I retrovirally 
transduced BL60 and Daudi SHIP2-deficient clones with a Citrin-tagged SHIP2 (CitSHIP2)-encoding 
construct. After selection, the Citrine-expressing sub-populations were additionally enriched by cell 
sorting. The reconstituted BL60 cells were sorted for CitSHIP2low- and CitSHIP2high-expressing cells. 
Western Blot analysis of cellular lysates showed that CitSHIP2low-expressing cells resembled 
expression of SHIP2 in BL60 wt cells (Figure 26 b). Analysis of Citrine expression by flow cytometry 
revealed CitSHIP2low-expressing cells as a heterogeneous population of both Citrine+ and Citrinelow 
cells (Figure 26 a). For further characterization, I tested for surface IgM-BCR expression, since 
different expression levels could interfere with BCR signaling intensity. BL60 SHIP2-deficient cells 
and CitSHIP2high-expressing cells displayed lower IgM expression levels compared to BL60 wt and 
CitSHIP2low-expressing cells (Figure 26 c), which was observed in three independent experiments 
(Figure 26 d). Western Blot analysis of cellular lysates revealed an enhanced expression of SHIP1 in 
all cells derived from the SHIP2-/- clone characterizing it as clonal effect (Figure 26 e).  
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Figure 26: Reconstitution of SHIP2-deficient BL60 cells, IgM and SHIP1 expression analysis.  
(a) SHIP2-deficient (SHIP2-/-) BL60 cells were reconstituted with a Citrine-tagged SHIP2 encoding construct 
(CitSHIP2) and analyzed for Citrine expression by flow cytometry in comparison to BL60 wild-type (wt) cells. 
(b) Lysates of BL60 wt, SHIP2-deficient, CitSHIP2low and CitSHIP2high cells were prepared and subjected to 
Western Blot analysis. Blots were decorated with α-SHIP2 antibody. α-actin served as loading control. 
Standard protein molecular masses are indicated in kDa. (c) Staining for surface IgM using an APC-tagged 
α-human IgM antibody. Samples were analyzed by flow cytometry. Unstained BL60 wt cells (dark grey) served 
as control. (d) Quantification of IgM expression of three independent experiments. Error bars indicate SD. (e) 
Lysates of BL60 wt, SHIP2-deficient and reconstituted CitSHIP2low and CitSHIP2high cells were subjected to 
Western Blot analysis. Blots were decorated with α-SHIP1 antibody. α-actin served as loading control (upper 
panel). Standard protein molecular masses are indicated in kDa. Ratio of signal intensities for α-SHIP1 to 
α-actin were calculated and are depicted in a bar diagram as means + SD of three independent experiments 
(lower panel). 
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Additionally, Daudi SHIP2-deficient cells were reconstituted with Citrine-tagged SHIP2 (CitSHIP2)-
encoding construct and cells were sorted for high (CitSHIP2high), medium (CitSHIP2med) and low levels 
(CitSHIP2low) of CitSHIP2 (Figure 27 a). Western Blot analysis of cellular lysates verified different 
expression levels of CitSHIP2 (Figure 27 b) and showed that SHIP2 expression of CitSHIP2low cells 
was closest to that in Daudi wt cells. Flow cytometry analysis of surface IgM revealed, in contrast to 
BL60-derived cells, comparable BCR expression in Daudi-derived cell lines (Figure 27 c) which was 
verified in three independent experiments (Figure 27 d). Differences in SHIP1 expression were not 
identified (data not shown). 
 
 
 
Figure 27: Reconstitution of SHIP2-deficient Daudi cells and IgM BCR expression.  
(a) SHIP2-deficient (SHIP2-/-) Daudi cells were reconstituted with a Citrine-tagged SHIP2 encoding construct 
(CitSHIP2), sorted for low, medium and high Citrine expression levels and analyzed for Citrine expression by 
flow cytometry in comparison to wild-type (wt, grey) Daudi cells. (b) Lysates of Daudi wt, SHIP2-deficient, 
CitHIP2low, CitSHIP2med and CitSHIP2high cells were subjected to Western Blot analysis. Blots were probed with 
α-SHIP2 antibody. α-actin served as loading control. Standard protein molecular masses are indicated in kDa. 
(c) Surface staining for IgM using an APC-tagged α-human IgM antibody. Samples were analyzed by flow 
cytometry. Unstained wt BL60 cells (dark grey) served as control. (d) Quantification of IgM expression of three 
independent experiments. Data represent means + SD.  
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3.3.2 Negative role of SHIP2 in BCR-induced Ca2+ mobilization 
 
Before analyzing the role of SHIP2 in tonic BCR signaling, I tested its role in activated BCR signaling. 
To study BCR-induced mobilization of Ca2+, I stained cells with the calcium-sensitive dye Indo-1-AM 
for flow cytometry. When activated via the BCR, Daudi SHIP2-deficient cells displayed an increased 
Ca2+ response compared to Daudi wt cells, which could be fully reconstituted upon expression of 
the Citrine-tagged version of SHIP2 (Figure 28 a). Similar to Daudi SHIP2-deficient cells, BL60 SHIP2-
deficient cells, despite having a weaker Ca2+ signal than BL60 wt cells, showed an increased BCR-
induced Ca2+ response upon activation of the BCR when compared reconstituted cells (Figure 28 b). 
These data imply that SHIP2 has a similar negative regulatory function in the BCR-induced Ca2+ 
mobilization that is reported for SHIP1 (Okada et al. 1998; Manno et al. 2016). 
 
 
 
 
Figure 28: Ca2+ mobilization is increased in SHIP2-deficient BL cells.  
(a) Daudi wild-type (wt, black line), SHIP2-deficient (SHIP2-/-, light green line) and reconstituted cells 
(CitSHIP2high, dark green line) as well as (b) BL60 wt (black line), SHIP2-deficient (SHIP2-/-, dark blue line) and 
reconstituted cells (CitSHIP2high, light blue line) were loaded with the calcium-sensitive dye Indo-1-AM and 
analyzed by flow cytometry. A baseline was recorded for 25 s before the IgM BCR was stimulated with 5 µg/ml 
F(ab’)2 α-IgM and Ca2+ flux monitored for up to 300 s. Displayed Ca2+ mobilization assays represent three 
independent experiments with similar results.  
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3.3.2.1 SHIP2 negatively regulates downstream BCR signaling 
 
Based on the identified impact of SHIP2 on BCR-induced Ca2+ mobilization, I next aimed at 
investigating further pathways in the BCR signal transduction. This was done by Western Blot 
analysis of cellular lysates derived from Daudi cells, which were left either untreated or were 
stimulated via the BCR for 5 or 15 min. Daudi cells were used to avoid artefacts due to different BCR 
surface expression found in the generated BL60 cell lines. 
 
To test for an early event in activated BCR signaling, I first analyzed the phosphorylation of Syk by 
using α-phospho-Syk and α-actin antibodies, respectively (Figure 29 a). Strong BCR-induced signals 
for phosphorylation of Syk were detected and found to be comparable among cell lines, indicating 
that SHIP2 does not affect Syk activation. 
 
The activation of MAPKs is an important process downstream of BCR engagement. Hence, I tested 
for the BCR-induced activation of ERK by probing membranes with α-phospho ERK (α-pERK) 
antibody (Figure 29 b). Re-probing of the blot with α-pan ERK and α-actin antibodies, respectively, 
served as loading controls. Upon BCR stimulation, ERK was phosphorylated in all cell lines, however 
to the highest extent in Daudi wt cells. When compared to reconstituted cells, SHIP2-deficient cells 
appear to activate ERK more efficiently further indicating a negative regulatory role of SHIP2 in 
activated BCR-signaling.  
 
Additionally, I tested for phosphorylation of the MAPKs p38 and JNK by Western Blot analysis of 
cellular lysates using respective phospho-specific and control antibodies. Daudi wt cells displayed 
an overall stronger phosphorylation of p38 compared to SHIP2-deficient cells, which was, however, 
constitutive and not BCR-inducible (Figure 29 c). When probing for phosphorylation of the MAPK 
JNK, I observed phosphorylation of JNK already in unstimulated cells, which was slightly increased 
upon BCR stimulation (Figure 29 d). SHIP2-deficient cells displayed a lower level of JNK 
phosphorylation in unstimulated cells as well as BCR-stimulated cells compared to wt and 
CitSHIP2low-expressing cells implying a role of SHIP2 in the BCR-dependent JNK activation. 
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Figure 29: Analysis of key MAPK signaling proteins activated upon BCR stimulation.  
SHIP2-deficient (SHIP2-/-) Daudi cells were reconstituted and sorted for low and medium expression levels of 
CitSHIP2 (CitSHIP2low and CitSHIP2med), were stimulated via the IgM-BCR using 10 µg/ml F(ab’)2 α-IgM for 
indicated time points or left unstimulated (0’). Daudi wild-type (wt) cells served as control. Lysates were 
prepared and subjected to Western Blot analysis. (a) Probing with α-SHIP2 (first panel) and α-actin (second 
panel) antibodies served as control. To analyze the impact of SHIP2 on BCR-induced activation, blots were 
probed with different phospho-specific antibodies detecting Syk (a, third panel), ERK (b, first panel), p38 (c, 
first panel) and JNK (d, first panel). For analysis of total protein expression, blots were re-probed with 
α-panERK (b, second panel) or α-JNK (d, second panel) or with α-actin for loading control (a-d, lower panels). 
Standard protein molecular masses are indicated in kDa. Blots represent data obtained in three independent 
experiments. 
 
 
SHIP2 dephosphorylates PI(3,4,5)P3 to PI(3,4)P2 and thereby regulates the PI3K-AKT pathway in 
several cell types (Backers et al., 2003; C.-H. Fu et al., 2014; Taylor et al., 2000; Yang et al., 2014). 
Therefore, I tested for phosphorylation of key proteins involved in PI3K-AKT signaling. Since the 
regulatory subunit of PI3K, p85, is activated early in this pathway, I started by probing Western Blots 
prepared as described above with a phospho-specific α-p85 antibody (Figure 30 a). While all cell 
lines displayed a robust and similar phosphorylation of p85 already in resting cells, BCR engagement 
appears to cause a reduction in p85 phosphorylation. An impact of SHIP2 on this process remains 
unclear. In contrast to p85, phosphorylation of AKT is induced upon BCR stimulation (Figure 30 b). 
In Daudi wt and CitSHIP2-expressing cells, AKT phosphorylation decreased after 15 min of BCR 
stimulation but not in SHIP2-deficient cells. In line with these results, phosphorylation of FOXO1, a 
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downstream target of AKT, was also phosphorylated upon BCR activation and downregulated after 
15 min of BCR stimulation in all but SHIP2-deficient cells (Figure 30 c). Taken together, these results 
demonstrate that SHIP2 negatively regulates the BCR-induced activation of AKT-dependent 
signaling events. 
 
 
 
 
Figure 30: Analysis of key PI3K signaling proteins activated upon BCR stimulation.  
SHIP2-deficient (SHIP2-/-) Daudi cells were reconstituted and sorted for low and medium levels of CitSHIP2 
(CitSHIP2low and CitSHIP2med), were stimulated via the IgM-BCR using 10 µg/ml F(ab’)2 α-IgM for indicated 
time points or left unstimulated (0’). Daudi wild-type (wt) cells served as control. Lysates were prepared and 
subjected to Western Blot analysis. To analyze the impact of SHIP2 on BCR-induced activation, blots were 
probed with different phospho-specific antibodies for (a) p85 (first panel), (b) AKT (first panel) and (c) FOXO1 
(first panel). For analysis of total protein expression, blots were re-probed with α-panAKT (b, second panel) 
or with α-actin for loading control (a-c, lower panels). Standard protein molecular masses are indicated in kDa. 
Blots represent data obtained in three independent experiments. 
 
 
3.3.2.2 SHIP2 inhibition by small molecules mimics the loss of SHIP2 in BL cell lines 
  
Another approach to decipher the role of SHIP2 in BL-dependent BCR signaling was the application 
of a selective small molecule SHIP2 inhibitor AS1949490 to complement my cell-based SHIP2-
deficient model system. The inhibitor targets the phosphatase domain of SHIP2 and was reported 
to have a 30-fold affinity for SHIP2 over SHIP1 (IC50 0.62 µM for human SHIP2) (Suwa et al. 2009). 
Since Daudi SHIP2-deficient cells displayed a robust Ca2+ phenotype upon BCR activation, I used Ca2+ 
mobilization assays to titrate the effective concentration of the inhibitor. Prior to the measurement, 
cells were treated with the desired concentration of the inhibitor or DMSO for 30 min. At a 
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concentration of 5 µM AS1949490, the Ca2+ response of Daudi wt (Figure 31 a) and CitSHIP2high-
expressing cells (Figure 31 b) resembled DMSO-treated Daudi SHIP2-deficient cells, while the BCR-
induced Ca2+ mobilization of SHIP2-deficient Daudi cells was only mildly affected upon treatment of 
AS1949490 compared to DMSO (Figure 31 c). To sum up, at a concentration of 5 µM, the SHIP2 
inhibitor AS1949490 was able to mimic the impact of SHIP2 deficiency on the BCR-induced Ca2+ 
mobilization and revealed only mild side effects. 
 
 
 
 
 
 
Figure 31: Titration of SHIP2 inhibitor AS1949490 concentration in Ca2+ mobilization assays.  
Daudi wild-type (wt), SHIP2-deficient (SHIP2-/-) and reconstituted (CitSHIP2high) cells were loaded with the 
calcium-sensitive dye Indo-1-AM. 30 min before the measurement, cells were incubated with DMSO or 5 µM 
AS1949490. Before BCR stimulation with 5 µg/ml F(ab’)2 α-human IgM, a baseline was recorded for 25 s and 
Ca2+ flux was monitored for up to 300 s. (a) Ca2+ flux of DMSO-treated (grey line) and AS1949490-treated 
(black line) Daudi wt cells compared to DMSO-treated SHIP2-/- cells (green line). (b) Ca2+ flux of DMSO-treated 
Daudi wt (grey line) and SHIP2-/- cells (green line) compared to AS1949490-treated CitSHIP2high cells (cyan line). 
(c) Ca2+ mobilization in Daudi SHIP2-/- cells treated with DMSO (green line) or AS1949490 (blue line). Plots are 
representative of three independent experiments. 
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3.3.3 SHIP2 influences proliferation and apoptosis in BL cells 
 
Having two cell line systems and a potent SHIP2 inhibitor on hand, I aimed to analyze the relevance 
of SHIP2 for the survival of BL cell lines. To verify these observations, I performed XTT-based 
proliferation and apoptosis assays to decipher the influence of SHIP2 in the SHIP2-deficient cell line 
model systems.  
 
3.3.3.1 SHIP2 positively regulates proliferation 
 
For proliferation assays, 6000 cells were seeded per well of a 96-well plate and their proliferation 
was indirectly monitored by their metabolic activity in an XTT-based proliferation assay. Proliferation 
assays were performed in 5% FCS medium as described previously. After three days, Daudi wt cells 
showed higher numbers of metabolically active cells compared to SHIP2-deficient cells (Figure 32 a). 
However, expression of CitSHIP2 could not sufficiently restore the numbers of living cells, although 
CitSHIP2high-expressing cells showed a trend to partially restore the phenotype. 
 
To circumvent possible clonal effects, I included treatment with the SHIP2 inhibitor AS1949490 and 
repeated the experiment. Treatment with DMSO was used as control. In all Daudi cell lines, 
proliferation of cells was decreased upon treatment with 5 µM AS1949490 after d2 and d4 of the 
analysis compared to DMSO treated cells (Figure 32 b). At this concentration, the inhibitor was also 
able to decrease the number of SHIP2-deficient cells, indicating that side effects of the inhibitor 
affect Daudi cell survival.  
 
I used the same experimental set up to analyze proliferation of BL60 cell lines (Figure 32 c). Here, 
the inhibitor specifically decreased proliferation in cells expressing SHIP2, while SHIP2-deficient cells 
were only mildly affected compared to DMSO treated cells. In summary, both loss of SHIP2 or 
inhibition of its phosphatase activity decreased numbers of metabolically active BL cells but this 
effect could not be fully reconstituted.  
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Figure 32: Loss of SHIP2 and SHIP2 inhibition reduced proliferation in BL60 and Daudi cells.  
(a) Daudi wild-type (wt, grey), SHIP2-deficient (SHIP2-/-, green) and reconstituted CitSHIP2low (light green) and 
CitSHIP2high cells (beige) were analyzed in XTT-proliferation assays at d0 and d3 in 5% FCS medium or (b) 
additionally treated with 5µM AS1949490 or DMSO and analyzed at d0 (grey), d2 (green) and d4 (beige). Data 
are means + SD of three independent experiments. (c) Proliferation of BL60 wt, SHIP2-deficient (SHIP2-/-) and 
reconstituted CitSHIP2low and CitSHIP2high cells was analyzed in 5% FCS medium at d0 (grey), d1 (blue), d3 (light 
blue) and d4 (beige) upon treatment with 5 µM AS1949490 or DMSO. Data are means + SD of two (d2, d4) 
and four (d0, d3) independent experiments.  
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3.3.3.2 SHIP2 partially inhibits apoptosis 
 
With respect to the proliferation assays, it remained unclear if SHIP2 directly influences cell 
proliferation or whether the observed effect is caused by increased cell death upon loss of SHIP2. 
To this end, I performed apoptosis assays by culturing cells in 1% FCS medium for three days and 
staining them at d3 with APC-tagged Annexin V and PI to distinguish live, early and late apoptotic 
cells by flow cytometry. 
 
For Daudi SHIP2-deficient cells, the percentage of living cells was decreased by approximately 10% 
compared to Daudi wt and CitSHIP2-expressing cells (CitSHIP2med not shown), while the percentage 
of late apoptotic cells was increased (Figure 33 a). The effect of SHIP2 loss was even more 
pronounced in BL60 cells (Figure 33 b). In BL60 cells, SHIP2-deficiency decreased the percentage of 
living cells by approximately 20%, whereas percentages for both early and late apoptotic cells were 
significantly increased. CitSHIP2low-expressing cells were able to fully functionally compensate for 
loss of SHIP2. In contrast, CitHIP2high-expressing cells could only partially protect SHIP2-deficient 
cells from early apoptosis.  
 
To analyze apoptosis induction in BL60 cells independent of different IgM BCR expression levels, I 
repeated the experiment by culturing BL60 wt and BL60 SHIP2-deficient cells with 5 µM AS1949490 
or DMSO in 1% FCS medium and analyzed the cells at d2. In reference to the proliferation assays, I 
expected no induction of apoptosis in BL60 SHIP2-deficient cells upon inhibitor treatment. Indeed, 
while SHIP2-deficient cells were not affected by the inhibitor, the number of late apoptotic cells in 
BL60 wt cells increased approximately 20% upon treatment with 5 µM AS1949490 compared to 
DMSO control cells (Figure 33 c). In summary, SHIP2 is likely to partially protect BL cells from 
apoptosis.  
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Figure 33: Loss of SHIP2 induced apoptosis in BL cell lines.  
Daudi and BL60 parental (wt, grey), SHIP2-deficient (SHIP2-/-, green or blue, respectively and reconstituted 
cells (CitSHIP2low (light green or light blue, respectively) & CitSHIP2high (beige)) were cultured in 1% FCS 
medium and analyzed by flow cytometry at d3 using APC-tagged Annexin V and PI. For analysis, cell 
populations were distinguished into live (Annexin V-/PI-), early apoptotic (Annexin V+/PI-), late apoptotic 
(Annexin V+/PI+) and all apoptotic (Annexin V+) cells. (a) Analysis of apoptosis induction upon loss of SHIP2 in 
Daudi cells. (b) Apoptosis assay for SHIP2 deficiency in BL60 cells. Data represent means of five experiments 
(BL60) or represent means of four experiments performed in duplicates (Daudi). Error bars represent SD. (c) 
Representative apoptosis assay of BL60 wt and SHIP2-/- cells upon treatment with 5 µM AS1949490 or DMSO 
in 1% FCS medium for two days.  
Results 
79 
 
3.3.4 Analysis of tonic BCR signaling pathways in SHIP2-deficient cells 
 
In the previous proliferation and apoptosis assays, I could show that both loss of SHIP2 or inhibition 
of its phosphatase activity led to apoptosis in BL cell lines. To elucidate the underlying signaling 
pathways, I aimed to decipher differences in phosphorylation events by analyzing the phospho-
proteome of SHIP2-deficient compared to Daudi wt cells by quantitative mass-spectrometry (MS). 
To this end, I used the stable isotope labeling with amino acids in cell culture (SILAC) approach. For 
SILAC-labeling, SHIP2-deficient cells were grown in media containing normal (light) amino acids, 
while Daudi wt cells were cultured in media containing heavy isotope amino acids. If heavy isotope 
amino acids are incorporated during protein synthesis, the overall molecular mass of the protein 
increases. By mixing light and heavy labeled samples in a 1:1 ratio, this mass-shift can be used to 
distinguish the relative intensities of both the phosphorylated or un-phosphorylated peptide in the 
MS spectra (Zhang & Neubert 2009; Mann 2006). To ensure complete incorporation of labeled 
amino acids, cells were cultured at a similar density in light (K0/R0) or heavy (K8/R10) medium for 
7 days before lysates were prepared. Samples were sent for MS analysis to the DKTK Proteomics 
Core Facility, University Hospital Frankfurt. There, samples were separated by size via SDS-PAGE and 
processed for liquid chromatography MS (LC-MS)/MS analysis as described in Corso et al. 2016. 
 
In the scatter plot, log(2) converted relative abundance (H/L ratio) of differentially phosphorylated 
proteins was plotted against the -log(10) converted t-test p value (Figure 34). Phosphorylated 
proteins with a log(2) converted H/L ratio of >2 were considered to be specifically enriched in Daudi 
wt cells, while proteins with a log(2) H/L ratio of <-2 were considered to be enriched in SHIP2-
deficient cells (Table 20). In Daudi wt cells, phosphorylation of transcription factors such as the TATA 
element modulatory factor (TMF1) and Transcription elongation factor A like 3 (TCEAL3) were 
enhanced. While not much is known about TCEAL3, TMF1 is described to mediate STAT3 
degradation, thereby omitting its function as transcription activator (Perry et al. 2004). Also, 
increased phosphorylation of Nuclear nutoantigenic sperm protein (NASP) was detected.  
Knockdown of the testicular form of NASP, which is expressed in cancer cells, was previously shown 
to cause G1 phase arrest through ERK/MAPK pathway signaling (Fang et al. 2015). 
 
Additionally, the Mitogen-activated protein kinase kinase kinase 2 (MAP3K2) was identified to be 
phosphorylated at S153. MAP3K2 regulates JNK and ERK5 signaling pathways by phosphorylation 
and subsequent activation of MAP2K7 and MAP2K5, respectively (Cheng, et al., 2000; Zhou et al., 
1995).   
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Table 23: Overview phospho-proteome analysis of Daudi wt and SHIP2-deficient cells.  
Daudi wt cells were cultured in heavy (K8/R10) SILAC medium while Daudi SHIP2-deficient cells (SHIP2-/-) were 
grown in light SILAC medium (K0/R0). Cells were lysed and subjected for global phospho-proteome analysis 
by quantitative mass-spectrometry. Phosphorylation of proteins of with a log(2) H/L ratio >2 were considered 
to be enriched in Daudi wt cells, with a log(2) H/L ratio <-2 enriched in SHIP2-deficient cells. 
 
 
 
 
 
Figure 34: Analysis of the phospho-proteome of Daudi wt and SHIP2-deficient cells. 
Daudi wt cells were cultured in heavy (K8/R10) SILAC medium while Daudi SHIP2-deficient cells (SHIP2-/-) were 
grown in light SILAC medium (K0/R0). Cells were lysed and subjected for analysis of the global phospho-
proteome by quantitative mass-spectrometry. For the scatter plot, the log(2) converted heavy (K8/R10)/light 
(K0/R0) ratio was plotted against the -log(10) converted t-test p value. Phosphorylation of proteins of with a 
log(2) H/L ratio >2 were considered to be enriched in Daudi wt cells.  
 
Protein Gene p-sites Mean log2 H/L 
Transcriptional Regulators 
   
TATA element modulatory factor TMF1 S344 5,16 
Transcription elongation factor A protein-like 3 TCEAL3 S121 2,97 
Transcription elongation factor A protein-like 3 TCEAL3 S65 2,33 
Leucine-rich repeat flightless-interacting protein 1 LRRFIP1 S714 2,25 
Serine/arginine repetitive matrix protein 2 SRRM2 T1043 -2,61 
Membrane proteins 
   
CD44 antigen CD44 S330 3,32 
Solute carrier family 26 member 6 SLC26A6 S752 2,33 
Protein unc-79 homolog UNC79 S1479 -3,38 
Cell cycle & Proliferation 
   
Nuclear autoantigenic sperm protein NASP S497 3,03 
Mitogen-activated protein kinase kinase kinase 2 MAP3K2 S153 2,31 
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Notably, this phospho-proteome analysis represents a single experiment and hence is somewhat 
preliminary. Further changes might be identified in additional analyses for which samples have been 
prepared but mass-spectrometry was not yet completed within the time frame of this thesis. Hence, 
I aimed at the biochemical analysis of tonic BCR signaling.  
 
Based on my findings that SHIP2 regulates the PI3K pathway in activated BCR signaling, I assessed 
the role of SHIP2 in tonic activation of the PI3K pathway in the generated BL cell lines. I prepared 
cellular lysates of resting wt, SHIP2-deficient and CitSHIP2-expressing Daudi and BL60 cells, 
respectively, and compared different levels of phosphorylation by Western Blot analysis using 
phospho-specific antibodies.  
 
I started by analyzing the phosphorylation of p85, the regulatory subunit of PI3K. In Daudi SHIP2-
deficient cells, the tonic phosphorylation of p85 was decreased, which was partially reverted in 
CitSHIP2low-expressing cells (Figure 35 a). In contrast, in BL60 SHIP2-deficient cells and CitSHIP2high-
expressing cells, phosphorylation of p85 was increased compared to parental and CitSHIP2low-
expressing cells (Figure 35 b).  
Similar to SHIP2, the phosphatase PTEN can decrease the pool of PI(3,4,5)P3 and is therefore 
described to negatively regulate PI3K signaling. I tested for phosphorylation of PTEN at 
S380/T382/383 which is described to lead to loss of its phosphatase activity and activation of the 
PI3K pathway (Patsoukis et al. 2013; Vazquez et al. 2000). While no changes in phosphorylation of 
PTEN were detected in Daudi-derived cellular lysates, BL60 SHIP2-deficient and CitSHIP2high-
expressing cells displayed a stronger phosphorylation compared to BL60 wt and CitSHIP2low- 
expressing cells (Figure 35 c & d).  
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Figure 35: Analysis of proximal tonic BCR signaling upon loss of SHIP2.  
Lysates of Daudi wild-type (wt, grey), SHIP2-deficient (SHIP2-/-, green), CitSHIP2low (light green), CitSHIP2med 
(dark grey) and CitSHIP2high cells (beige) (a & c) as well as BL60 wt (grey), SHIP2-deficient (SHIP2-/-, blue), 
CitSHIP2low (light blue) and CitSHIP2high cells (beige) (b & d) were prepared and evaluated by Western Blot 
analysis by probing with (a & b) phospho-specific α-p85 and (c & d) phospho-specific α-PTEN antibodies. 
Membranes were re-probed with α-actin for loading control. For each protein analyzed, exemplary 
immunoblots are shown (a-d, upper panels). Standard protein molecular masses are indicated in kDa. Ratios 
of signal intensities of α-pp85 and α-pPTEN to that of α-actin (a-d, lower panels)  were calculated and depicted 
as bar diagrams as the means + SD of two (Daudi pPTEN) or three independent experiments (others). 
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Downstream of PI3K activation, AKT is phosphorylated at T308 and S473 to be fully activated. By 
probing blots with a phospho-specific-α-AKT (S473) antibody, samples of both SHIP2-deficient cell 
lines showed an increase in AKT phosphorylation, although to a different extent (Figure 36 a & b). 
The phosphorylation of AKT in BL60 SHIP2-deficient cells was almost doubled compared to BL60 wt 
and CitSHIP2low-expressing cells. CitSHIP2high-expressing cells could reduce AKT phosphorylation to 
some extent, although not to a comparable level as seen in BL60 and CitSHIP2low-expressing cells. 
In contrast, in Daudi SHIP2-deficient cells, the increase in AKT phosphorylation was not as 
pronounced as seen in BL60 cells. However, with increasing expression levels of CitSHIP2, the effect 
could be fully restored, thereby suggesting a concentration-dependent effect of SHIP2. FOXO1 is 
phosphorylated at T24 by AKT, which retains FOXO1 in the cytoplasm. In line with AKT activation, 
phosphorylation of FOXO1 was increased in both Daudi and BL60 SHIP2-deficient cells (Figure 36 c 
& d). In BL60 cells, only the CitSHIP2low-expressing but not CitSHIP2high- expressing cells showed 
FOXO1 phosphorylation comparable to wt cells. In Daudi cells, loss of SHIP2 also led to increased 
FOXO1 phosphorylation, which could be restored by expression of CitSHIP2. In summary, SHIP2 is a 
negative regulator of the AKT signaling also in the context of tonic BCR signaling.   
 
Since an increased AKT activity in absence of SHIP2 does not explain its role in apoptosis and given 
the fact that the phospho-proteome analysis implicated a role of SHIP2 in MAPK signaling in a tonic 
signaling state, I analyzed the tonic MAPK activity in the generated cell lines by Western Blot analysis 
as described above. 
 
In SHIP2-deficient and CitSHIP2high-reconstituted BL60 cells, MAPK ERK phosphorylation was 
elevated compared to BL60 wt and CitSHIP2low-expressing cells (Figure 37 b). In SHIP2-deficient 
Daudi cells and their CitSHIP2-expressing sub-clones, a reduced phosphorylation of ERK was 
identified compared to Daudi wt cells, indicating a clonal effect (Figure 37 a). Similar to ERK, 
phosphorylation of the MAPK p38 was decreased in SHIP2-deficient Daudi cells and could not be 
restored by CitSHIP2 expression (Figure 37 c). In BL60 cells, levels of p38 phosphorylation remained 
similar among cell lines (Figure 37 d). Analysis for JNK-activation revealed that SHIP2-deficiency in 
Daudi and BL60 cells causes a marked reduction of JNK phosphorylation that was found to be 
restored in CitSHIP2low-expressing cells (Figure 36 e & f), indicating a concentration dependent effect 
of SHIP2 in JNK phosphorylation. 
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Figure 36: Analysis of tonic AKT signaling upon loss of SHIP2.  
Lysates of Daudi wild-type (wt, grey), SHIP2-deficient (SHIP2-/-, green), CitSHIP2low (light green), CitSHIP2med 
(dark grey) and CitSHIP2high cells (beige) (a & c) as well as BL60 wt (grey), SHIP2-deficient (SHIP2-/-, blue), 
CitSHIP2low (light blue) and CitSHIP2high cells (beige) (b & d) were prepared and analyzed by Western Blot 
analysis by probing with (a & b) phospho-specific α-AKT and (c & d) phospho-specific α-FOXO1 antibodies. 
Membranes were re-probed with α-panAKT (a & b) and α-actin (c & d) for loading control. For each protein 
analyzed, exemplary immunoblots are shown (a-d, upper panels). Standard protein molecular masses are 
indicated in kDa. Ratios of signal intensities of α-pAKT and α-pFOXO1 to that of α-panAKT or α-actin, 
respectively (a-d, lower panels) were calculated and depicted in bar diagrams as the means + SD of three 
independent experiments. 
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Figure 37: Analysis of tonic MAPK signaling upon loss of SHIP2. For legend see next page. 
Results 
86 
 
 
Figure 37 (previous page): Analysis of tonic MAPK signaling upon loss of SHIP2.  
Lysates of Daudi wild-type (wt, grey), SHIP2-deficient (SHIP2-/-, green), CitSHIP2low (light green), CitSHIP2med 
(dark grey) and CitSHIP2high cells (beige) (a & c) as well as BL60 wt (grey), SHIP2-deficient (SHIP2-/-, blue), 
CitSHIP2low (light blue) and CitSHIP2high cells (beige) (b & d) were prepared and analyzed by Western Blot 
analysis by probing with (a & b) phospho-specific α-ERK, (c & d) phospho-specific α-p38 and (e & f) phospho-
specific α-JNK antibodies. Membranes were re-probed with α-panERK (a & b), α-JNK (e) and α-actin (c, d, e & 
f) for loading control. For each protein analyzed, exemplary immunoblots are shown (a-f, upper panels). 
Standard protein molecular masses are indicated in kDa. Ratios of signal intensities of α-pERK, α-pp38 and 
α-pJNK to that of α-panERK (a&b) or α-actin (c, d, e & f), respectively, (a-f, lower panels) were calculated and 
depicted in bar diagrams as the means + SD of three independent experiments. 
 
 
 
To confirm these results, I additionally performed intracellular staining using an α-phospho-JNK 
(T183/Y185) Alexa Fluor® 647 - tagged antibody. For this analysis, I mixed Daudi SHIP2-deficient cells 
with Daudi CitSHIP2med-expressing and BL60 SHIP2-deficient with BL60 CitSHIP2high-expressing cells. 
This allowed gating for a Citrine-negative population of SHIP2-deficient cells and a Citrine-positive 
population of reconstituted cells. Thereby, I could mitigate effects potentially caused by sample 
processing. For a positive control, I used BCR-stimulated BL60 wt cells. As shown in Figure 38 a, BCR-
engagement led to a slight shift in the phospho-JNK signal. Analysis of JNK phosphorylation in the 
mixed Daudi sample revealed a mildly enhanced phosphorylation of JNK in the presence of CitSHIP2 
compared to SHIP2-deficient cells (Figure 38 b, upper panel). This observation was confirmed by 
analyzing the mixed sample of BL60 SHIP2-deficient and CitSHIP2high-expressing cells (Figure 38 b, 
lower panel). The observed shift of the signal in CitSHIP2-expressing cells was similar to that caused 
by BCR engagement described above. Hence, flow cytometric analysis confirmed a SHIP2-
dependent activation of JNK in Daudi and BL60 cell lines. In summary, while the impact of SHIP2 on 
the tonic activation of ERK and p38 remains unclear, these data revealed a marked positive 
regulatory role of SHIP2 on the tonic activation of JNK in BL cell lines. 
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Figure 38: Intracellular staining for JNK phosphorylation.  
For flow cytometric analysis of JNK phosphorylation, BL cell lines were fixed, permeabilized and stained with 
α-pJNK (T183/Y185) Alexa Fluor® 647 antibody. (a) BL60 wild-type (wt) cells were either stimulated with 
10 µg/ml F(ab’)2 α-IgM (red) or left unstimulated (blue). Unstained cells (grey) served as control. SHIP2-
deficient Daudi (blue, Citrine-) and CitSHIP2med (green, Citrine+) cells (b, upper panel) as well as SHIP2-deficient 
BL60 (blue, Citrine-) and CitSHIP2high (green, Citrine+) cells (b, lower panel) were mixed to be analyzed in the 
same sample. Plots show representative results of two independent experiments.  
 
 
To further confirm these data, I included the SHIP2 inhibitor AS1949490 for the analysis of tonic 
signaling pathways. To this end, I treated Daudi wt, SHIP2-deficient and CitSHIP2low-expressing cells 
with 5 µM SHIP2 inhibitor AS1949490 or DMSO for 30 min before cell lysis, subjected lysates to 
Western Blot analysis and probed blots with phospho-specific antibodies.  
 
Phosphorylation of the PI3K subunit p85 was not changed upon inhibitor treatment in Daudi wt 
cells, while both for Daudi SHIP2-deficient and CitSHIP2low-expressing cells phosphorylation of p85 
was decreased after inhibitor treatment (Figure 39 a). By probing with phospho-specific PTEN 
antibody, I found a small increase in PTEN phosphorylation in all Daudi cell lines (Figure 39 b). 
Phosphorylation of PTEN is associated with activation of the PI3K pathway. Downstream of PI3K 
activation, AKT was increasingly phosphorylated upon SHIP2 inhibitor treatment in all Daudi cell 
lines (Figure 39 c), while FOXO1 phosphorylation was only positively affected in Daudi wt cells and 
in CitSHIP2low-expressing cells (Figure 39 d). In summary, signaling via the PI3K-AKT pathway in Daudi 
cells was increased upon SHIP2 inhibitor treatment.   
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Figure 39: SHIP2 inhibition affects PI3K signaling in Daudi cells.  
Daudi wild-type (wt), SHIP2-deficient (SHIP2-/-) and CitSHIP2low-expressing cells were treated with 5 µM 
AS1949490 (+, light grey) or DMSO (-, dark grey) for 30 min prior to cell lysis. Lysates were subjected to 
Western Blot analysis and blots were decorated with (a) phospho-specific α-p85, (b) phospho-specific α-PTEN, 
(c) phospho-specific α-AKT and (d) phospho-specific α-FOXO1 antibodies. Treatment with α-actin and 
α-panAKT antibodies was performed for loading control. For each protein analyzed, exemplary immunoblots 
are shown (a-d, upper panels). Standard protein molecular masses are indicated in kDa. Ratios of signal 
intensities of α-p85, α-pPTEN, α-pAKT and α-pFOXO1 to that of α-panAKT (c) or α-actin (a, b & d), respectively, 
(a-d) lower panels) were calculated and depicted as bar diagrams as the means + SD of two (pPTEN), four 
(pp85) or five (pAKT, pFOXO1) independent experiments. 
 
 
To test whether the SHIP2 inhibitor could also mimic the effect of loss of SHIP2 concerning MAPK 
signaling, I probed Western Blots with phospho-specific α-ERK antibody. Although the effect was 
not as pronounced in Daudi wt cells, SHIP2-deficient and CitSHIP2low-expressing cells showed an 
increase in ERK phosphorylation upon inhibitor treatment in comparison to DMSO treated cells 
(Figure 40 a). In contrast, phosphorylation of MAPK p38 was mildly reduced in all cell lines when 
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treated with the inhibitor (Figure 40 b). Also, phosphorylation of MAPK JNK was affected by SHIP2 
inhibitor treatment. Upon SHIP2 inhibition, all Daudi cell lines showed a decrease in JNK 
phosphorylation, however, the effect was more prominent in Daudi wt and CitSHIP2low-expressing 
cells (Figure 40 c). In summary, SHIP2 inhibitor AS1949490 was able to induce a downregulation of 
phosphorylation of MAPK p38 and JNK, whereas ERK phosphorylation was increased upon SHIP2 
inhibitor treatment.  
 
 
 
Figure 40: SHIP2 inhibition affects MAPK signaling in Daudi cells. 
Daudi wild-type (wt), SHIP2-deficient (SHIP2-/-) and CitSHIP2low-expressing cells were treated with 5 µM 
AS1949490 (+, light grey) or DMSO (-, dark grey) for 30 min prior to cell lysis. Lysates were subjected to 
Western Blot analysis and blots were decorated with (a) phospho-specific α-ERK, (b) phospho-specific α-p38 
and (c) phospho-specific α-JNK antibodies. Treatment with α-actin and α-panERK and α-JNK antibodies was 
performed for loading control. For each protein analyzed, exemplary immunoblots are shown (a-d, upper 
panels). Standard protein molecular masses are indicated in kDa. Ratios of signal intensities of α-pERK, α-pp38 
and α-pJNK to that of α-panERK (a), α-actin (b) and α-JNK (c) respectively, (a-c) lower panels) were calculated 
and depicted as bar diagrams as the means + SD of two (pp38), three (pJNK) or five (pERK) independent 
experiments. 
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Next, I aimed to verify if the main effectors found to be differentially regulated upon SHIP2 inhibition 
in Daudi cells are also similarly regulated in BL60 cells. Therefore, I used BL60 wt, SHIP2-deficient, 
CitSHIP2low- and CitSHIP2high-expressing cells and prepared lysates as described above. Lysates were 
subjected to Western Blot analysis and blots were probed with phospho-specific antibodies against 
key effector proteins AKT, ERK and JNK. Similar to Daudi cells, AKT phosphorylation was increased 
in all BL60 cell lines upon SHIP2 inhibitor treatment (Figure 41 a), as well as ERK phosphorylation 
(Figure 41 b). However, JNK phosphorylation was not changed upon SHIP2 inhibitor treatment 
(Figure 41 c). In summary, while phosphorylation of AKT and ERK was similarly regulated in Daudi 
and BL60 cells, JNK phosphorylation in BL60 cells was not affected by the SHIP2 inhibitor in contrast 
to Daudi cells. This indicates that JNK signaling via SHIP2 might be differentially regulated in Daudi 
and BL60 cells. In BL60 cells, JNK phosphorylation is more likely dependent on the adaptor function 
rather than the phosphatase activity of SHIP2, which is more relevant for JNK phosphorylation in 
Daudi cells.  
 
 
 
Figure 41: SHIP2 inhibition affects signaling in BL60 cells.  
BL60 wild-type (wt), SHIP2-deficient (SHIP2-/-), CitSHIP2low- and CitSHIP2high-expressing cells were treated with 
5 µM AS1949490 (+) or DMSO (-) for 30 min prior to cell lysis. Cellular lysates were subjected to Western Blot 
analysis and blots were decorated with (a) phospho-specific α-AKT (b) phospho-specific α-ERK and (c) 
phospho-specific α-JNK antibodies (upper panels). Treatment with antibodies detecting total protein levels 
(second panels) and α-actin (lower panels) served as controls. Standard protein molecular masses are 
indicated in kDa. Blots are representative of two independent experiments.  
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3.3.5 BCR-induced JNK signaling in SHIP2-deficient BL60 cells 
 
Because the JNK phenotype in BL60 SHIP2-deficient cells was so pronounced and not regulated by 
the SHIP2 inhibitor, I wanted to elucidate if the JNK signaling pathway in BL60 could still be regulated 
by other means. To this end, I stimulated BL60 wt, SHIP2-deficicient, CitSHIP2low- and CitSHIP2high-
expressing cells with 5 µg/ml F(ab’)2 α-IgM for 10 min to check for BCR-dependent JNK activation. 
As controls, I treated cells with pervanadate for 10 min to inhibit protein tyrosine phosphatases or 
left cells untreated. After treatment, cells were lysed and evaluated by Western Blot analysis using 
phospho-specific antibodies. 
As a control for induction of BCR signal transduction events, phosphorylation of Syk and ERK was 
analyzed and found to be phosphorylated in a BCR-inducible manner (Figure 42). While Syk was also 
phosphorylated in pervanadate-treated cells, phosphatase inhibition was apparently not sufficient 
to induce phosphorylation further downstream of BCR signal transduction. The different efficiency 
in Syk and ERK phosphorylation among the different cell lines correlates with the differences in BCR 
surface expression described in 3.3.1. In addition, BCR-engagement led to a slight increase of JNK 
phosphorylation in BL60 wt cells which was even less in SHIP2-deficient or CitSHIP2high-expressing 
cells, indicating a more general defect of JNK activation in these cells. 
 
 
 
Figure 42: JNK signaling is increased upon BCR stimulation in BL60 cells. For legend see next page. 
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Figure 42 (previous page): JNK signaling is increased upon BCR stimulation in BL60 cells.  
BL60 wt, SHIP2-deficient (SHIP2-/-), CitSHIP2low - and CitSHIP2high - expressing cells were left untreated or were 
incubated with 5 µg/ml F(ab’)2 α-IgM or Pervanadate (PerVO4) for 10 min prior to cell lysis. Lysates were 
subjected to Western Blot analysis and blots were decorated with phospho-specific antibodies for BCR 
effector proteins SyK (upper panel), ERK (second panel) and JNK (fourth panel). α-actin and antibodies 
detecting total levels of ER and JNK protein were used for loading control (lower panel and third as well as 
fifth panel, respectively). Standard protein molecular masses are indicated in kDa. 
 
 
3.3.6 Tonic BCR signaling regulates SHIP2-dependent JNK activation in BL60 cells 
 
Although I could show that BCR engagement can induce low levels of JNK activation, it remained 
unclear whether the effect of SHIP2 on JNK phosphorylation in resting cells was related to tonic BCR 
signaling. To address this, I generated cell lines that inducibly downregulate the BCR and hence 
abrogate tonic BCR signals. For this, I silenced gene expression of CD79A, which is needed for BCR 
surface expression, by using short hairpin RNA (shRNA) targeting CD79A. BL60 wt, SHIP2-deficient, 
CitSHIP2low- and CitSHIP2high-expressing cells were lentivirally transduced with a doxycycline-
inducible shCD79A expression plasmid (LT3-GECIR shCD79a-1) and a control shRNA (shCtrl, LT3-
GECIR shGL2) in a collaboration with Dr. Doebele, Department of Medicine II, Hematology 
& Oncology, University Hospital Frankfurt. Since both shRNA expression plasmids are also carrying 
a mCherry expression cassette, transduced cells could be analyzed for successful integration by flow 
cytometry. After transduction, approximately 60% of cells were positive for mCherry expression 
(data not shown). However, CitSHIP2low-expressing cells were no longer positive for Citrine 
expression, therefore they were excluded from further analyses. 
 
First, I aimed to check the function of the shRNAs. To this end, I seeded cell lines at a similar density 
in fresh medium and treated cells with 250 ng/ml doxycycline (Dox) for 48 h or left them untreated. 
To check for induction of shRNAs, cells were analyzed by flow cytometry by staining with APC-
conjugated α-human IgM antibody (Figure 43 a). Upon induction with doxycycline (+ Dox), all cell 
lines carrying the shCD79A expression plasmid showed a reduction of IgM-BCR expression 
compared to untreated (- Dox) cells. Induction of control shRNA did not alter IgM-BCR expression 
levels (data not shown). To test whether JNK phosphorylation levels were altered upon knockdown 
of CD79A, I prepared lysates of + Dox and - Dox cells and performed Western Blot analysis testing 
for JNK phosphorylation (Figure 43 b). Upon treatment with doxycycline, phosphorylation of JNK 
was reduced in BL60 wt and CitSHIP2high-expressing cells by 18% and 36%, respectively, when 
compared to their untreated counterparts. JNK phosphorylation was also decreased in SHIP2-
deficient cells, however only by 6%. In summary, these results indicate that SHIP2-dependent JNK 
activation is influenced by tonic BCR signaling in BL60 cells.  
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Figure 43: SHIP2-dependent JNK activation is influenced by tonic BCR signaling in BL60 cells.  
BL60 wild-type (wt), SHIP2-deficient (SHIP2-/-) and CitSHIP2high-expressing cells were transduced with 
doxycycline-inducible plasmids encoding for shCD79A. (a) Cells were stained with APC-conjugated α-human 
IgM antibody and analyzed for IgM surface expression by flow cytometry when treated with (+) or without (-) 
250 ng/ml doxycycline (Dox) for 48 h. (b) Following Dox treatment, wells were lysed and subjected to Western 
Blot analysis for JNK phosphorylation status using phospho-specific α-JNK antibody (upper panel). Re-probing 
with α-JNK (second panel) and α-actin (third panel) antibodies was used for loading control. Standard protein 
molecular masses are indicated in kDa. Ratios of signal intensities of α-pJNK to that of α-JNK were calculated 
and depicted as a bar diagram and reduction of signal intensities of untreated to treated cells was calculated 
(lower panel). 
 
 
3.3.6 Establishing an inducible shCD79A system in Daudi cells 
 
Similar to the approach described for the BL60 cell lines, I next assessed whether the identified 
SHIP2-dependent signaling processes are part of the tonic BCR signaling network in Daudi cells. For 
this purpose, Daudi wt, SHIP2-deficient and CitSHIP2low-expressing cells were lentivirally transduced 
with the same shRNA expression plasmids as described above and tested for their functionality 48h 
after doxycycline induction. For testing, I used Daudi SHIP2-deficient and CitSHIP2low-expressing 
cells both transduced either with constructs encoding for shCD79A or shCtrl and compared CD79A 
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expression levels by Western Blot analysis (Figure 44 a). In shCD79A transduced cell lines, 
doxycycline treatment led to reduced expression levels of CD79A compared to untreated cells, 
whereas shCtrl transduced cell lines were not affected by doxycycline. Transduced plasmids also 
carry a GFP-encoding cassette to check for sufficient induction by doxycycline. Re-probing of the 
membrane with α-GFP antibody confirmed doxycycline-induced GFP expression. Additionally, I 
stained all doxycycline-treated samples with APC-conjugated α-human IgM antibody and analyzed 
IgM surface expression levels by flow cytometry (Figure 44 b). Only in shCD79A transduced cells, 
doxycycline treatment decreased IgM-BCR expression levels, proving the validity of the 
experimental setup for further analyses.  
 
 
Figure 44: shCD79A specifically decreases CD79A and IgM expression in Daudi cells.  
Daudi SHIP2-deficient (SHIP2-/-) and CitSHIP2low-expressing cells were transduced with constructs encoding 
doxycycline-inducible shCD79A or control (shCtrl) shRNAs and were induced with (+) 250 ng/ml doxycycline 
(Dox) for 48 h or left untreated (-). (a) Cells were then lysed and subjected to Western Blot analysis followed 
by probing for total protein expression of CD79A and GFP using α-CD79A (upper panel) and α-GFP antibodies 
(second panel), respectively. α-actin was used for loading control (lower panel). Standard protein molecular 
masses are indicated in kDa. (b) Following Dox-treatment, cells were stained with APC-conjugated α-human 
IgM antibody and analyzed for IgM surface expression by flow cytometry.  
 
 
Next, I aimed to identify the optimal induction time to analyze shCD79A cells. Since shCD79A 
induction in Daudi cells had been proven to be toxic over the course of 10 days (Corso et al. 2016), 
I aimed for a sufficient reduction in IgM-BCR expression without affecting the viability of cells. I 
treated Daudi wt, SHIP2-deficient and CitSHIP2low-expressing cells with 250 ng/ml doxycycline for 
48 h or 72 h and analyzed IgM surface expression levels as described previously (Figure 45 a). 
Although all cell lines already showed reduction of IgM expression after 48h, IgM expression was 
further reduced after 72 h. Thus, untreated cells and cells treated with Dox for 72 h were lysed and 
subjected to Western Blot analysis. By probing with α-CD79a antibody, I could verify a decline of 
CD79A expression in Dox-treated cells (Figure 45 b), which correlated with GFP expression, thereby 
indicating the activity of the shRNA. Because knockdown CD79A is supposed to decrease tonic and 
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thereby PI3K signaling of the BCR, I additionally analyzed phosphorylation of PI3K subunit p85. 
Treatment with Dox enhanced p85 phosphorylation in all cell lines. (Figure 45 c). However, 
phosphorylation of AKT downstream of p85 was found to be reduced upon CD79A knockdown 
(Figure 44 d).  In summary, CD79A knockdown was sufficiently induced after 72h and was able to 
decrease tonic PI3K signaling on the level of AKT phosphorylation. 
 
 
 
Figure 45: shCD79A knockdown decreases IgM expression and AKT signaling in Daudi cells. 
Daudi wild-type (wt), SHIP2-deficient (SHIP2-/-) and CitSHIP2low-expressing cells were transduced with 
constructs encoding doxycycline-inducible shCD79A or control (shCtrl) shRNA and were induced with (+) 
250 ng/ml doxycycline (Dox) for 48 h or 72 h or left untreated (-). (a) Cells were stained with APC-conjugated 
α-human IgM to test for IgM surface expression by flow cytometry. (b-d) 72 h after Dox induction, cells were 
lysed and subjected to Western Blot analysis. (b) Analysis for CD79A expression and Dox induction by probing 
with α-CD79A (upper panel) and α-GFP (second panel), respectively. Re-probing with α-actin (lower panel) for 
loading control. To test for PI3K-AKT pathway activation, blots were decorated with phospho-specific (c) α-p85 
and (d) α-AKT antibodies (c & d, upper panels). Re-probing with α-panAKT (d, second panel) and α-actin 
antibodies (c & d, lower panels) for loading control. Standard protein molecular masses are indicated in kDa. 
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3.3.7 Tonic BCR signaling via SHIP2 activates JNK signaling in Daudi cells 
 
Next, I aimed to analyze the effect of CD79A knockdown in the context of SHIP2-dependent 
regulation of tonic BCR signaling pathways. I used Daudi-derived cells for this analysis due to 
aberrant BCR expression levels in BL60-derived cells as described in 3.3.1. For this purpose, I also 
included the SHIP2 inhibitor AS1949490 in the experiment. Daudi cells transduced with constructs 
encoding shCD79A were induced with Dox for 72 h, harvested and treated with 5µM AS1949490 for 
30 min in RPMI only or left untreated. Cells were subsequently lysed and subjected to Western Blot 
analysis.  
 
In order to check for sufficient induction of shRNAs, I started by probing membranes with α-GFP 
antibody (Figure 46 a). GFP expression was sufficiently induced upon doxycycline treatment to 
comparable levels in all cell lines.  To test for activation of the PI3K pathway, I decorated membranes 
with α-pAKT and α-pFOXO1 antibodies, respectively (Figure 46 b & c). Expectedly, knockdown of 
CD79A decreased AKT and FOXO1 phosphorylation in all Daudi cell lines. Treatment with the SHIP2 
inhibitor elevated AKT and FOXO1 phosphorylation levels in Daudi wt and CitSHIP2low-expressing 
cells independent of CD79A knockdown, whereas in SHIP2-deficient cells, phosphorylation of AKT 
and FOXO1 was not affected by the SHIP2 inhibitor.  
 
Based on my findings described in section 3.3.4, I now tested the activation of MAPK JNK and ERK 
in this experimental setup. Upon CD79A knockdown, ERK phosphorylation was only minimally 
affected in Daudi wt cells but no differences were observed in Daudi SHIP2-deficient and 
CitSHIP2low-expressing cells (Figure 46 d). Moreover, I probed blots with phospho-specific α-JNK 
antibody (Figure 46 e). In all CD79A knockdown samples, JNK phosphorylation was decreased 
compared to untreated samples, indicating that phosphorylation of JNK is dependent on tonic BCR 
signaling. For Daudi wt and CitSHIP2low-expressing cells, the reduction in JNK phosphorylation was 
more severe, namely 17% and 21%, respectively, compared to untreated cells. In contrast, SHIP2-
deficient cells only displayed a reduction in phosphorylation of 11% upon CD79A knockdown. In 
summary, these data show that the SHIP2-dependent regulation of the JNK pathway is part of the 
tonic BCR signaling network.  
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Figure 46: SHIP2-dependent JNK activation is influenced by tonic BCR signaling in Daudi cells.  
Daudi wild-type (wt), SHIP2-deficient (SHIP2-/-) and CitSHIP2low-expressing cells were transduced with 
plasmids encoding for doxycycline-inducible shCD79A or control (shCtrl) shRNA and were induced with (+, 
dark grey) 250 ng/ml doxycycline (Dox) for 72 h or left untreated (-, light grey). Before lysis, cells were either 
treated with 5 µM AS1949490 (+) for 30 min or left untreated (-). Lysates were subjected to Western Blot 
analysis. (a) Dox-induced GFP expression was detected with α-GFP antibody (upper lane) and equal loading 
was tested with α-actin (lower panel). (b) Phosphorylation of AKT was analyzed using phospho-specific α-AKT 
antibody (upper panel), α-panAKT (second panel) and α-actin (third panel) for loading control. Ratios of signal 
intensities of α-pAKT to that of α-panAKT were calculated and depicted as a bar diagram (lower panel). (c) 
Probing membranes with phospho-specific α-FOXO1 antibody (upper panel) and re-probing with α-actin 
(lower panel). (d) Analysis of ERK signaling using phospho-specific α-ERK antibody (upper panel), α-panERK 
(second panel) and α-actin (third panel). Ratios of signal intensities of α-pERK to that of α-panERK were 
calculated and depicted in a bar diagram (lower panel). (e) JNK signaling upon CD79A knockdown was 
analyzed by probing with phospho-specific α-JNK antibody (upper panel), α-JNK (second panel) and α-actin 
antibodies (third panel). Ratios of signal intensities of α-pJNK to that of α-JNK were calculated and depicted 
as a bar diagram and reduction of signal intensities of untreated to treated cells was calculated (lower panel). 
Quantification data are means + SD of two independent experiments. Standard protein molecular masses are 
indicated in kDa
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4 Discussion 
 
Tonic signaling via the BCR and subsequent activation of the PI3K pathway is believed to be of 
central importance for the survival and proliferation of BL cells (Schmitz et al. 2012), but the 
underlying molecular details remain unclear to date. Based on a proteogenomic screen in different 
BL cell lines, I have characterized the function of Nck1, BIG2 and SHIP2 in BL-specific tonic BCR 
signaling. My data imply that beyond the PI3K pathway, the activity of the MAPK JNK is regulated 
by Nck1, SHIP2 and BIG2 upon tonic BCR signaling. Hence, my study sheds some light on the 
molecular aspects of BL-specific tonic BCR signaling and emphasizes the JNK pathway to be a 
promising target for novel therapeutic approaches for BL.  
 
4.1 Redundant and non-redundant functions of Nck proteins in BL signaling  
 
Upon BCR stimulation, the adaptor protein Nck is recruited to the phosphorylated non-ITAM 
tyrosine (Y204) in Igα via its SH2 domain in addition to bind to proline-rich regions of the adaptor 
BCAP via its SH3 domains in DT40 chicken B cells (Castello et al. 2013). Tyrosine phosphorylation of 
BCAP by Syk and Btk allows binding of the PI3K subunit p85 (Okada et al. 2000), thereby linking 
activation of the BCR to PI3K activation and localization. Here, I provide evidence that Nck1 and 
Nck2 also regulate PI3K activation in tonic BCR signaling of BL cells and additionally identified Nck1 
to promote JNK and p38 MAPK signaling.  
 
4.1.1 Nck1 and Nck2 regulate PI3K-AKT activation in tonic BCR signaling  
 
Evidence for the impact of Nck1/2 on tonic BCR signaling via the PI3K pathway, which has been 
reported to be crucial for survival of BL cells (Schmitz et al., 2014), comes from DG75 cell lines 
lacking expression of either or both Nck proteins that I generated during this thesis. According to 
my analyses, Nck1 deficiency leads to lower phosphorylation levels of the PI3K effectors AKT and 
FOXO1 under tonic signaling conditions. In comparison, loss of Nck2 expression only led to a mild 
decrease in AKT and FOXO1 phosphorylation. Although, according to these results, Nck1 appears to 
be the dominant isoform involved in tonic PI3K-AKT activation, Nck2 expression further increases 
the efficiency of AKT activation. In line with these findings, Nck-dependent AKT activation was also 
observed in mouse B cells (Castello et al. 2013). Although not particularly addressed in the study, 
the phosphorylation of AKT was reduced in absence of Nck1 and Nck2 already in resting cells hence 
supporting the positive role of Nck1 and Nck2 for PI3K-AKT signaling in the context of tonic BCR 
signaling identified in this thesis.  
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Noteworthy, the functional reconstitution of Nck1- and Nck1-2-deficient DG75 cell lines was only 
partly successful, which is in line with lower levels of the pivotal Nck-PI3K adaptor BCAP. In the 
context of activated BCR signaling, BCAP deletion leads to an almost complete block in BCR-
mediated AKT phosphorylation (Aiba et al. 2007; Okada et al. 2000), whereas the impact of BCAP 
expression for tonic BCR signaling has not been tested. However, the reduction of AKT 
phosphorylation in both Nck1- and Nck1-2 deficient DG75 cell lines might be potentiated by lower 
BCAP expression in these cell lines and the cause of insufficient functional reconstitution. 
Nevertheless, the fact that I could observe some reconstitution allows for the conclusion that Nck1 
in co-operation with Nck2 regulates the PI3K pathway in the tonic BCR signaling network of DG75 
cells.  
 
While my study is the first to show a role of Nck proteins in the activation of the PI3K pathway in 
tonic BCR signaling, studies are available assessing the role of Nck proteins in activated receptor 
signaling (Lu et al. 2015; Castello et al. 2013). Castello and colleagues found reduced BCR-induced 
Ca2+ mobilization in Nck-deficient mouse B cells and DT40 cells (Castello et al. 2013). While in DT40 
cells Nck2 is the only expressed Nck protein, loss of Nck2 did not further attenuate the Ca2+ signal 
in Nck1-deficient mouse B cells. Similar to mouse B cells, I found a marked reduction of BCR-induced 
Ca2+ mobilization in Nck1-deficienct DG75 cells and no effect of Nck2 in these experiments. These 
data are further corroborated be the fact that the PI3K-inhibitor Wortmannin significantly 
decreased BCR-induced Ca2+ mobilization in Nck1-expressing but not Nck1-deficient cells. These 
results indicate that in human B cells, Nck1 is signaling upstream of BCR-dependent PI3K activation 
(Castello et al. 2013). However, in contrast to the reports and to my analyses of tonic BCR signaling, 
I could not identify an impact of Nck1 on the PI3K effectors AKT and FOXO1 following BCR 
stimulation. Because my focus was on the investigation of tonic BCR signaling I did not further asses 
the Nck function in activated BCR signaling, but the data indicate, that for an efficient activation of 
AKT and FOXO1 not only Nck1 but also Nck2 is important. This is supported by findings in naïve 
mouse B cells (Castello et al. 2013), showing that although already decreased in Nck1 KO mouse B 
cells, AKT and FOXO1 phosphorylation was more attenuated in B cells derived from Nck1-2 KO mice. 
In summary, I could show that Nck proteins are relevant for efficient PI3K signaling in the tonic BCR 
signaling network of BL cells.  
 
 
 
 
Discussion 
100 
 
4.1.2 Nck1 is required for efficient p38 activation in tonic BCR signaling 
 
Beyond the PI3K pathway, activation of different MAPK is a hallmark of BCR signaling. I could show 
that in resting BL cell lines the MAPKs ERK, p38 and JNK are phosphorylated indicating their 
activation. While I found no impact of Nck proteins on the efficiency of ERK activation, p38 MAPK 
phosphorylation was reduced in the absence of Nck1 but not Nck2.  This effect seems to be specific 
for tonic BCR signaling since p38 phosphorylation was not altered by Nck1 deficiency after BCR 
engagement. This is in agreement with studies in Jurkat T cells (Ngoenkam et al. 2014) and in mouse 
B cell lymphoma cells (Mizuno et al. 2002), which reported Nck proteins did not alter p38 signaling 
after TCR and BCR receptor stimulation, respectively. A potential candidate linking Nck1 to p38 
activation could be the Nck-interacting kinase (NIK, also known as MAP4K4) which was shown to 
activate p38 signaling during mouse gastrulation (Zohn et al. 2006). Indeed, NIK was found to be 
tonically phosphorylated in our phospho-proteomic approaches but the exact molecular 
mechanism how Nck1 regulates the p38 pathway in tonic BCR signaling remains to be studied. 
 
4.1.3 Nck1-dependent JNK activation in tonic and activated BL signaling 
 
JNK is another MAPK I found to be regulated by Nck proteins in tonic BCR signaling. Nck1- and 
Nck1-2-deficient DG75 cells displayed lower levels of JNK phosphorylation, which could be partially 
restored by expression of Nck1 or both Nck isoforms, respectively. Again, Nck1 was identified as the 
primary isoform involved in this process but Nck2 expression further augments JNK activation. The 
role of Nck proteins in JNK activation does not appear to be restricted to tonic BCR signaling since 
the BCR-induced activation of JNK was compromised in the absence of Nck1, too. 
 
From the literature, two possible mechanisms of how Nck1 helps to activate JNK are conceivable. 
First, a loss of BCAP recruitment in absence of Nck1 might cause insufficient JNK phosphorylation. 
Studies of BCAP-deficient DT40 chicken B cells revealed that following BCR engagement BCAP is 
required for efficient JNK activation (Okada et al. 2000). Since BCAP expression was also reduced in 
Nck1- and Nck1-2-deficient DG75 cells and their sub-clones, this might explain - similar to AKT - the 
only partial restoration of JNK phosphorylation after reconstitution of my cell lines. Okada and 
colleagues proposed that loss of BCAP reduced PI3K activation and caused decreased JNK signaling 
via the PH-domain containing guanine-exchange factor Vav. Hence, Nck1 via recruitment of BCAP 
and subsequent activation of the PI3K-Vav signaling axis could orchestrate JNK activation in the tonic 
BCR signaling network of BL cells.  
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A second possible way for Nck to control JNK activation might be mediated by its interaction with 
SLP65. The BCR-induced association of SLP65 and Nck has been shown to activate JNK signaling in 
the mouse B cell lymphoma cell line WEHI-231 (Mizuno et al. 2002). However, WEHI-231 cells show 
characteristics of immature B cells including growth arrest and apoptosis upon BCR stimulation 
(Benhamou et al. 1990), which was not observed germinal-center derived BL DG75 cells (data not 
shown). Differences in the net-result of BCR signaling might also be reflected by different regulatory 
mechanisms in signaling pathways. Thus, whether the SLP65/Nck1, the BCAP/Nck1 interaction, or 
both are required for efficient JNK activation in BL cells needs further investigation. In conclusion, I 
could identify an impact of Nck proteins on different signaling pathways in the tonic BCR signaling 
network of BL cells. How this Nck-dependent signaling might contribute to the survival and 
proliferation of BL cells will be discussed in the next section. 
 
 
4.1.4 Nck proteins affect survival and proliferation of DG75 BL cells 
 
The fate of a cell to live or die depends on activation and inhibition of different signaling pathways 
triggered by extrinsic pro-survival signals or intrinsic and extrinsic stress-signals. Proliferation and 
apoptosis therefore represent the net-result of integration of different signaling pathways. With 
regard to the role of Nck in tonic BCR signaling, these pathways include - but might not limited to - 
the PI3K-AKT, p38, and JNK pathways. In the following chapter, I will discuss these pathways with 
respect to proliferation and apoptosis.  
   
I could show that DG75 cells lacking expression of Nck1, Nck2, or both isoforms have an attenuated 
proliferation in comparison to DG75 wt cells. However, reconstituted cells were not able to 
compensate for growth differences, indicating clonal effects altering proliferation. This is in part also 
reflected by the analysis of signaling pathways since re-expression of Nck proteins was only partially 
able to reconstitute the phenotypes observed for PI3K-AKT, p38, and JNK signaling. Lower levels of 
PI3K-AKT signaling are likely causing decreased cell cycle activity in Nck-deficient cells. In 
mammalian cells, AKT can phosphorylate GSK3β at S9 resulting in inhibition of its kinase activity 
(Cross et al. 1995; Fang et al. 2000). Following, the cell-cycle promoting protein Cyclin D1 is released 
from GSK3β-dependent negative regulation (Diehl et al. 1998). In line with its described suppression 
of cell proliferation in other cells, GSK3β functions as a metabolic senor that restricts cell mass 
accumulation in GC B cells (Jellusova et al. 2017; Cui et al. 1998). Interestingly, PI3K and AKT were 
identified to act as upstream regulators of JNK and Cyclin D1 in human bronchial epithelial cells, and 
signaling via the PI3K/AKT/JNK/cyclin D axis promoted cell growth (Ding et al. 2009).  
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In addition, reconstitution of the AKT and JNK phosphorylation in Nck1- and Nck1-2-deficient cells 
was challenging, indicating a possible causal dependency of AKT and JNK activity. Notably, JNK has 
been described to control PI3K and AKT in other cells (Chen et al. 2016), and thus it remains to be 
analyzed how the interdependency between these pathways is organized in tonic BCR signaling. 
Functionally, increased signaling via JNK and p38 is associated with increased survival and cell 
growth  in BL cells (Gururajan et al. 2005; Horie et al. 2007). Lower signaling intensity of AKT, JNK 
and p38 thus might contribute to proliferative defects in Nck-deficient cells.  
 
Decreased AKT signaling identified in Nck-deficient cells may also limit the repression of pro-
apoptotic effector proteins such as FOXO, Bad and Caspase-9 (Cardone et al. 1998; Downward 2004), 
leading to an increase of pro-apoptotic signaling. This corresponds to Nck2-deficient cells which 
showed a higher number of apoptotic cells compared to DG75 wt and Citrine-Nck2-expressing cells. 
In contrast, Nck1-deficient cells displayed lower numbers of apoptotic cells, which cannot be 
explained based on this dataset. However, it is conceivable that serum-limiting conditions (1% FCS), 
which were necessary for induction of apoptosis, might be the cause for this phenotype. In 
hepatocytes, Nck1 was identified to negatively regulate PI3K-AKT signaling in response insulin and 
growth factors PDGF and EGF (Li et al. 2014). In the absence of growth-factors provided by the 
serum, Nck1 may inhibit PI3K activation leading to decreased survival of Nck1-expressing cells. 
While this is purely speculative, this may provide an explanation for the proliferative advantage of 
Nck1-deficient cells observed in serum-limiting apoptosis assays.  
 
In summary, Nck-deficient cells showed proliferative defects possibly mediated via decreased 
activation of AKT and decreased activation of JNK and p38 signaling pathways in Nck1-deficient cells. 
The absence of complete reconstitution within these signaling pathways is presumably also the 
cause for insufficient functional reconstitution in proliferation assays. Despite these difficulties, I 
identified Nck1 as a novel regulator for effector proteins AKT, JNK and p38 in the context of tonic 
BCR signaling.  
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4.2 BIG2 is mediating survival signaling in Daudi BL cells 
 
In my thesis, I provide evidence for the importance of the Brefeldin-A-inhibited guanine exchange 
factor 2 (BIG2), encoded by the ARFGEF2 gene, for the survival of BL cells. Phospho-proteome 
analysis revealed BIG2 to be phosphorylated in tonic BCR signaling and moreover was identified to 
be crucial for survival of BL cells (Corso et al. 2016). While there have been no further reports 
investigating the role of BIG2 in B cells, in other cells BIG2 has been reported to be involved in vesicle 
trafficking between the Golgi and the recycling endosomes and was described to play a role in actin 
cytoskeleton organization by regulating FilaminA phosphorylation (Shin et al. 2004; Zhang et al. 
2012). Here, I show that BIG2 may control survival in Daudi BL cells by promoting high levels of 
c-MYC expression.  
 
4.2.1 Loss of BIG2 leads to augmented apoptosis of Daudi cells 
 
To characterize the role of BIG2 in the context of BCR signaling, I generated a BIG2-deficient cell line 
on the background of Daudi BL cells. While activated BCR signaling i.e. the BCR-induced Ca2+ 
mobilization was not affected by BIG2, BIG2-deficient cells showed a drastic decrease in 
proliferation compared to Daudi wt cells, which could not be mitigated upon expression of Citrine-
tagged-BIG2. This lack of complete reconstitution implies that BIG2-deficient cells might have 
adapted during their generation to cope with the loss of BIG2. However, it was still apparent that 
loss of BIG2 hindered proliferation, similarly as seen for BL cell lines Daudi, DG75 and BL41 upon 
shRNA-mediated “knockdown” of BIG2 (Corso et al. 2016).  
 
Besides the proliferation defect, apoptosis was increased in BIG2-deficient Daudi cells compared to 
Daudi wt cells in serum-deprived medium. The same effect was observed in DG75 and Daudi cells 
upon shRNA-mediated “knockdown” of BIG2 (Corso et al. 2016), indicating that BIG2-expression is 
crucial for survival of BL cells by limiting spontaneous apoptosis. Interestingly, the apoptosis rate of 
BIG2-deficient cells was only restored by reconstitution with moderate expression levels that 
resemble the endogenous situation. In contrast, stronger BIG2 expression revealed an apoptosis 
rate similar to BIG2-deficient cells, showing that the amount of BIG2 in BL cells appear to be critical 
and overexpression might potentially cause secondary effects interfering with the survival of BL cells. 
These analyses show that despite the obvious clonal specificities caused by the BIG2 deficiency, the 
generated cell lines provide a basis for the further analysis of BIG2 in the tonic BCR signaling network 
of BL cells.  
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4.2.2 BIG2 increases survival of BL cells by decreasing c-MYC protein levels  
 
Continuous expression of the proto-oncogene c-MYC is a prerequisite for BL lymphomagenesis and 
is essential for BL proliferation and survival (Sampson et al. 2007; Gomez-Curet et al. 2006). This 
was demonstrated by multiple studies using pharmacological inhibitors (Yin et al. 2003), the c-MYC 
inducible cell line P493-6 (Pajic et al. 2000) and mouse models for MYC-induced lymphomagenesis 
(Harris et al. 1988; Park et al. 2005).  
 
Similar to a report stating that c-MYC mRNA expression was decreased upon knockdown of BIG1 
and BIG2 in HeLa cells (Li et al. 2016), I identified decreased c-MYC protein levels in BIG2-deficient 
Daudi cells. c-MYC expression could be reconstituted by the re-expression of BIG2, further 
emphasizing the BIG2 specificity of this effect. Since c-MYC is known to regulate cell growth by 
increasing metabolic activity essential for BL proliferation and survival (Spender & Inman 2014; 
Gomez-Curet et al. 2006), a decrease in c-MYC expression is likely to explain the defects in 
proliferation observed in BIG2-deficient Daudi cells.  
 
A model how BIG2 could modulate c-MYC expression was proposed by Li and colleagues. BIG2, via 
its N-terminal AKAP (A-kinase anchoring protein) domain, can assemble cAMP-dependent Protein 
kinase A (PKA) (Li et al. 2003). Moreover, BIG2 forms a complex with BIG1 that can bind β-catenin, 
which is phosphorylated by PKA. Phosphorylated β-catenin can translocate into the nucleus to 
induce subsequent transcription of T cell factor/ lymphoid enhancer binding factor (TCF/LEF) genes 
(Li et al., 2016), which are known to drive expression of c-MYC and cyclin D1 (He et al. 1998; 
Shtutman et al. 1999). However, in BL  cells c-MYC is under the control of Ig enhancer elements 
while the normal c-MYC allele is considered to be silent (ar-Rushdi et al. 1983; Spender & Inman 
2014). Thus, it is unlikely that the proposed pathway is regulating c-MYC expression in BL cells.  
 
A possible candidate mediating the BIG2-dependent c-MYC expression is the MAPK JNK. JNK 
phosphorylation was decreased in BIG2-deficient cells and could be reconstituted with Citrine-
tagged BIG2. JNK is known to enhance c-MYC expression in repose to growth factor receptor 
activation (Iavarone et al. 2003) and was found to regulate proliferation and c-MYC expression in 
lymphoma B cell lines (Gururajan et al. 2005). In the aforementioned study, authors proposed that 
c-MYC, despite its translocation, might still be regulated by the MAPK pathway. Therefore, JNK 
signaling could potentially link BIG2 and c-MYC expression levels.  
 
Another candidate potentially linking BIG2 and c-MYC expression is the associate of MYC-1 (AMY-1). 
AMY-1 is a c-MYC-binding protein known enhance c-MYC transcription and activity (Taira et al. 1998). 
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Additionally, AMY-1 co-precipitates with BIG1 and BIG2 and binds to AKAPs (Ishizaki et al. 2006), 
several of which were found to be phosphorylated in resting BL cells (Corso et al. 2016). Hence, loss 
of BIG2 may therefore result in decreased c-MYC levels in BL cells by loss if its association to AMY-1. 
However, we don’t have further hints for an involvement of AMY-1 in tonic BCR signaling and 
therefore the question whether BIG2 regulates c-MYC levels in BL cells via JNK, AMY-1, or by a 
different pathway remains to be determined. 
 
4.2.3 The GEF activity of BIG2 might contribute to survival signaling 
 
Additionally, BIG2 was reported to interact with Filamin A, an actin-crosslinking protein (Hartwig & 
Stossel 1981), in the Golgi and along the plasma membrane. Phosphorylation of Filamin A induces 
the recruitment of BIG2 from the Golgi to the cell membrane in melanoma and mouse 
neuroblastoma cells (Sheen 2014; Zhang et al. 2012; Zhang et al. 2013) and interaction with 
Filamin A is crucial for BIG2-dependent activation of ADP-ribosylation factor (ARF) 1 at the cell 
membrane (Zhang et al. 2013). On a functional level, ARF1 knockdown decreased cyclin D1 levels 
and inhibited cell proliferation due to less efficient ARF1-dependent activation of the PI3K pathway 
in ovarian cancer cells (Gu et al. 2017). Similarly, a CRISPR dropout screen identified ARF1 to be 
crucial for survival of BL cell lines in addition to shRNA data showing Filamin A to be essential for 
DG75 BL cell survival (unpublished data, kindly provided by Dr. Oellerich). These data indicate the 
GEF-activity of BIG2 for ARF1 activation could also be relevant for BIG2-dependent survival signaling 
in BL. 
 
4.2.4 Altered PI3K signaling may enable survival of BIG2-deficient cells  
 
In contrast to studies using for a shRNA-based “knockdown” models of either BIG2 in HeLa cells or 
ARF1 in an ovarian carcinoma cell line (Gu et al., 2017; Li et al., 2016), I found AKT and FOXO1 to be 
stronger phosphorylated in the absence of BIG2. Hence, it might be possible that during the 
generation of BIG2-deficient cells AKT signaling enabled the survival of BIG2-deficient Daudi cells. 
However, since the effect could be reconstituted, I propose that activation of the AKT signaling is 
likely a specific response of the BL signaling network upon loss of BIG2. 
 
On another note, I identified the Growth factor receptor bound protein 2 (Grb2) to be slightly 
enriched in BIG2-deficient Daudi cells, which was previously reported by others upon BIG2-
knockdown in HeLa cells (Shen et al. 2012). Grb2 is an adaptor protein, which is involved in many 
different signaling pathways including MAPK pathways in Epidermal growth factor (EGF) and BCR 
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signaling. Recently, Grb2 was reported to directly associate with the Igα subunit of the BCR via the 
non-ITAM Y204 following BCR activation (Vanshylla et al. 2018) and BIG2 was identified in high 
throughput interactome analysis to interact with CD79B (Huttlin et al. 2017) thereby providing a 
possible link of BIG2 and Grb2 to the BCR signaling complex. In addition, Grb2-deficient mouse B 
cells were reported to display strongly reduced AKT activation (Ackermann et al. 2011) and Grb2 is 
suggested to bind to modulators of PI3K-AKT signaling including BCAP and CD19 (Neumann et al. 
2009). Therefore, it was proposed by others that Grb2 association to these proteins might be 
important for activation of the PI3K-AKT pathway (Ackermann et al. 2011). In response to EGF 
signaling, Grb2 was described to recruit ARF1, which becomes activated by a GEF leading to 
activation of the PI3K-AKT pathway (Haines et al. 2014). Increased Grb2 expression might therefore 
enable increased activation of AKT signaling as seen in BIG2-deficienct cells. However, a mechanism 
how BIG2 regulates Grb2 expression levels remains unclear for now.  In conclusion, I propose that 
increased AKT signaling - Grb2-dependent or not - enables BIG2-deficient Daudi cells to survive 
despite their detrimental deletion of BIG2. 
 
Taken together, I could show that BIG2 is relevant for survival of Daudi BL cells by regulation of 
c-MYC expression levels. c-MYC expression could be mediated by a MAPK JNK, as reported in other 
B cell lymphoma lines. The activation of AKT signaling might contribute to survival of Daudi BIG2-
deficient cells, eventually by a Grb2-dependent mechanism. However, further experiments will be 
necessary to identify causal effects of the identified correlations to decipher the BIG2-dependent 
signaling network in BL in more detail.  
 
 
4.3 Impact of SHIP2 on BL survival and signaling  
 
The 5’-inositol phosphatase SHIP2 was previously found to be phosphorylated at S132 during tonic 
BCR signaling when compared to CD79A “knockdown” DG75 cells (Corso et al. 2016). This finding 
together with the likely involvement in PI3K signaling due to its enzymatic activity tempted me to 
analyze the role of SHIP2 in the BCR-dependent survival of BL cells. While the role of the sister 
protein SHIP1 in BCR signaling has been well described (Okada et al. 1998; Manno et al. 2016; Pauls 
& Marshall 2017), little is known about the function of SHIP2 in B cells. In this study, I could confirm 
the essential role of SHIP2 by showing that deletion of SHIP2 as well as inhibition of its phosphatase 
function limits proliferation of BL cell lines and induces apoptosis. While loss of SHIP2 or SHIP2 
inhibition in BL cell lines promoted signaling of PI3K-AKT pathway, signaling of the MAPK JNK was 
attenuated in activated and tonic BCR signaling.  
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4.3.1 SHIP2 is relevant for survival of BL cells 
 
Evidence for the essential role of SHIP2 in the BCR-dependent BL survival arises from proliferation 
and apoptosis assays that revealed an anti-apoptotic role of SHIP2 in Daudi and BL60 cells. Numbers 
of living BL cells were decreased upon knockout of SHIP2 as well as upon inhibition of its 
phosphatase function using the small molecule inhibitor AS1949490. Notably, in normal culture 
conditions, SHIP2-deficient BL60 cells showed no defect in proliferation, which is possibly caused by 
the identified clonal upregulation of SHIP1. These clonal differences were mitigated by the use of 
the SHIP2 inhibitor AS1949490 which prevented proliferation in all SHIP2-expressing cells. Similar 
correlations were shown in other cell types using AS1949490 (Saurus et al. 2017; Agollah et al. 2014), 
a pan-SHIP inhibitor in SHIP1-deficient cells (Fuhler et al. 2012), or SHIP2 depletion (Ghosh et al. 
2018). SHIP2 overexpression was also described to inhibit cell proliferation and to induce apoptosis 
in other cells (Gorgani-Firuzjaee et al. 2015; Ye et al. 2016), further emphasizing the pro-survival 
function of SHIP2 and indicating the importance of SHIP2 expression levels. 
 
The SHIP2 inhibitor AS1949490 also decreased numbers of SHIP2-deficient Daudi cells, whereas 
SHIP2-deficient BL60 cells were able to proliferate despite inhibitor treatment. Drug sensitivity and 
resistance are highly sensitive to the number of cell divisions during the course of a response assay 
(Hafner et al. 2016). During my experimental work, I observed Daudi cells to proliferate at a slower 
rate than BL60 cells (undocumented observation). Although proliferation assays were performed 
with the same inhibitor concentration, SHIP2-deficient Daudi cells were therefore exposed to a 
higher inhibitor to cell concentration than SHIP2-deficient BL60 cells over the course of the 
experiment. While this dose-dependent effect must be considered, it also implies an off-target 
activity of the inhibitor. Although AS1949490 was reported to be over twenty times more potent 
against SHIP2 than SHIP1 (Suwa et al. 2009; Thomas et al. 2016), additional SHIP1 inhibition cannot 
be excluded as a cause for the reduced proliferation rate in SHIP2-deficient cells.  
 
Apoptosis assays confirmed the pro-survival function of SHIP2, since SHIP2-deficient Daudi and BL60 
cells were more prone to apoptosis under serum-limiting conditions. The data obtained from 
experiments with the BL60 cell lines bear the obstacle that here the surface BCR expression is 
reduced in SHIP2-deficient and CitSHIP2high-expressing cells but not those cells that were 
reconstituted with SHIP2 expression levels more resembling the endogenous situation (CitSHIP2low). 
These differences in surface IgM expression levels might be responsible for the insufficient 
functional reconstitution, because the cells gain less pro-survival tonic BCR signals than BCRhigh-
expressing cells (Yasuda et al. 2017). Still, the pro-apoptotic effect of SHIP2 appears to be valid and 
not just caused by low BCR expression, because the SHIP2 inhibitor AS1949490 was able to induce 
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apoptosis in BL60 wt cells, whereas SHIP2-deficient cells were not affected. Due to time limitations, 
I could not obtain further experimental data that would allow to determine whether the augmented 
apoptosis observed in CitSHIP2high-expressing cells was due low BCR expression levels or caused by 
SHIP2 overexpression, as reported for other cells (Gorgani-Firuzjaee et al. 2015; Ye et al. 2016).  In 
summary these analyses provide evidence that SHIP2 is an important factor for the survival of BL 
cells and imply that the expression level of SHIP2 is a crucial parameter for its pro-survival function. 
 
4.3.2 Despite the pro-survival effect of SHIP2, AKT signaling is augmented in SHIP2-
deficient cells 
 
For many B cell neoplasms, including BL, the PI3K-AKT pathway has been described to be essential 
(Xu et al. 2013; Schmitz et al. 2012; Evangelisti et al. 2018; Tabe et al. 2014; Batlevi & Younes 2017). 
Consequently, 5’-inositol phosphatases SHIP1 and SHIP2 had been described to act as negative 
regulators and hence as tumor suppressors by hydrolyzing the PI3K product PI(3,4,5)P3 (Miletic et 
al. 2010). However, the produced PI(3,4)P2 was reported to correlate with AKT phosphorylation at 
S473 in B cells and was found to be important for overall AKT activity thus suggesting a potential 
function of SHIP1 and SHIP2 as proto-oncogenes (Fuhler et al. 2012; Li & Marshall 2015; Ma et al. 
2008).  
 
This could explain why I found increased AKT and FOXO1 activities in SHIP2-deficient and 
AS1949490-treated BL cells. Similar results have been reported previously in other cells upon 
shRNA-based SHIP2 “knockdown” or treatment with AS1949490 (Agollah et al. 2014). Despite the 
reduced BCR surface expression in the SHIP2-deficient BL60 cells discussed above, I found the 
inhibitory effect of SHIP2 in both Daudi and BL60 cells further demonstrating the specific role of 
SHIP2 in this pathway. Similar to the proliferation and apoptosis assays discussed above, only the 
SHIP2-deficient cells reconstituted with SHIP2 expression levels similar to the endogenous SHIP2 
expression and not BL60 CitSHIP2high-expressing were able to restore the AKT phosphorylation to 
the level of wt BL60 cells. SHIP2-deficient Daudi cells showed increased levels of AKT 
phosphorylation upon treatment with AS1949490, further confirming an off-target activity of the 
inhibitor, previously discussed in chapter 4.3.1. The negative regulatory function of SHIP2 on AKT 
activity is not restricted to tonic BCR signaling since I found prolonged BCR-induced phosphorylation 
of the PI3K effectors AKT and its target FOXO1 in the absence of SHIP2, which is in agreement with 
studies of receptor tyrosine kinase signaling (Liu et al. 2015; Wang et al. 2004). The inhibitory role 
in activated BCR signaling is further demonstrated by my results that the BCR-induced Ca2+ 
mobilization is decreased in the presence of SHIP2  as previously described for SHIP1 in DT40 chicken 
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B cells (Okada et al. 1998; Manno et al. 2016). Since AS1949490 treatment enhanced Ca2+ 
mobilization in SHIP2-expressing but not in SHIP2-deficient Daudi cells, I conclude that this effect is 
likely to be dependent on the phosphatase activity of SHIP2.  
 
Although PI3K activation is classically described to activate AKT signaling, AKT activation inversely 
correlated with phosphorylation of the PI3K subunit p85 in Daudi cells under tonic BCR signaling 
conditions. AS1949490 treatment or SHIP2 deletion slightly decreased phosphorylation of the PI3K 
subunit p85. Additionally, p85 phosphorylation was stronger after induced “knockdown” of CD79A 
knockdown. While an impact of Doxycycline treatment in these experiments cannot be excluded 
because it has been reported to be associated with activation of the PI3K-AKT pathway in other cells 
(Chang et al. 2014), AKT phosphorylation was decreased in CD79A knockdown cells, which is in 
agreement with observations by others (Schmitz et al. 2012; Corso et al. 2016; Yasuda et al. 2017). 
These data indicate that SHIP2 attenuates AKT activity by acting downstream of PI3K activation, 
possibly by providing PI(3,4)P2. SHIP2 product PI(3,4)P2 was shown to have a relatively similar 
specificity for AKT as PI(3,4,5)P3 (Manna et al. 2007). However, PDK1, which facilitates AKT 
phosphorylation at T308, prefers binding to PI(3,4,5)P3 (Alessi et al. 1997; Xie et al. 2013) and 
increased PI(3,4,5)P3 levels in the absence of SHIP2 could augment the PDK-dependent AKT 
phosphorylation.  
 
Additionally, the tandem PH-containing proteins (TAPP)1 and TAPP2 have been shown to specifically 
bind to the SHIP2 product PI(3,4,)P2 and are proposed to activate a negative feedback loop 
terminating BCR-dependent PI3K-AKT signaling (Manna et al. 2007; Landego et al. 2012; Xie et al. 
2013). Hence, the less efficient production of PI(3,4,)P2 in the absence of SHIP2 could compromise 
this inhibitory loop and thus prolong PI3K-AKT signaling. In summary, my results confirm the 
expected inhibitory role of SHIP2 in activated and tonic BCR signaling of BL cells. This is in apparent 
contrast to the pro-survival function of SHIP2 revealed by the proliferation/apoptosis assays 
discussed above, but could imply that SHIP2 functions beyond the regulation of AKT activity may be 
more important for providing tonic BCR-dependent survival signals to BL cells. 
 
4.3.3 JNK phosphorylation is regulated by tonic BCR signaling in a SHIP2-dependent 
manner 
 
JNK phosphorylation and activation is classically associated with induction of apoptosis by 
expression of pro-apoptotic genes and activation of the caspase cascade (reviewed in Dhanasekaran 
& Reddy 2008). However, JNK inhibitor studies showed that JNK has a unique pro-survival role in 
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murine and human B cell lymphomas (Gururajan et al. 2005), which is further supported by shRNA 
screens indicating the relevance of JNK proteins for survival of BL cells (unpublished data, kindly 
provided by Dr. Oellerich). In this study, I could show that SHIP2 is a positive regulator of JNK activity 
in the tonic BCR signaling network presumably contributing to survival of BL cells. The relevance of 
SHIP2 expression for JNK phosphorylation in the context of tonic BCR-signaling was identified in 
immunoblot analysis and confirmed by intracellular staining of SHIP2-deficient BL60- and Daudi-
derived cell lines. Additionally, decreased activation of JNK signaling in Daudi SHIP2-deficient cells 
was also confirmed by phospho-proteomics. Here, samples derived from Daudi wt cells displayed a 
stronger phosphorylation of MAP3K2 in comparison to samples from SHIP2-deficient cells. MAP3K2 
subsequently activates MAP2K7 which in turn can activate JNK  phosphorylation and signaling 
(Cheng et al. 2000).  
 
Since to my knowledge there are no studies linking SHIP2 and JNK to tonic BCR signaling, I also 
analyzed the SHIP2-dependent JNK activation upon engagement of the BCR for comparison. BCR 
engagement has been reported to induce JNK phosphorylation in DT40 chicken B cells (Okada et al. 
2000) and mouse splenic B cells (O’Neill et al. 2009). In mouse B cells, JNK phosphorylation was 
associated with trafficking of internalized BCR complexes (O’Neill et al. 2009) or regulation of BCR-
mediated proliferation (Han et al. 2003), further indicating the important function of JNK activation 
in B cells. 
 
Following BCR engagement, JNK phosphorylation was impaired in SHIP2-deficient Daudi and BL60 
cells but not in their respective parental or CitSHIP2low-expressing cells. This indicates a positive 
correlation of SHIP2 expression, JNK activation and the intensity of BCR signaling. Notably, in SHIP2-
deficient BL60 and CitSHIP2high-expressing cells, phosphorylation of JNK, as well as Syk and ERK was 
impaired upon BCR engagement. This might imply a more general defect in JNK activation possibly 
caused by lower BCR surface expression levels. Nevertheless, BCR engagement increased JNK 
phosphorylation in a SHIP2-dependent manner.  
 
Since the phosphatase function of SHIP2 was also shown to be crucial for cytoskeletal re-
organization during lamellipodia formation and migration of cells (Erneux et al., 2011; Ghosh et al., 
2018; Kato et al., 2012; Prasad, Topping, & Decker, 2001; Venkatareddy et al., 2011), JNK regulation 
by SHIP2 could be independent of tonic BCR signaling. However, my CD79A “knockdown” 
experiments prove that the SHIP2 function is related to tonic BCR signals. Because CD79A is 
necessary for BCR surface expression (Venkitaraman et al., 1991), “knockdown” of CD79A results in 
decreased tonic BCR signaling and thus serves as a negative control.  
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While ERK phosphorylation was not significantly changed upon CD79A “knockdown”, JNK levels 
were decreased in all tested Daudi-derived cell lines, however to a lower degree in SHIP2-deficient 
cells. A similar effect was observed in SHIP2-deficient BL60 cells, thereby suggesting that SHIP2 is 
mediating tonic BCR signaling to regulate JNK phosphorylation. The observation that CD79A 
“knockdown” further decreased JNK phosphorylation even in SHIP2-deficient cells also implies that 
SHIP2 is an important but not exclusive mediator of JNK activation. 
 
While I could show that SHIP2-dependent JNK activation is indeed regulated by tonic BCR-signaling, 
the mechanism how SHIP2 is mediating this process is less clear. Inhibition of the catalytic activity 
of SHIP2 by AS1949490 resulted in decreased levels of JNK phosphorylation in Daudi but not in BL60 
cells. While these differences could simply be cell line dependent, it remains unclear whether the 
phosphatase activity of SHIP2 is required for efficient JNK activation or whether SHIP2 adapter 
functions mediate this process. Support for the latter was published in 2008, when SHIP2 was 
identified to positively regulate JNK signaling via the JNK-interacting protein 1 (JIP1) independent of 
its phosphatase activity (Xie et al. 2008). However, immunoblot analysis of BL60 and Daudi cell 
lysates showed no specific signal for JIP1 (data not shown), indicating that JIP1 is not expressed. 
This observation is in line with data from the human protein atlas database, in which Daudi cells are 
listed negative for JIP1 RNA expression (Thul et al. 2017). Furthermore, a connection of SHIP2 and 
JNK activation had previously been described in breast cancer stem cells but, similar to my findings, 
JIP1 was not detected in SHIP2-immunoprecipitates (Fu et al., 2014). Thus, the mechanism how 
SHIP2 is regulating JNK phosphorylation independent of JIP1 awaits further investigation. In 
following experiments, generation and expression of catalytically inactive SHIP2 mutants or SHIP2 
mutants defective for certain binding sites of interacting proteins may help to elucidate the 
underlying mechanism of SHIP2-dependent JNK activation. 
 
A promising candidate mediating SHIP2-dependent JNK activation that is dependent on the inositol 
5’ phosphatase activity might be the B cell adaptor protein of 32 kDa (Bam32, also referred to as 
DAPP1). Bam32 is phosphorylated by Src-family kinases and recruited to the BCR in a PI3K-
dependent manner and is able to activate JNK signaling independent of PLCɣ2 (Han et al. 2003). 
Interestingly, Bam32 binds with high affinity to PI(3,4)P2 and its recruitment is therefore enhanced 
by phosphatases SHIP1 and SHIP2 (Allam & Marshall 2005). Since the phosphatase function of SHIP2 
was relevant in Daudi cells, Bam32 could be a possible mediator of SHIP2-dependent JNK activation. 
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A schematic depiction of a possible mechanism for SHIP2-dependent JNK activation in Daudi cells is 
summarized in Figure 46. Upon tonic BCR signaling, the PI3K is active and produces PI(3,4,5)P3, 
which is dephosphorylated by SHIP1 and SHIP2 to PI(3,4)P2. This creates an equilibrium of PIPs 
resulting in constitutive phosphorylation of JNK and survival of BL cells (Figure 46 a). In SHIP2-
deficient BL cells, the equilibrium of PIPs shifts to higher levels of PI(3,4,5)P3 and lower levels of 
PI(3,4)P2 (Figure 46 b). Lower PI(3,4)P2 levels correlate with reduced JNK phosphorylation, possibly 
mediated by reduced membrane recruitment of the PI(3,4)P2-binding adaptor protein Bam32. 
Inefficient JNK signaling is likely contributing to apoptosis in SHIP2-deficient cells.  
 
 
 
 
Figure 47: Model for SHIP2-dependent JNK activation upon tonic BCR signaling. 
(a) Tonic BCR signaling in BL cells is mediated by activation of PI3K, which phosphorylates membrane bound 
PI(4,5)P2 at the 3’ position generating PI(3,4,5)P3. Inositol 5’ phosphatases SHIP1 and SHIP2 can decrease the 
pool of PI(3,4,5)P3 by generating PI(3,4)P2. JNK is constitutively phosphorylated in BL cells, possibly involving 
the PI(3,4)P2-binding protein Bam32. (b) Upon loss of SHIP2 or SHIP2 inhibition, PI(3,4,5)P3 dephosphorylation 
to PI(3,4)P2 is limited to SHIP1 activity. JNK phosphorylation decreases in the absence of SHIP2 possibly caused 
by lower levels of PI(3,4)P2 mediating membrane recruitment of Bam32. Impaired JNK activation may lead to 
apoptosis in SHIP2-deficient cells. Grey arrows indicate phosphorylation levels of JNK in response to BCR 
signaling.   
  
 
In summary, loss of SHIP2 increased AKT signaling but led to decreased levels of JNK 
phosphorylation and contributed to apoptosis in BL cell lines Daudi and BL60. In addition, I could 
show that JNK activation was dependent on tonic BCR signals and that signaling - although not 
exclusively - was regulated by SHIP2, thereby possibly identifying a new pathway that is regulated 
by tonic BCR signaling.  
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4.4 BCR-dependent JNK signaling in B cells 
 
During my work on this thesis, the JNK pathway was recurrently regulated by the analyzed BL 
effector proteins. Previous studies had described JNK signaling to be necessary for proliferation of 
primary B cells and B cell neoplasms including BL, DLBCL of both subtypes, follicular lymphoma and 
multiple myeloma (Gururajan et al. 2005; Schmid et al. 2015; Knies et al. 2015; Hideshima et al. 
2003). Here, I could show that JNK signaling is regulated by tonic signals of the BCR and thereby 
may be a novel, putatively druggable pathway for the treatment of BL. The JNK pathway is one of 
the major signaling hubs of the MAPK signaling pathways. JNK signaling can be activated by a 
plethora of mechanisms ranging from G-protein couples receptors, to growth factors, cytokines or 
cellular stress (Lopez-Ilasaca 1998; Cano et al. 1994; Westwick et al. 1994; Hibi et al. 1993). Here, I 
would like to briefly summarize how JNK signaling can be activated by the BCR. 
 
In B cells, activation of JNK signaling so far only described upon BCR engagement. A central protein 
in the activation of JNK is the adaptor SLP65. SLP65 is constitutively associated with small GEF Vav 
(Wienands et al. 1998), which is activated upon tyrosine phosphorylation by tyrosine kinases like 
Syk (Deckert et al. 1996). Following, Vav can activate several Rho-family GTPases such as RhoA and 
Rac1 (Saci & Carpenter 2005; Brezski & Monroe 2007). Besides Vav, SLP65 also recruits PLCɣ2, and 
activation of both PLCɣ2 and Rac1 is necessary for subsequent JNK activation (Ishiai et al. 1999). In 
addition, SLP65 also associates to Nck, and this complex was previously shown to activate JNK 
activation in B cells (Mizuno et al. 2002). Upstream of SLP65, Syk triggers activation of both the 
PLCy2- and Vav-dependent Rac1 pathways (Ishiai et al. 1999; Teramoto et al. 1997), while SHP1 is a 
negative regulator of JNK signaling (Mizuno et al. 2002). Downstream of Rac1, MAP3Ks including 
ASK1 and MAP3K2 are activated which can in turn activate MAPK2s such as MAP2K7 which 
subsequently phosphorylate JNK MAPKs (reviewed in Dhanasekaran & Reddy 2008). When 
phosphorylated, JNK can translocate into the nucleus where it can activate its target transcription 
factors including c-Jun, c-MYC or Elk-1 (reviewed in Zeke et al. 2016). 
In addition, signaling via the PI3K-AKT pathway is also involved in BCR-dependent JNK activation, 
however, the mode for activation is less clear. Loss of the Nck1-interacting protein BCAP, which is 
phosphorylated by Syk and Btk, reduced PI3K activation and authors proposed a pathway involving 
recruitment of Vav by its PH-domain to mediate JNK signaling (Okada et al. 2000). Moreover, the 
adaptor protein Bam32 is recruited to the BCR in a PI3K-dependent manner and is able to activate 
JNK signaling independent of PLCɣ2 (Han et al. 2003). Interestingly, Bam32 binds with high affinity 
to PI(3,4)P2 and its recruitment is therefore enhanced by phosphatases SHIP1 and SHIP2 (Allam & 
Marshall 2005).  
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More recently, another pathway for BCR-dependent JNK activation has been identified that involves 
ezrin, a member of the ezrin/radixin/moesin (ERM) family of proteins, which cross-link the plasma 
membrane to the actin cytoskeleton and are important for the assembly of BCR microclusters 
(Treanor et al. 2011). Ezrin, which localizes in a pre-formed complex with Syk in unstimulated cells, 
is phosphorylated by Syk upon IgM stimulation (Parameswaran et al. 2013). In turn, Syk-specific 
ezrin phosphorylation induces association of MAP2K7 and JNK followed by subsequent JNK 
activation.     
 
Although studies so far only focused antigen-dependent instead of tonic BCR-dependent JNK 
phosphorylation, activation of the JNK cascade is complex and can be accomplished by different 
signaling networks. Despite this complexity, all pathways described so far are dependent on Syk 
activation following BCR engagement. Thus, Syk might also be a promising candidate to act as an 
upstream regulator for newly identified mediators of BL-specific tonic JNK signaling including SHIP2, 
Nck1 and BIG2. Generated cell lines could be treated with a SYK inhibitor and tested for JNK 
phosphorylation in the presence or absence of SHIP2, Nck1 and BIG2. Further studies determining 
interacting proteins necessary for JNK activation will help to gain a deeper insight into the survival-
relevant role of JNK activation in the context of tonic BL-specific BCR signaling.  
 
4.5 CRISPR/Cas9-based gene editing – challenges and what to consider 
 
While having been able to characterize some aspects of BL-specific tonic BCR signaling, the 
experimental approach of CRISPR/Cas9-mediated gene targeting bears the risk to miss some 
functional aspects. This is likely due to the fact that the cells were given time to adapt for the missing 
signaling effector, i.e. by changing expression levels of certain proteins. In the previous chapters, I 
have already described some effects like the downregulation of BCAP in Nck1-deficient cells, the 
upregulation of SHIP1 or different BCR-expression levels in SHIP2-deficient BL60 cells. Due to these 
clonal effects, I cannot exclude that additional signaling pathways might be mediated by analyzed 
BL-effector proteins that were not identified with the CRISPR/Cas9 gene targeting approach.  
 
To address this, different strategies targeting the transcript or protein instead of the gene itself 
might help to reveal further signaling pathways. Common technologies used for these applications 
include the use of small-molecule inhibitors - if available - or dominant negative mutant proteins 
(Sheppard 1994; Arkin et al. 2014). In addition, inducible RNA interference (RNAi) systems mediate 
a post-transcriptionally, specific and transient loss of protein expression and are extensively used 
for reverse genetics approaches (Boettcher & McManus 2015). Moreover, CRISPR interference 
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(CRISPRi) or transcription activator-like effector (TALE) transcriptional repressors prevent the 
transcription of the gene of interest in the nucleus (Cong et al. 2012; Qi et al. 2013; Gilbert et al. 
2013). Here, similar to RNAi, the expression of the gene of function is reduced but not completely 
abrogated. Therefore, these methods sometimes do not mirror the complete loss of function 
induced by genetic approaches and also display their fair share of off-target activity (Boettcher & 
McManus 2015). To achieve a post-transcriptional loss of protein function, systems enabling 
directed ubiquitylation and subsequent proteasomal degradation may be used. Auxin-inducible 
degron systems were initially established in plants but previously also used in human cells rapidly 
targeting nuclear and cytoplasmic proteins as well as proteins assembled in protein complexes 
(Holland et al. 2012; Natsume et al. 2016). The reported rapid depletion of target proteins by 
proteasomal degradation could therefore be beneficial to study survival-relevant proteins in BL.   
 
In summary, although the CRISPR/Cas9-genome editing approach came with some challenges, I 
nevertheless was able to characterize BL-specific effector proteins involved in the pro-survival tonic 
BCR signaling. However, for further studies the aforementioned strategies should be considered to 
avoid putative clonal artefacts, which might allow to identify potential effector functions beyond 
the ones described in this thesis.  
 
5 Summary and Conclusion 
 
The results of my PhD project reveal molecular details of how tonic BCR signaling contributes to the 
survival of BL cells. Previously, tonic BL-specific signaling via the BCR was mainly associated with the 
PI3K-AKT pathway contributing to survival and proliferation of BL cells. However, the underlying 
molecular details remained unclear. Based on a proteogenomic screen in different BL cell lines, I 
have characterized the function of Nck1, BIG2 and SHIP2 in BL-specific tonic BCR signaling using 
CRISPR/Cas9 gene editing of BL cell lines. My data demonstrate that the BL-specific BCR-effector 
proteins Nck1, SHIP2 and BIG2 regulate the activity of the MAPK JNK in tonic BCR signaling 
conditions. In agreement with previous inhibitor studies, constitutive JNK activation in BL cell lines 
could be linked to overall survival and was confirmed to be mediated by tonic BCR signals. In 
summary, my study sheds some light on the molecular aspects of BL-specific tonic BCR signaling and 
emphasizes that beyond PI3K signaling the JNK pathway may be a promising target for novel 
approaches in the treatment of BL. 
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